"term","context"
"25-30% DUCTAL COMPONENT","CANCER_TYPE_DETAILED:Prostate Adenocarcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRAD;TMB_NONSYNONYMOUS:1.06666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0091;SAMPLE_TYPE:Primary;OS_MONTHS:52.92;OS_STATUS:0:LIVING;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:52.92;TISSUE_SOURCE_SITE:YL;ICD_O_3_SITE:C61.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C61;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:3/13/14;PATH_T_STAGE:T3b;HISTOLOGICAL_DIAGNOSIS:Prostate Adenocarcinoma, Other Subtype;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1653;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-YL-A8HJ.A4B8AFC5-774E-4FB2-8191-735949EC3E42.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:370;SITE_OF_TUMOR_TISSUE:Prostate;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;HISTOLOGICAL_SUBTYPE:25-30% ductal component;LYMPH_NODES_EXAMINED:NO;LATERALITY:Bilateral;PRIMARY_SITE_PATIENT:Overlapping / Multiple Zones;TARGETED_MOLECULAR_THERAPY:YES;CLIN_M_STAGE:M0;GLEASON_SCORE:9;BONE_SCAN_RESULT:Normal (no evidence of prostate cancer) [cM0];BIOCHEMICAL_RECURRENCE_INDICATOR:NO;CT_SCAN_AB_PELVIS_INDICATOR:YES;CT_SCAN_AB_PELVIS_RESULTS:No Evidence of Extraprostatic Extension;DAYS_TO_BONE_SCAN_PERFORMED:54;DAYS_TO_CT_SCAN_AB_PELVIS:-34;DAYS_TO_PSA:1589;DIAGNOSTIC_MRI_RESULT:NO;GLEASON_PATTERN_PRIMARY:4;GLEASON_PATTERN_SECONDARY:5;GLEASON_PATTERN_TERTIARY:3;INITIAL_PATHOLOGIC_DIAGNOSIS_METHOD:Core needle biopsy;PSA_MOST_RECENT_RESULTS:0.03;TUMOR_LEVEL:Apex|Middle|Base"
"AB","CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"ACANTHOLYTIC","CANCER_TYPE_DETAILED:Cutaneous Squamous Cell Carcinoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:CSCC;TMB_NONSYNONYMOUS:41.6333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:65;SAMPLE_TYPE:Metastasis;OS_MONTHS:56.0;OS_STATUS:0:LIVING;PRIMARY_SITE:Uknown;AJCC_STAGING_EDITION:4.0;HISTOLOGICAL_SUBTYPE:Acantholytic;M_STAGE:1;PURITY:30%;TUMOR_SIZE:N.d.;T_STAGE:Tx;N_STAGE:0;PRIOR_TREATMENT:Surgery +Xrt;DIFFERENTIATION:Moderate;PURITY_ABSOLUTE:20.00%;TOTAL_MUTATIONS:1885;TREATMENT_TYPE:Surgery;DISEASE_STATUS:Recurrent;DISTANT_METS:Yes;IMMUNOSUPPRESSION:No;A_C:0.0203;A_G:0.039;A_T:0.0203;ABSOLUTE_CANCER_DNA_FRACTION:0.31;C_A:0.0369;C_G:0.0535;C_T:0.7652;DETAILED_METASTATIC_SITE:Parotid;EFS_MONTHS:55.5;EFS_STATUS:0:Censored;HAS_OTHER_CANCER:No;INVASION_DEPTH:N.d.;PNI:No;CC_TT:0.0572;DISEASE_RECURRENCE_OR_PERSISTENCE:No;DISTANT_RECURRENCE_NUM:1;EVENT_DETAILS:Censored;INTERVAL_FROM_INDEX_LESION_TO_PRESENT_LESION:32.15342466;INTERVAL_FROM_LAST_LESION_TO_STUDY:33;INVADE_BONE:Yes;INVADE_LARGER_THAN_SUBCUTANEOUS_TISSUE:No;INVADE_SKULL_BASE:No;LOCAL_RECURRENCE_NUM:0;MULTIPLE_HN_CSCC:No;OTHER_DNP:0.0075;OTHER_SKIN_TUMORS:No;PERSISTANT_DISEASE_TUMOR_STUDIED:No;RECURRENT_DISEASE_TUMOR_STUDIED:No;RECURRENT_FREE_INTERVAL_MONTHS:55.53"
"ACC","CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA RELATED CHANGES","CANCER_TYPE_DETAILED:Acute Myeloid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AML;TMB_NONSYNONYMOUS:0.5;SOMATIC_STATUS:Matched;SEX:Male;AGE:77;TUMOR_TISSUE_SITE:Bone marrow;WHO_CLASS:Acute Myeloid Leukemia With Myelodysplasia Related Changes;CYTOGENETICS:46,XY;GERMLINE_CONTROL:CD3+ T cell"
"ACYC","CANCER_TYPE_DETAILED:Adenoid Cystic Carcinoma;CANCER_TYPE:Salivary Gland Cancer;ONCOTREE_CODE:ACYC;SOMATIC_STATUS:Matched;SEX:Male;AGE:39;SAMPLE_TYPE:Primary;PRIMARY_SITE:Salivary gland;TUMOR_TISSUE_SITE:Salivary gland;PLATFORM:Targeted Sequencing;TUMOR_STAGE:III;STUDY:ACyC (FMI 2014);FUSION_STATUS:NO;GENOMIC_ALTERATIONS:0;METASTATIC_TUMOR_INDICATOR:No;PATIENT_GRADE:Intermediate;ACTIONABLE_ALTERATIONS:0"
"ADENOCARINOMA","CANCER_TYPE_DETAILED:Ovary/Fallopian Tube;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OVARY;TMB_NONSYNONYMOUS:7.9;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.3612;HISTOLOGICAL_SUBTYPE:Adenocarinoma;DOUBLING_TIME:34;P53:MT;EPITHELIAL:Yes;MDR:352"
"AMELANOTIC NODULAR","CANCER_TYPE_DETAILED:Cutaneous Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:SKCM;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0047;OS_MONTHS:31.94;OS_STATUS:0:LIVING;PFS_MONTHS:21.64;PFS_STATUS:1:Progressed;SUBTYPE:amelanotic nodular;TUMOR_TYPE:Melanoma;HISTOLOGY:cutaneous;RECIST_RESPONSE:clinical benefit;CENSORED:LIVING;DRUG_TYPE:anti-CTLA-4;RECIST:PR;AGE_START_IO:74.0;OTHER_CONCURRENT_THERAPY:no;ROH_RESPONSE:clinical benefit;VA_RESPONSE:clinical benefit"
"AML WITH BIALLELIC MUTATIONS OF CEBPA","CANCER_TYPE_DETAILED:AML with Biallelic Mutations of CEBPA;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLCEBPA;TMB_NONSYNONYMOUS:0.133333333;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:8.78;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:78.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:8.5;AGE_AT_PROCUREMENT:79;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy;HEMOGLOBIN_LEVEL:10.6;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.75;CURRENT_STAGE:Induction;FUSION:None;GROUP:Post-Chemotherapy|Residual Disease;KARYOTYPE:45,X,-Y[19]/46,XY[1];PB_BLAST_PERCENTAGE:72;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:87;CEBPA_MUTATION:1031?1032 ins AAC; MAF 50%;CUMULATIVE_TREATMENT_REGIMENS:Decitabine;CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Decitabine;LDH_LEVEL:460;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:-1;ELN_2008:Intermediate-II;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:32.3;INDUCTION_RESPONSE:Refractory;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:103.6;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3.4;PB_ALT_LEVEL:19;PB_AST_LEVEL:41;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:1;PB_LYMPHOCYTES_PERCENTAGE:17;PB_MONOCYTES_PERCENTAGE:4;PB_NEUTROPHILS_PERCENTAGE:1;PRIOR_CANCER:Bladder Cancer;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with mutated CEBPA;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with mutated CEBPA;SURFACE_ANTIGENS:CD7, CD13, CD33, partial CD34, CD117, CD123, HLA-DR, MPO +;TOTAL_PROTEIN_LEVEL:6.2;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"AML WITH MUTATED CEBPA","CANCER_TYPE_DETAILED:AML with Biallelic Mutations of CEBPA;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLCEBPA;TMB_NONSYNONYMOUS:0.133333333;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:8.78;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:78.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:8.5;AGE_AT_PROCUREMENT:79;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy;HEMOGLOBIN_LEVEL:10.6;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.75;CURRENT_STAGE:Induction;FUSION:None;GROUP:Post-Chemotherapy|Residual Disease;KARYOTYPE:45,X,-Y[19]/46,XY[1];PB_BLAST_PERCENTAGE:72;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:87;CEBPA_MUTATION:1031?1032 ins AAC; MAF 50%;CUMULATIVE_TREATMENT_REGIMENS:Decitabine;CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Decitabine;LDH_LEVEL:460;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:-1;ELN_2008:Intermediate-II;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:32.3;INDUCTION_RESPONSE:Refractory;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:103.6;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3.4;PB_ALT_LEVEL:19;PB_AST_LEVEL:41;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:1;PB_LYMPHOCYTES_PERCENTAGE:17;PB_MONOCYTES_PERCENTAGE:4;PB_NEUTROPHILS_PERCENTAGE:1;PRIOR_CANCER:Bladder Cancer;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with mutated CEBPA;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with mutated CEBPA;SURFACE_ANTIGENS:CD7, CD13, CD33, partial CD34, CD117, CD123, HLA-DR, MPO +;TOTAL_PROTEIN_LEVEL:6.2;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"AML WITH MUTATED NPM1","CANCER_TYPE_DETAILED:AML with Mutated NPM1;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLNPM1;TMB_NONSYNONYMOUS:0.1;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:13.98;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:73.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:94;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:73;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s);FAB:M1;HEMOGLOBIN_LEVEL:6.8;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.79;CURRENT_STAGE:Experimental;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:97;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:94;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|MiDAC|AC220 (Ambit);CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Experimental;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:AC220 (Ambit);LDH_LEVEL:441;MOST_RECENT_TREATMENT_DURATION:30;MOST_RECENT_TREATMENT_TYPE:Targeted Therapy - Kinase Inhibitor(s);PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:5;ELN_2008:Intermediate-I;ELN_2017:Favorable or Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Positive;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:19.3;INDUCTION_RESPONSE:Complete Response;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:100.5;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Positive;PB_ALBUMIN_LEVEL:4.1;PB_ALT_LEVEL:19;PB_AST_LEVEL:28;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:2;PB_MONOCYTES_PERCENTAGE:1;PB_NEUTROPHILS_PERCENTAGE:0;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with mutated NPM1;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with mutated NPM1;SURFACE_ANTIGENS:CD11b, CD13, CD33, dim CD56, CD64, CD117, and dim MPO positive, CD34 negative, HLA-DR negative;TOTAL_PROTEIN_LEVEL:7.6;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"AML WITH MUTATED RUNX1","CANCER_TYPE_DETAILED:AML with Mutated RUNX1;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLRUNX1;TMB_NONSYNONYMOUS:3.7300941196;SOMATIC_STATUS:Matched;STUDY:MSKCC;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:AML with mutated RUNX1"
"AML WITH MYELODYSPLASIA-RELATED CHANGES","CANCER_TYPE_DETAILED:AML with Myelodysplasia-Related Changes;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLMRC;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:0.1;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:72.0;CHEMOTHERAPY:No;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:97;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:72;CAUSE_OF_DEATH_SOURCE:Dead-Other;CENTER:1;FAB:M4;HEMOGLOBIN_LEVEL:5.6;SAMPLE_SITE:Leukapheresis;CREATININE_LEVEL_PRERESECTION:0.96;CURRENT_STAGE:NONE;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:96;WHOLE_EXOME_SEQUENCING:No;BM_BLAST_PERCENTAGE:95;CEBPA_MUTATION:Negative;CURRENT_REGIMEN:NONE;LDH_LEVEL:697;MOST_RECENT_TREATMENT_TYPE:NONE;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2008:Intermediate-I;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Positive;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:16.5;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:114;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:2.7;PB_ALT_LEVEL:47;PB_AST_LEVEL:58;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:3;PB_MONOCYTES_PERCENTAGE:0;PB_NEUTROPHILS_PERCENTAGE:1;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with myelodysplasia-related changes;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with myelodysplasia-related changes;SURFACE_ANTIGENS:Blasts: partial CD13, CD34, CD38, CD58, dim CD123, cTdT, HLA-DR, and partial/dim cMPO positive; Promonocyte/monoblast: CD11b, CD14, dim CD33, CD38, CD58, CD64, HLA-DR and dim cMPO positive;TOTAL_PROTEIN_LEVEL:4.9"
"AML, NOS","CANCER_TYPE_DETAILED:AML, NOS;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLNOS;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Unmatched;SEX:Male;OS_MONTHS:10.16;OS_STATUS:1:DECEASED;ETHNICITY:HispNative;PLATFORM:WES;AGE_AT_DIAGNOSIS:71.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:179.1;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:71;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s);FAB:NOS;HEMOGLOBIN_LEVEL:8.7;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.93;CURRENT_STAGE:Supportive/Palliative Care;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:60;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:81;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea;CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction | Experimental | Re-induction | Supportive/Palliative Care;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Supportive/Palliative Care | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Hydroxyurea;LDH_LEVEL:673;MOST_RECENT_TREATMENT_DURATION:9;MOST_RECENT_TREATMENT_TYPE:Supportive/Palliative Care;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:6;ELN_2008:Intermediate-I;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Positive;FLT3_NEGATIVE:Negative;INDUCTION_RESPONSE:Refractory;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:1;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3.3;PB_ALT_LEVEL:42;PB_AST_LEVEL:45;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:5;PB_MONOCYTES_PERCENTAGE:24;PB_NEUTROPHILS_PERCENTAGE:4;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute myeloid leukaemia, NOS;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Acute myeloid leukaemia, NOS;SURFACE_ANTIGENS:CD13, CD34, CD38, CD117, CD123, HLA-DR;TOTAL_PROTEIN_LEVEL:6.9;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA","CANCER_TYPE_DETAILED:Angioimmunoblastic T-Cell Lymphoma;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:AITL;TMB_NONSYNONYMOUS:3.91487879;SOMATIC_STATUS:Unmatched;SEX:Female;FRACTION_GENOME_ALTERED:0.0013;SAMPLE_TYPE:Primary;OS_MONTHS:12.03;OS_STATUS:1:DECEASED;PRIMARY_SITE:Lymph node;SAMPLE_CLASS:Tumor;TUMOR_PURITY:50;SAMPLE_COVERAGE:1033;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Unknown;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Unmatched;DNA_INPUT:250"
"ANSC","CANCER_TYPE_DETAILED:Primary Myelofibrosis;CANCER_TYPE:Myeloproliferative Neoplasms;ONCOTREE_CODE:PMF;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:6.22;OS_STATUS:0:LIVING;ETHNICITY:White;PLATFORM:WES;AGE_AT_DIAGNOSIS:66.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Myelodysplastic Syndromes;WBC:239;AGE_AT_PROCUREMENT:67;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:6;TREATMENT_TYPE:Standard Chemotherapy;BRAF_MUTATION:p.G469A, MAF 7%;SAMPLE_SITE:Bone Marrow Aspirate;CURRENT_STAGE:Unknown;FUSION:None;GROUP:Residual Disease;KARYOTYPE:46,XY[17];PB_BLAST_PERCENTAGE:5;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:5;CUMULATIVE_TREATMENT_REGIMENS:Hydroxyurea;CUMULATIVE_TREATMENT_STAGES:Unknown;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:Hydroxyurea;MOST_RECENT_TREATMENT_DURATION:263;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:Yes;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited;DIAGNOSIS_AT_INCLUSION:Myelodysplastic Syndromes;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2008:Not Enough Information;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:p.G12S, MAF 18%;PB_MONOCYTES_PERCENTAGE:1;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Primary myelofibrosis;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Primary myelofibrosis;SURFACE_ANTIGENS:Not detected for the FLT3 Internal Tandem Duplication (ITD). Not detected for the FLT3 TKD Mutation. No BCR-ABL1 transcripts are detected. MLL partial tandem duplication (MLL-PTD) is not detected. Pathogenic alterations are detected in the ASXL1, BRAF, EZ"
"APAD","CANCER_TYPE_DETAILED:Appendiceal Adenocarcinoma;CANCER_TYPE:Appendiceal Cancer;ONCOTREE_CODE:APAD;SEX:Female;AGE:64.16700745;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:Yes;CARBOPLATIN_TX:No;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:Yes;PLATINUM_TX:Yes;RADIOTHERAPY_TX:No;TARGETED_TX:Yes;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:3rd tertile;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:3rd tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:3rd tertile;TERT_PLATINUM_TX:3rd tertile;TERT_TARGETED_TX:3rd tertile;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:3rd tertile;TERT_TOPO_II_INH_TX:No treatment;TIME_FROM_DX_TO_SEQ:2440;TIME_TO_BLOOD_DRAW_FROM_TX:2388;TOPO_I_TX:Yes;TOPO_II_TX:No;XRT_TX:No"
"APL WITH PML-RARA","CANCER_TYPE_DETAILED:APL with PML-RARA;CANCER_TYPE:Leukemia;ONCOTREE_CODE:APLPMLRARA;TMB_NONSYNONYMOUS:0.9;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:0.23;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:65.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:9.8;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:65;CAUSE_OF_DEATH_SOURCE:Dead-Other;CENTER:1;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy;FAB:M3;HEMOGLOBIN_LEVEL:6.8;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.6;CURRENT_STAGE:Induction;FUSION:PML-RARA;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,X,der(X)add(X)(p22.1)add(X)(q22~24),add(7)(p15),der(15)t(15;17)(q22;q21),der(17)t(15;17)(q22;q21)inv(17)(q21q21)del(17)(q21)[17]/46,XX[3];PB_BLAST_PERCENTAGE:57;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:72;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:ATRA (Tretinoin)|3+7 (Cytarabine, Daunorubicin);CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:3+7 (Cytarabine, Daunorubicin);LDH_LEVEL:398;MOST_RECENT_TREATMENT_DURATION:3;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Unusual t(15;17), with the fusion signal on the derivative chromosome 15;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:5;ELN_2008:Adverse;ELN_2017:Favorable;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Positive;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:20.7;INDUCTION_RESPONSE:Unknown;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:90.2;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:2.9;PB_ALT_LEVEL:24;PB_AST_LEVEL:33;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:36;PB_MONOCYTES_PERCENTAGE:1;PB_NEUTROPHILS_PERCENTAGE:8;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA;SURFACE_ANTIGENS:partial CD2, CD13, CD33, partial CD34, CD117, CD123, MPO-positive;TOTAL_PROTEIN_LEVEL:5.6;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"ASPS","CANCER_TYPE_DETAILED:Alveolar Soft Part Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ASPS;TMB_NONSYNONYMOUS:2.4;SEX:Female;OS_MONTHS:154;OS_STATUS:0:LIVING;PRIMARY_SITE:Lung;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:17;SAMPLE_TIMEPOINT:Relapse;TISSUE_SEQUENCED:Lung;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:26.0;DIAGNOSTIC_CATEGORY:Sarcoma;GMED_OS_MONTHS:145;SAMPLE_TESTED_CATEGORY:Relapse/refractory"
"ASTROCYTOMA_GRADE_III-IV","CANCER_TYPE_DETAILED:Cervical Squamous Cell Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CESC;SEX:Female;ETHNICITY:Caucasian;PRIMARY_SITE:Central_Nervous_System;SUBTYPE:Astrocytoma;TUMOR_TYPE:glioma;HISTOLOGY:Glioma;MUTATION_RATE:115.8864018;ANNOTATION_SOURCE:ACHILLES;HIST_SUBTYPE1:astrocytoma_Grade_III-IV;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:central_nervous_system;LINEAGE_SUB_SUBTYPE:astrocytoma;LINEAGE_SUBTYPE:glioma;NAME:SF767;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:cervix"
"ATL","CANCER_TYPE_DETAILED:Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:STAD;TMB_NONSYNONYMOUS:7.16666666667;SEX:Female;AGE:59;FRACTION_GENOME_ALTERED:0.2996;SAMPLE_TYPE:Metastasis;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Stomach;SUBTYPE:Adenocarcinoma;TUMOR_TYPE:stomach;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:134.9948889;GENOME_DOUBLINGS:1;GEOGRAPHIC_DISTRIBUTION:korea;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:scatlered floating; suspention;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:gastric;LINEAGE_SUBTYPE:gastric_adenocarcinoma;NAME:SNU-620;PATHOLOGIST_ANNOTATION:Gastric:Carcinoma;SITE_OF_FINDING:ascites;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:stomach"
"ATYPICAL CHRONIC MYELOID LEUKAEMIA, BCR-ABL1 NEGATIVE","CANCER_TYPE_DETAILED:Atypical Chronic Myeloid Leukemia, BCR-ABL1-;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:ACML;TMB_NONSYNONYMOUS:0.766666667;SOMATIC_STATUS:Matched;SEX:Female;OS_STATUS:0:LIVING;ETHNICITY:HispNative;PLATFORM:WES;AGE_AT_DIAGNOSIS:47.0;CHEMOTHERAPY:No;DIAGNOSIS:Myelodysplastic/Myeloproliferative Neoplasms;WBC:31.85;AGE_AT_PROCUREMENT:47;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:1;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:NONE;FUSION:None;GROUP:Residual Disease;KARYOTYPE:47,XX,+8,del(11)(q23)[18];PB_BLAST_PERCENTAGE:17;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:10;CEBPA_MUTATION:Negative;CURRENT_REGIMEN:NONE;LDH_LEVEL:283;MOST_RECENT_TREATMENT_TYPE:NONE;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Missing MLL signal;DIAGNOSIS_AT_INCLUSION:Myelodysplastic/Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Atypical chronic myeloid leukaemia, BCR-ABL1 negative;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Atypical chronic myeloid leukaemia, BCR-ABL1 negative;SURFACE_ANTIGENS:CD13, CD33, CD34, CD38, CD58, CD117, CD123, and partial HLA-DR"
"ATYPICAL CHRONIC MYELOID LEUKEMIA, BCR-ABL1-","CANCER_TYPE_DETAILED:Atypical Chronic Myeloid Leukemia, BCR-ABL1-;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:ACML;TMB_NONSYNONYMOUS:0.766666667;SOMATIC_STATUS:Matched;SEX:Female;OS_STATUS:0:LIVING;ETHNICITY:HispNative;PLATFORM:WES;AGE_AT_DIAGNOSIS:47.0;CHEMOTHERAPY:No;DIAGNOSIS:Myelodysplastic/Myeloproliferative Neoplasms;WBC:31.85;AGE_AT_PROCUREMENT:47;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:1;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:NONE;FUSION:None;GROUP:Residual Disease;KARYOTYPE:47,XX,+8,del(11)(q23)[18];PB_BLAST_PERCENTAGE:17;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:10;CEBPA_MUTATION:Negative;CURRENT_REGIMEN:NONE;LDH_LEVEL:283;MOST_RECENT_TREATMENT_TYPE:NONE;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Missing MLL signal;DIAGNOSIS_AT_INCLUSION:Myelodysplastic/Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Atypical chronic myeloid leukaemia, BCR-ABL1 negative;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Atypical chronic myeloid leukaemia, BCR-ABL1 negative;SURFACE_ANTIGENS:CD13, CD33, CD34, CD38, CD58, CD117, CD123, and partial HLA-DR"
"ATYPICAL LUNG CARCINOID","CANCER_TYPE_DETAILED:Atypical Lung Carcinoid;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:ALUCA;TMB_NONSYNONYMOUS:1.5;SOMATIC_STATUS:Matched;SEX:Female;AGE:63;FRACTION_GENOME_ALTERED:0.1959;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Lung;ANALYSIS_COHORT:LUNG;BIOPSY_SITE:Lung;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:12"
"B-CELL_ALL","CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLL;TMB_NONSYNONYMOUS:2.87341935688;SEX:Male;FRACTION_GENOME_ALTERED:0.0313;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:B-Cell_All;HISTOLOGICAL_SUBTYPE:Acute_Lymphoblastic_B_Cell_Leukaemia;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Haematopoietic"
"BASALOID PENILE SQUAMOUS CELL CARCINOMA","CANCER_TYPE_DETAILED:Basaloid Penile Squamous Cell Carcinoma;CANCER_TYPE:Penile Cancer;ONCOTREE_CODE:BPSCC;SEX:Male;AGE:51.53456497;RACE:White;SMOKING_STATUS:Current Smoker;TREATMENT_STATUS:Untreated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:No;CHEMO_TX:No;CISPLATIN_TX:No;CYTOTOXIC_TX:No;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:No treatment;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:No treatment;TIME_FROM_DX_TO_SEQ:196;TOPO_I_TX:No;TOPO_II_TX:No;XRT_TX:No"
"BENIGN PT","CANCER_TYPE_DETAILED:Benign Phyllodes Tumor of the Breast;CANCER_TYPE:Breast Sarcoma;ONCOTREE_CODE:BPT;TMB_NONSYNONYMOUS:0.533333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:55;ETHNICITY:Chinese;HISTOLOGICAL_DIAGNOSIS:Benign PT;TUMOR_SIZE:180;SURGERY:Excision;MEAN_COVERAGE:50;NUM_SOMATIC_MUTATION:16"
"BILIARY TRACT CANCER","CANCER_TYPE_DETAILED:Gallbladder Cancer;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:GBC;TMB_NONSYNONYMOUS:0.0333333333333;SEX:Female;AGE:43;FRACTION_GENOME_ALTERED:0.0060;PFS_STATUS:Yes;RADIATION_THERAPY:No;STAGE:Stage I;RFS_STATUS:Yes;SURGERY:Yes;DEATH:Yes;LOCALIZED_VS_METS_AT_DX:Localized;ANY_LINE_CHEMO:Yes;ANY_LINE_HORMONE:No;ANY_LINE_IMMUNO:0;ANY_LINE_IODINE:No;ANY_LINE_NTRK:Yes;ANY_LINE_TARGETED:Yes;ANY_SYSTX:Yes;CANCER_TYPE_HISTOLOGY:Biliary Tract Cancer;DOB_LASTFU_TIME_YRS:50;DOB_PROG_START_TIME_YRS:46;DOB_PROG_TIME_YRS:47;DOB_RECUR_START_TIME_YRS:43;DOB_RECUR_TIME_YRS:46;DOB_REPORT_TIME_YRS:46;DOB_TISSUE_TIME_YRS:46;LINE_OBR_CHEMO:PR;LINE_OBR_CHEMO_G:Response;LINE_OBR_IMMUNO_G:Unknown/NA;LINE_OBR_NOTRK:PR;LINE_OBR_NOTRK_G:Response;LINE_OBR_NTRK:PR;LINE_OBR_NTRK_G:Response;LINE_OBR_TARGETED:PR;LINE_OBR_TARGETED_G:Response;LINE1_BR_NOTRK:PR;LINE1_BR_NOTRK_G:Response;NUM_LINES:8;NUM_LINES_CHEMO:4;NUM_LINES_HORMONE:0;NUM_LINES_IMMUNO:0;NUM_LINES_IODINE:0;NUM_LINES_NTRK:3;NUM_LINES_TARGETED:2;POS_ARCHER:Negative;POS_CYTOGENETICS:Negative;POS_IMPACT:Positive;POS_METHOD:IMPACT Only;PROG_DEATH:Yes;PROG_DEATH_TIME_YRS:4;PROG_EVAL_C:Yes;RECUR_EVAL_C:Yes;TISSUE_REPORT_TIME_YRS:0"
"BILIARY TRACT CANCER, NOS","CANCER_TYPE_DETAILED:Biliary Tract;CANCER_TYPE:Biliary Tract Cancer, NOS;ONCOTREE_CODE:BILIARY_TRACT;SEX:Female;AGE:58.10540771;RACE:White;SMOKING_STATUS:Former Smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:No;ANTIMETABOLITE_TX:Yes;CARBOPLATIN_TX:No;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:Yes;PLATINUM_TX:Yes;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:No treatment;TERT_ANTIMETABOLITE_TX:2nd tertile;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:1st tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:2nd tertile;TERT_PLATINUM_TX:2nd tertile;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:No treatment;TIME_FROM_DX_TO_SEQ:114;TIME_TO_BLOOD_DRAW_FROM_TX:56;TOPO_I_TX:No;TOPO_II_TX:No;XRT_TX:No"
"BLADDER/URINARY TRACT CANCER, NOS","CANCER_TYPE_DETAILED:Bladder/Urinary Tract;CANCER_TYPE:Bladder/Urinary Tract Cancer, NOS;ONCOTREE_CODE:BLADDER;TMB_NONSYNONYMOUS:18.59567425;SOMATIC_STATUS:Matched;PFS_MONTHS:1.2;COHORT:Bladder;PURITY:0.73;MSI_STATUS:MSS;MUTATION_BURDEN:19.60784314;AMPLIFICATION_STATUS:no;CLONALITY:clonal;BEST_ORR:PD;BUBBLE_GROUP:S310 Hotspot;CENTRAL:CONCORDANT;COVERAGE:1217;CRITERIA:RECIST;DATA:IMPACT;DOMAIN:Furin-like _ECD;DURATION_OF_THERAPY_DAYS:28;GENE:ERBB2;IMPACT:410;LOCAL_TEST:AMPLICON - VHIO;MULTI_ERBB2:no;ONCOPRINT:YES;ONGOING_TREATMENT:NO;QUALIFYING_MUT:S310Y;TUMOR_CHANGE:33.33333333;WATERFALL_GROUP:S310 Hotspot"
"BLAST_PHASE_CHRONIC_MYELOID_LEUKAEMIA","CANCER_TYPE_DETAILED:Chronic Myelogenous Leukemia;CANCER_TYPE:Blood Cancer;ONCOTREE_CODE:CML;TMB_NONSYNONYMOUS:3.75754838976;SEX:Male;FRACTION_GENOME_ALTERED:0.1164;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Cml;HISTOLOGICAL_SUBTYPE:Blast_Phase_Chronic_Myeloid_Leukaemia;HISTOLOGICAL_TYPE:Haematopoietic Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"BLCA","CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:3.16666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:57;FRACTION_GENOME_ALTERED:0.0033;SAMPLE_TYPE:Primary;OS_MONTHS:7.33;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:7.1;TISSUE_SOURCE_SITE:BL;ICD_O_3_SITE:C67.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C67.9;ICD_O_3_HISTOLOGY:8120/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2/28/11;GRADE:High Grade;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;HISTOLOGICAL_DIAGNOSIS:Muscle invasive urothelial carcinoma (pT2 or above);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:127;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-BL-A13I.976FBDBF-55C5-4957-986B-D2DE85FF7540.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:410;SMOKING_PACK_YEARS:15;WEIGHT:51;SITE_OF_TUMOR_TISSUE:Bladder;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:Non-Papillary;TOBACCO_SMOKING_HISTORY_INDICATOR:2;HEIGHT:157;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Transurethral resection (TURBT);PRIMARY_SITE_PATIENT:Bladder - NOS;SMOKING_YEAR_STARTED:27;PROJECT_CODE:TCGA;DISEASE_CODE:FPPP;OCCUPATION_CURRENT:Dental Assistant"
"BLOOD CANCER","CANCER_TYPE_DETAILED:Chronic Myelogenous Leukemia;CANCER_TYPE:Blood Cancer;ONCOTREE_CODE:CML;TMB_NONSYNONYMOUS:3.75754838976;SEX:Male;FRACTION_GENOME_ALTERED:0.1164;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Cml;HISTOLOGICAL_SUBTYPE:Blast_Phase_Chronic_Myeloid_Leukaemia;HISTOLOGICAL_TYPE:Haematopoietic Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"BLOOD CANCER, NOS","CANCER_TYPE_DETAILED:Myeloid Neoplasm;CANCER_TYPE:Blood Cancer, NOS;ONCOTREE_CODE:MNM;TMB_NONSYNONYMOUS:0.433333333333;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:1.6;OS_STATUS:1:DECEASED;GENE_PANEL:Enhanced exome;AGE_AT_DIAGNOSIS:83.5;PRIOR_TREATMENT:Azacitidine x 1 cycle;SOURCE:WashU_on_study;BONE_MARROW_LEUKEMIC_BLAST_PERCENTAGE:16;DISEASE:MDS;PERFORMANCE_STATUS:1;PERIPHERAL_BLASTS_PERCENTAGE:0.0;AML_FAB:refractory anemia with excess blasts-2;CYCLES_COMPLETED:1.0;CYTOGENETIC_RISK:Int;IPSS_MDS:2.0;KYRYOTYPE:normal;MORPHOLOGIC_RESPONSE:PD;PERIPHERAL_BLOOD_WBC:1.2;TRANSPLANT:No"
"BORDERLINE PT","CANCER_TYPE_DETAILED:Borderline Phyllodes Tumor of the Breast;CANCER_TYPE:Breast Sarcoma;ONCOTREE_CODE:BLPT;TMB_NONSYNONYMOUS:2.26666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:38;ETHNICITY:Chinese;HISTOLOGICAL_DIAGNOSIS:Borderline PT;TUMOR_SIZE:95;SURGERY:Excision;MEAN_COVERAGE:79;NUM_SOMATIC_MUTATION:68"
"BRCA","CANCER_TYPE_DETAILED:Invasive Breast Cancer;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:3.93333333333;SOMATIC_STATUS:Unmatched;SAMPLE_CLASS:Tumor;SEQUENCING_TYPE:Targeted"
"BRCA_LUMA","CANCER_TYPE_DETAILED:Breast Invasive Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:ILC;TMB_NONSYNONYMOUS:0.8;SOMATIC_STATUS:Matched;SEX:Female;AGE:55;FRACTION_GENOME_ALTERED:0.7787;SAMPLE_TYPE:Primary;OS_MONTHS:133.0505967;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:59.44044449;TISSUE_SOURCE_SITE:Columbia University;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8520/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:1/13/14;PFS_MONTHS:59.44044449;AJCC_STAGING_EDITION:6TH;PFS_STATUS:1:PROGRESSION;TUMOR_TISSUE_SITE:Breast;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE X;SUBTYPE:BRCA_LumA;TUMOR_TYPE:Infiltrating Lobular Carcinoma;PATH_T_STAGE:TX;RADIATION_THERAPY:No;DAYS_LAST_FOLLOWUP:4047;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-20211;MSI_SENSOR_SCORE:0.55;CANCER_TYPE_ACRONYM:BRCA;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3319;PATH_N_STAGE:NX;TISSUE_SOURCE_SITE_CODE:3C;DSS_MONTHS:133.0505967;PERSON_NEOPLASM_CANCER_STATUS:With Tumor;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;PATH_M_STAGE:MX;BUFFA_HYPOXIA_SCORE:-21;RAGNUM_HYPOXIA_SCORE:0;WINTER_HYPOXIA_SCORE:-28;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"BRCA_LUMB","CANCER_TYPE_DETAILED:Breast Invasive Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:0.933333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:62;FRACTION_GENOME_ALTERED:0.5340;SAMPLE_TYPE:Primary;OS_MONTHS:48.45974291;OS_STATUS:0:LIVING;RACE:Black or African American;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:48.45974291;TISSUE_SOURCE_SITE:Columbia University;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8500/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:7/28/14;PFS_MONTHS:48.45974291;AJCC_STAGING_EDITION:7TH;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Breast;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE IIB;SUBTYPE:BRCA_LumB;TUMOR_TYPE:Infiltrating Ductal Carcinoma;PATH_T_STAGE:T2;RADIATION_THERAPY:No;DAYS_LAST_FOLLOWUP:1474;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-22848;MSI_SENSOR_SCORE:0.31;CANCER_TYPE_ACRONYM:BRCA;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3266;PATH_N_STAGE:N1A;TISSUE_SOURCE_SITE_CODE:3C;DSS_MONTHS:48.45974291;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;PATH_M_STAGE:M0;BUFFA_HYPOXIA_SCORE:-5;RAGNUM_HYPOXIA_SCORE:12;WINTER_HYPOXIA_SCORE:-10;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"BRCA_NORMAL","CANCER_TYPE_DETAILED:Breast Invasive Carcinoma (NOS);CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCNOS;TMB_NONSYNONYMOUS:0.5;SOMATIC_STATUS:Matched;SEX:Female;AGE:70;FRACTION_GENOME_ALTERED:0.0008;SAMPLE_TYPE:Primary;OS_MONTHS:8.514975178;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:8.514975178;TISSUE_SOURCE_SITE:UCSF;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8200/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:6/30/11;PFS_MONTHS:8.514975178;AJCC_STAGING_EDITION:6TH;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Breast;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE I;SUBTYPE:BRCA_Normal;TUMOR_TYPE:Other;PATH_T_STAGE:T1C;DAYS_LAST_FOLLOWUP:259;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-25833;MSI_SENSOR_SCORE:0.2;CANCER_TYPE_ACRONYM:BRCA;IN_PANCANPATHWAYS_FREEZE:Yes;PATH_N_STAGE:N0;TISSUE_SOURCE_SITE_CODE:A1;DSS_MONTHS:8.514975178;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;PATH_M_STAGE:M0;BUFFA_HYPOXIA_SCORE:-35;RAGNUM_HYPOXIA_SCORE:-16;WINTER_HYPOXIA_SCORE:-40;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"BREAST INVASIVE CARCINOSARCOMA, NOS","CANCER_TYPE_DETAILED:Breast Invasive Carcinosarcoma, NOS;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:CSNOS;TMB_NONSYNONYMOUS:5.18818857;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.1583;SAMPLE_TYPE:Metastasis;RACE:WHITE;ETHNICITY:Unknown whether Spanish or not;PRIMARY_SITE:Breast;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Lung;MSI_SCORE:0.18;MSI_TYPE:Stable;AGE_AT_SEQ_REPORTED_YEARS:57;AGE_CURRENT:61"
"BREAST INVASIVE DUCTAL CARCINOMA","CANCER_TYPE_DETAILED:Breast Invasive Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:1.366666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:50;FRACTION_GENOME_ALTERED:0.4696;SAMPLE_TYPE:Primary;OS_MONTHS:17.21;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:12.71;TISSUE_SOURCE_SITE:AR;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8500/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:6/28/11;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIIA;HISTOLOGICAL_DIAGNOSIS:Infiltrating Ductal Carcinoma;HISTORY_OTHER_MALIGNANCY:Yes;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2007;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1416;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-AR-A1AR.747FB91B-F523-4FA0-91DD-6014EF55643D.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:250;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N2;AJCC_TUMOR_PATHOLOGIC_PT:T1;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Core needle biopsy;PRIMARY_SITE_PATIENT:Left Lower Inner Quadrant;IHC_HER2:Negative;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);PATH_MARGIN:Negative;ER_STATUS_BY_IHC:Negative;PR_STATUS_BY_IHC:Negative;STAGING_SYSTEM:Axillary lymph node dissection alone;SURGICAL_PROCEDURE_FIRST:Lumpectomy"
"BRONCHIOALVEOLAR_CARCINOMA","CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:41.4666666667;SEX:Male;FRACTION_GENOME_ALTERED:0.5624;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Lung;SUBTYPE:Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma;TUMOR_TYPE:lung_NSC;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:218.724336;GENOME_DOUBLINGS:1;DOUBLING_TIME:73.9;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:adherenet;DISEASE_ONTOLOGY:bronchioalveolar_carcinoma; non-small_cell lung_cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI+10%FBS;HIST_SUBTYPE1:bronchioloalveolar_adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUB_SUBTYPE:NSCLC_adenocarcinoma;LINEAGE_SUBTYPE:NSCLC;NAME:NCI-H358;PATHOLOGIST_ANNOTATION:Lung:NSCLC_Adeno;PROTEOMICS_TMT_LABEL:126;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lung_NSC"
"BRONCHIOLOALVEOLAR_ADENOCARCINOMA","CANCER_TYPE_DETAILED:Non-Small Cell Lung Cancer;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:NSCLC;TMB_NONSYNONYMOUS:2.76290322777;SEX:Male;FRACTION_GENOME_ALTERED:0.2885;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lung_Nsc;HISTOLOGICAL_SUBTYPE:Bronchioloalveolar_Adenocarcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"B_CELL_MEDIASTINAL_LARGE","CANCER_TYPE_DETAILED:Diffuse Large B-Cell Lymphoma, NOS;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:DLBCLNOS;TMB_NONSYNONYMOUS:9.46666666667;SUBTYPE:B-cell, Non-Hodgkins, Mediastinal Large;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:b_cell_mediastinal_large;LINEAGE_SUBTYPE:non_hodgkin_lymphoma"
"CANCER OF UNKNOWN PRIMARY","CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:5.08374193909;SEX:Male;FRACTION_GENOME_ALTERED:0.5864;PRIMARY_SITE:Salivary Gland;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Other;HISTOLOGICAL_SUBTYPE:Mucoepidermoid_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"CANCER OF UNKNOWN PRIMARY, NOS","CANCER_TYPE_DETAILED:Cancer of Unknown Primary, NOS;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:CUPNOS;TMB_NONSYNONYMOUS:13.83516952;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.4925;SAMPLE_TYPE:Metastasis;OS_MONTHS:1.282;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Cancer of Unknown Primary;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Liver;TUMOR_PURITY:30;MSI_SCORE:0.44;MSI_TYPE:Stable;SAMPLE_COVERAGE:623;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:75;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;RELIGION:JEWISH;AGE_CURRENT:74;ARCHER:YES;PED_IND:No;PARTC_CONSENTED_12_245:NO;PARTA_CONSENTED_12_245:YES"
"CARCINOID","CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:8.06767742508;SEX:Female;FRACTION_GENOME_ALTERED:0.7674;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Other;HISTOLOGICAL_TYPE:Carcinoid-Endocrine Tumour;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"CARCINOID TUMOR","CANCER_TYPE_DETAILED:Carcinoid Tumor;CANCER_TYPE:Other;SEX:Female;AGE:17.38809013;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:224"
"CARCINOID-ENDOCRINE TUMOUR","CANCER_TYPE_DETAILED:Mixed Cancer Types;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:MIXED;TMB_NONSYNONYMOUS:8.06767742508;SEX:Female;FRACTION_GENOME_ALTERED:0.7674;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Other;HISTOLOGICAL_TYPE:Carcinoid-Endocrine Tumour;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"CARCINOMA WITH SQUAMOUS DIFFERENTIATION","CANCER_TYPE_DETAILED:Squamous Cell Carcinoma of Gallbladder;CANCER_TYPE:Carcinoma with Squamous Differentiation;TMB_NONSYNONYMOUS:2.93615909284;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2220;SAMPLE_TYPE:Metastasis;OS_MONTHS:20.46817248;OS_STATUS:1:DECEASED;ETHNICITY:White;PRIMARY_SITE:Gallbladder;GENE_PANEL:IMPACT410;METASTATIC_SITE:Liver;TUMOR_PURITY:30;MSI_SCORE:0.51;MSI_TYPE:Stable;SAMPLE_COVERAGE:328;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORTED_YEARS:59;RELIGION:CATHOLIC/ROMAN;AGE_CURRENT:58;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:NO;CVR_TMB_SCORE:3;PARTA_CONSENTED_12_245:YES;DATE_ADDED:4/7/15;MONTH_ADDED:2015/04;WEEK_ADDED:2015, Wk. 15;CRDB_CONSENT_DATE_DAYS:21213;CRDB_OFF_STUDY_DAYS:21402;CRDB_SURVIVAL_STATUS:Dead;CRDB_TREATMENT_END_DAYS:21402;CVR_TMB_COHORT_PERCENTILE:37.9;CVR_TMB_TT_COHORT_PERCENTILE:48.8;SAMPLE_NAME:P-0003363-T01-IM5;CBIOPORTAL_SAMPLE_CLASS:Tumor;OS_MONTHS_DIAG_TO_COLL:0;OS_MONTHS_DIAGNOSIS_TO_FU:20.46817248;OVERALL_SURVIVAL_MONTHS:20.46817248;TUMOR_STAGE_COLLECTION:4"
"CARCINOSARCOMA-MAMMARY GLAND","CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:12;SOMATIC_STATUS:Matched;SEX:Female;AGE:74;FRACTION_GENOME_ALTERED:0.2795;SAMPLE_TYPE:Primary;HISTOLOGICAL_SUBTYPE:Carcinosarcoma-mammary gland; breast;DOUBLING_TIME:53.8;P53:MT;CATEGORY_SAMPLE:Primary;EPITHELIAL:Yes"
"CARCINOSARCOMA-MAMMARY GLAND; BREAST","CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:12;SOMATIC_STATUS:Matched;SEX:Female;AGE:74;FRACTION_GENOME_ALTERED:0.2795;SAMPLE_TYPE:Primary;HISTOLOGICAL_SUBTYPE:Carcinosarcoma-mammary gland; breast;DOUBLING_TIME:53.8;P53:MT;CATEGORY_SAMPLE:Primary;EPITHELIAL:Yes"
"CCOV","CANCER_TYPE_DETAILED:Clear Cell Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:CCOV;TMB_NONSYNONYMOUS:7.26666666667;SEX:Female;FRACTION_GENOME_ALTERED:0.6831;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, clear cell;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:155.1495548;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:RIKEN;CHARACTERISTICS:epithelial-like;GROWTH_MEDIUM:(DMEM: HamF12=1:1) +10%FBS;HIST_SUBTYPE1:clear_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:clear_cell;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:JHOC-5;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:0.1mM NEAA;TYPE_REFINED:ovary"
"CESC","CANCER_TYPE_DETAILED:Cervical Squamous Cell Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CESC;TMB_NONSYNONYMOUS:2.13333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:64;FRACTION_GENOME_ALTERED:0.1555;SAMPLE_TYPE:Primary;OS_MONTHS:68.79;OS_STATUS:1:DECEASED;RACE:WHITE;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:54.99;TISSUE_SOURCE_SITE:C5;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8072/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/12/11;GRADE:G2;AJCC_STAGING_EDITION:1995;HISTOLOGICAL_DIAGNOSIS:Cervical Squamous Cell Carcinoma;HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:3839;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-C5-A1BE.0A21AE44-27DF-4F41-BAB5-209A25087C0A.pdf;VIAL_NUMBER:B;SAMPLE_INITIAL_WEIGHT:40;WEIGHT:76;SITE_OF_TUMOR_TISSUE:Cervical;AJCC_METASTASIS_PATHOLOGIC_PM:MX;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T1b;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:3;HEIGHT:149;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Cone Biopsy / LEEP;CLINICAL_STAGE:Stage IB2;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);CORPUS_INVOLVEMENT:PRESENT;HYSTERECTOMY_TYPE:Radical Hysterectomy;KERATINIZATION_SQUAMOUS_CELL:Non-keratinizing squamous cell carcinoma;LYMPHOVASCULAR_INVOLVEMENT:PRESENT;MARGINS_INVOLVED_HYSTERECTOMY:Other Location, specify;OTHER_INVOLVED_MARGINS:Anterior lower uterine segment;POS_LYMPH_NODE_LOCATION:Pelvic (external iliac, internal iliac, obturator);PREGNANT_AT_DIAGNOSIS:NO"
"CESC_SQUAMOUSCARCINOMA","CANCER_TYPE_DETAILED:Cervical Squamous Cell Carcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:CESC;TMB_NONSYNONYMOUS:379.2;SOMATIC_STATUS:Matched;SEX:Female;AGE:51;FRACTION_GENOME_ALTERED:0.0479;SAMPLE_TYPE:Primary;OS_MONTHS:17.52309564;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:17.52309564;TISSUE_SOURCE_SITE:University of New Mexico;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8560/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:5/15/14;GRADE:G3;PFS_MONTHS:17.52309564;AJCC_STAGING_EDITION:2009;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Cervical;SUBTYPE:CESC_SquamousCarcinoma;TUMOR_TYPE:Adenosquamous;PATH_T_STAGE:T2A2;RADIATION_THERAPY:Yes;DAYS_LAST_FOLLOWUP:533;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-18886;MSI_SENSOR_SCORE:13.19;CANCER_TYPE_ACRONYM:CESC;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.6087;PATH_N_STAGE:N0;TISSUE_SOURCE_SITE_CODE:2W;DSS_MONTHS:17.52309564;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:Yes;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:No;WEIGHT:42;PATH_M_STAGE:M0;BUFFA_HYPOXIA_SCORE:33;RAGNUM_HYPOXIA_SCORE:22;WINTER_HYPOXIA_SCORE:28;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"CHOL EXTRA","CANCER_TYPE_DETAILED:Extrahepatic Cholangiocarcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:EHCH;TMB_NONSYNONYMOUS:2.2183106012;SEX:Female;FRACTION_GENOME_ALTERED:0.0132;SAMPLE_TYPE:Primary;OS_MONTHS:8.18;OS_STATUS:1:DECEASED;RACE:Asian-far east/indian subcont;PRIMARY_SITE:Liver;GENE_PANEL:IMPACT341;TUMOR_PURITY:50;SUBTYPE:Cholangio Extrahepatic;MSI_SCORE:0.09;MSI_TYPE:Stable;SAMPLE_COVERAGE:224;AGE_AT_SURGERY:68.58;FGA:0.013;AGE_AT_SEQUENCING:69.43;ORGAN_SYSTEM:Developmental GI Tract;AGE_AT_DEATH:70.12;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:No;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:CHOL extra"
"CHOLANGIOCARCINOMA; DISTAL","CANCER_TYPE_DETAILED:Extrahepatic Cholangiocarcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:EHCH;TMB_NONSYNONYMOUS:3.2;SOMATIC_STATUS:Matched;SEX:Female;AGE:70;FRACTION_GENOME_ALTERED:0.2422;SAMPLE_TYPE:Primary;OS_MONTHS:12.09;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:12.09;TISSUE_SOURCE_SITE:3X;ICD_O_3_SITE:C24.0;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C24.0;ICD_O_3_HISTOLOGY:8160/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:7/9/14;GRADE:G1;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IVB;HISTOLOGICAL_DIAGNOSIS:Cholangiocarcinoma; distal;HISTORY_OTHER_MALIGNANCY:No;PROSPECTIVE_COLLECTION:NO;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:386;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3X-AAVB.BEA4C577-73ED-48F0-9417-AA8BD143B5C8.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:420;WEIGHT:76;TUMOR_SITE:Bile duct;AJCC_METASTASIS_PATHOLOGIC_PM:M1;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T3;ECOG_SCORE:0;HEIGHT:170;PERINEURAL_INVASION:YES;VASCULAR_INVASION:None;FAMILY_HISTORY_OF_CANCER:NO;CREATININE_LEVEL_PRERESECTION:0.9;CREATININE_NORM_RANGE_LOWER:0.4;CREATININE_NORM_RANGE_UPPER:1.1;YEAR_OF_INITIAL_PATHOLOGIC_DIAGNOSIS:2012;BILIRUBIN_TOTAL:1.7;BILIRUBIN_TOTAL_NORM_RANGE_LOWER:0;BILIRUBIN_TOTAL_NORM_RANGE_UPPER:1.2;CHILD_PUGH_CLASSIFICATION:A;DEFINITIVE_SURGICAL_PROCEDURE:Pancreaticoduodenectomy (Whipple Resection);HISTORY_HEPATO_CARCINOMA_RISK_FACTORS:No History of Primary Risk Factors;PLATELET_NORM_RANGE_LOWER:150;PLATELET_NORM_RANGE_UPPER:400;PROTHROM_TIME_INR_NORM_RANGE_LOWER:0.9;PROTHROMBIN_TIME_INR_AT_PROCUREMENT:1.1;PROTHROMBIN_TIME_NORM_RANGE_UPPER:1.1;SERUM_ALBUMIN_NORM_RANGE_LOWER:3.3;SERUM_ALBUMIN_NORM_RANGE_UPPER:4.8;SERUM_ALBUMIN_PRERESECTION:4.3"
"CHRONIC MYELOGENOUS LEUKEMIA","CANCER_TYPE_DETAILED:Chronic Myelogenous Leukemia;CANCER_TYPE:Blood Cancer;ONCOTREE_CODE:CML;TMB_NONSYNONYMOUS:3.75754838976;SEX:Male;FRACTION_GENOME_ALTERED:0.1164;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Cml;HISTOLOGICAL_SUBTYPE:Blast_Phase_Chronic_Myeloid_Leukaemia;HISTOLOGICAL_TYPE:Haematopoietic Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"CHRONIC MYELOID LEUKEMIA, BCR-ABL1+","CANCER_TYPE_DETAILED:Atypical Chronic Myeloid Leukemia, BCR-ABL1-;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:ACML;TMB_NONSYNONYMOUS:0.766666667;SOMATIC_STATUS:Matched;SEX:Female;OS_STATUS:0:LIVING;ETHNICITY:HispNative;PLATFORM:WES;AGE_AT_DIAGNOSIS:47.0;CHEMOTHERAPY:No;DIAGNOSIS:Myelodysplastic/Myeloproliferative Neoplasms;WBC:31.85;AGE_AT_PROCUREMENT:47;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:1;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:NONE;FUSION:None;GROUP:Residual Disease;KARYOTYPE:47,XX,+8,del(11)(q23)[18];PB_BLAST_PERCENTAGE:17;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:10;CEBPA_MUTATION:Negative;CURRENT_REGIMEN:NONE;LDH_LEVEL:283;MOST_RECENT_TREATMENT_TYPE:NONE;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Missing MLL signal;DIAGNOSIS_AT_INCLUSION:Myelodysplastic/Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Atypical chronic myeloid leukaemia, BCR-ABL1 negative;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Atypical chronic myeloid leukaemia, BCR-ABL1 negative;SURFACE_ANTIGENS:CD13, CD33, CD34, CD38, CD58, CD117, CD123, and partial HLA-DR"
"CHRONIC_MYELOID_LEUKAEMIA","CANCER_TYPE_DETAILED:Chronic Myelogenous Leukemia;CANCER_TYPE:Blood Cancer;ONCOTREE_CODE:CML;TMB_NONSYNONYMOUS:3.75754838976;SEX:Male;FRACTION_GENOME_ALTERED:0.1164;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Cml;HISTOLOGICAL_SUBTYPE:Blast_Phase_Chronic_Myeloid_Leukaemia;HISTOLOGICAL_TYPE:Haematopoietic Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"CLASSICAL HCA","CANCER_TYPE_DETAILED:Hepatocellular Adenoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:LIAD;TMB_NONSYNONYMOUS:0.566666666667;SEX:Male;AGE:35;BMI:<= 25;ISHAK_FIBROSIS_SCORE:F0-F1;PATHOLOGICAL_DIAGNOSIS:Classical HCA;KNOWN_MOLECULAR_CLASSIFIER:bIHCA;NODULE_NUMBER:1;NODULE_SIZE:60;ORAL_CONTRACEPTION:No"
"CLEAR CELL PAPILLARY RENAL CELL CARCINOMA","CANCER_TYPE_DETAILED:Clear Cell Papillary Renal Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:CCPRC;SEX:Male;AGE:49.60438156;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:No;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:Yes;ANTIMETABOLITE_TX:Yes;CARBOPLATIN_TX:No;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:No;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:Yes;TAXANE_TX:No;TERT_ALKYLATING_TX:No treatment;TERT_ANTHRACYCLINE_TX:3rd tertile;TERT_ANTIMETABOLITE_TX:2nd tertile;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:2nd tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:No treatment;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:1st tertile;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:3rd tertile;TIME_FROM_DX_TO_SEQ:142;TIME_TO_BLOOD_DRAW_FROM_TX:114;TOPO_I_TX:No;TOPO_II_TX:Yes;XRT_TX:No"
"CML","CANCER_TYPE_DETAILED:Atypical Chronic Myeloid Leukemia, BCR-ABL1-;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:ACML;TMB_NONSYNONYMOUS:0.766666667;SOMATIC_STATUS:Matched;SEX:Female;OS_STATUS:0:LIVING;ETHNICITY:HispNative;PLATFORM:WES;AGE_AT_DIAGNOSIS:47.0;CHEMOTHERAPY:No;DIAGNOSIS:Myelodysplastic/Myeloproliferative Neoplasms;WBC:31.85;AGE_AT_PROCUREMENT:47;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:1;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:NONE;FUSION:None;GROUP:Residual Disease;KARYOTYPE:47,XX,+8,del(11)(q23)[18];PB_BLAST_PERCENTAGE:17;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:10;CEBPA_MUTATION:Negative;CURRENT_REGIMEN:NONE;LDH_LEVEL:283;MOST_RECENT_TREATMENT_TYPE:NONE;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Missing MLL signal;DIAGNOSIS_AT_INCLUSION:Myelodysplastic/Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Atypical chronic myeloid leukaemia, BCR-ABL1 negative;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Atypical chronic myeloid leukaemia, BCR-ABL1 negative;SURFACE_ANTIGENS:CD13, CD33, CD34, CD38, CD58, CD117, CD123, and partial HLA-DR"
"CNS","CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLL;SOMATIC_STATUS:Matched;SEX:Female;AGE:8.0;FRACTION_GENOME_ALTERED:0.1200;OS_MONTHS:114.0;OS_STATUS:1:DECEASED;RACE:White;ETHNICITY:Not Hispanic or Latino;MOLECULAR_SUBTYPE:ETV6-RUNX1;ANALYSIS_COHORT:DISCOVERY;PROTOCOL:AALL0232;WBC:117.0;OS_DAYS:3464.0;AGE_IN_DAYS:2872.0;DAYS_TO_EVENT:1764.0;FIRST_EVENT:Relapse;CNS_SITE_OF_RELAPSE:No;CNS_STATUS:CNS 1;KARYOTYPE:46,XX,t(1;17)(q42;q25),-2,add(16)(q22),+r[3]/46,XX[27];BONE_MARROW_SITE_OF_RELAPSE:Yes;DNA_INDEX:1;MLL_STATUS:Negative;OTHER_SITE_OF_RELAPSE:No;BCR_ABL1_STATUS:Negative;BM_DAY_29:1.0;BM_DAY_8:1.0;CELL_OF_ORIGIN:B-Precursor;CONGENITAL_ABNORMALITY:No;ETV6_RUNX1_FUSION_STATUS:Positive;MRD_PERCENT_DAY_29:0.03;MRD_PERCENT_DAY_29_SENSITIVITY:0.01;TCF3_PBX1_STATUS:Negative;TESTES_SITE_OF_RELAPSE:No;TRISOMY_4_10:Negative"
"CNS CANCER","CANCER_TYPE_DETAILED:Ependymomal Tumor;CANCER_TYPE:CNS Cancer;ONCOTREE_CODE:EPMT;SEX:Male;AGE:1;OS_MONTHS:16;OS_STATUS:0:LIVING;RACE:Other/Unavailable/Not Reported;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:5;TUMOR_TISSUE_SITE:Cerebellum/Posterior Fossa;TUMOR_TYPE:Progression;TREATMENT:Modified Treatment;CHEMOTHERAPY:Yes;SURGERY:No;TREATMENT_STATUS:Post-treatment;BRAF_STATUS:RELA Wild Type;AGE_AT_INITIAL_DIAGNOSIS:616;AGE_CLASS:[0,5);AGE_AT_CHEMOTHERAPY_START:1076;AGE_AT_LAST_KNOWN_CLINICAL_STATUS:1104;AGE_AT_SPECIMEN_DIAGNOSIS:797;BRAF_RELA_STATUS:RELA Wild Type;CANCER_PREDISPOSITIONS:Not Reported;CHEMOTHERAPY_AGENTS:Temozolomide;CHEMOTHERAPY_TYPE:Treatment follows other standard of care not associated with a current or past protocol;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;CTNNB1_STATUS:CTNNB1 WT;EPENDYMOMA_RELA_STATUS:RELA Wild Type;FORMULATION:Not Reported;H3F3A_CTNNB1_STATUS:CTNNB1 WT;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Ependymoma;INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Focal neurological deficit (cranial nerve palsies, motor deficits, sensory deficits),Other medical conditions NOS,Seizure disorder;MULTIPLE_MEDICAL_CONDITIONS:Yes;MULTIPLE_TUMOR_LOCATIONS:No;PROTOCOL_AND_TREATMENT_ARM:Not Reported;RADIATION:No;SAMPLE_ANNOTATION:Post-treatment;TIMING_OTHER_NOTES:Not Reported;TREATMENT_CHANGED:12 Month Update;TUMOR_LOCATION_CONDENSED:Posterior Fossa;UPDATED_GRADE:III"
"COAD","CANCER_TYPE_DETAILED:Colorectal Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COADREAD;TMB_NONSYNONYMOUS:4.53116129354;SEX:Male;FRACTION_GENOME_ALTERED:0.4099;PRIMARY_SITE:Large Intestine;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Colorectal;HISTOLOGICAL_SUBTYPE:Adenocarcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"COAD_GS","CANCER_TYPE_DETAILED:Colon Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COAD;TMB_NONSYNONYMOUS:2.066666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:80;FRACTION_GENOME_ALTERED:0.0607;SAMPLE_TYPE:Primary;OS_MONTHS:22.09290857;OS_STATUS:0:LIVING;RACE:Black or African American;ETHNICITY:Not Hispanic Or Latino;TISSUE_SOURCE_SITE:Indivumed;ICD_O_3_SITE:C18.2;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:Yes;ICD_10:C18.2;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:8/31/11;PFS_MONTHS:6.016372423;AJCC_STAGING_EDITION:7TH;PFS_STATUS:1:PROGRESSION;TUMOR_TISSUE_SITE:Colon;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE IIIC;SUBTYPE:COAD_GS;TUMOR_TYPE:Colon Adenocarcinoma;PATH_T_STAGE:T4A;RADIATION_THERAPY:No;DAYS_LAST_FOLLOWUP:672;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-29426;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:COAD;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.4019;PATH_N_STAGE:N2A;TISSUE_SOURCE_SITE_CODE:A6;DSS_MONTHS:22.09290857;PERSON_NEOPLASM_CANCER_STATUS:With Tumor;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:Yes;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:No;WEIGHT:70.3;PATH_M_STAGE:MX;BUFFA_HYPOXIA_SCORE:31;RAGNUM_HYPOXIA_SCORE:26;WINTER_HYPOXIA_SCORE:26;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"COLON ADENOCARCINOMA IN SITU","CANCER_TYPE_DETAILED:Colon Adenocarcinoma In Situ;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:CAIS;SEX:Male;FRACTION_GENOME_ALTERED:0.1791;SAMPLE_TYPE:Primary;PRIMARY_SITE:Rectum;TUMOR_PURITY:50;MSI_SCORE:0.13;MSI_TYPE:Stable;SAMPLE_COVERAGE:464;AGE_AT_DIAGNOSIS:51;STAGE_AT_DIAGNOSIS:Early stage (1-2);CVR_TMB_SCORE:12.3;TUMOR_LOCATION:Distal;WGD:FALSE;GROUP:Indeterminate-Indeterminate;SURVIVAL_STATUS:Alive;DRIVER1_CLONAL_CALL:Indeterminate;DRIVER1_MUTATION:KRAS p.G13D;DRIVER2_CLONAL_CALL:Indeterminate;DRIVER2_MUTATION:KRAS p.G12A;GENOMIC_QC:PASS;HIGHEST_LEVEL_ONCOKB:LEVEL_4;METASTATIC:Yes;METASTATIC_AT_DX:No"
"COLORECTAL HYPERMUTATED","CANCER_TYPE_DETAILED:Colon Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COAD;TMB_NONSYNONYMOUS:54.3486097293;SEX:Female;FRACTION_GENOME_ALTERED:0.1389;SAMPLE_TYPE:Primary;OS_MONTHS:31.15;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Cecum;GENE_PANEL:IMPACT341;TUMOR_PURITY:40;SUBTYPE:Colorectal Hypermutated;MSI_SCORE:45.94;MSI_TYPE:Instable;SAMPLE_COVERAGE:453;AGE_AT_SURGERY:74.95;FGA:0.139;AGE_AT_SEQUENCING:75.11;ORGAN_SYSTEM:Core GI;AGE_AT_DEATH:77.71;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:No;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:No;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:CRC HM"
"CONGENITAL FIBROSARCOMA","CANCER_TYPE_DETAILED:Congenital Fibrosarcoma;CANCER_TYPE:Fibrosarcoma;ONCOTREE_CODE:FIBS;TMB_NONSYNONYMOUS:0;SEX:Male;OS_MONTHS:57;OS_STATUS:0:LIVING;PRIMARY_SITE:Forearm;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:FFPE;AGE_AT_DIAGNOSIS:1;SAMPLE_TIMEPOINT:Metastatic;TISSUE_SEQUENCED:Lung;NGS_TEST:RNA-seq;AGE_TESTING_YEARS:2.0;DIAGNOSTIC_CATEGORY:Sarcoma;GMED_OS_MONTHS:48;SAMPLE_TESTED_CATEGORY:Primary disease"
"CRC HM","CANCER_TYPE_DETAILED:Colon Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:COAD;TMB_NONSYNONYMOUS:54.3486097293;SEX:Female;FRACTION_GENOME_ALTERED:0.1389;SAMPLE_TYPE:Primary;OS_MONTHS:31.15;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Cecum;GENE_PANEL:IMPACT341;TUMOR_PURITY:40;SUBTYPE:Colorectal Hypermutated;MSI_SCORE:45.94;MSI_TYPE:Instable;SAMPLE_COVERAGE:453;AGE_AT_SURGERY:74.95;FGA:0.139;AGE_AT_SEQUENCING:75.11;ORGAN_SYSTEM:Core GI;AGE_AT_DEATH:77.71;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:No;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:No;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:CRC HM"
"CSCC","CANCER_TYPE_DETAILED:Cutaneous Squamous Cell Carcinoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:CSCC;TMB_NONSYNONYMOUS:9.43333333333;SUBTYPE:Squamous Cell Carcinoma;LINEAGE:epidermoid_carcinoma;LINEAGE_SUBTYPE:skin_squamous"
"CUTANEOUS MALIGNANCY OF HAIR MATRIX CELLS","CANCER_TYPE_DETAILED:Pilomatrix carcinoma;CANCER_TYPE:Cutaneous malignancy of hair matrix cells;ONCOTREE_CODE:CUP;TMB_NONSYNONYMOUS:0.933333333333;SEX:Male;OS_MONTHS:13;OS_STATUS:1:DECEASED;PRIMARY_SITE:Scalp;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:Fresh frozen;AGE_AT_DIAGNOSIS:14;SAMPLE_TIMEPOINT:Diagnostic;TISSUE_SEQUENCED:Scalp;NGS_TEST:Tumor-normal  WES; RNA-seq;AGE_TESTING_YEARS:14.0;DIAGNOSTIC_CATEGORY:Other- Solid Tumor;GMED_OS_MONTHS:13;SAMPLE_TESTED_CATEGORY:Primary disease"
"DEDIFFERENTIATED","CANCER_TYPE_DETAILED:Chondrosarcoma;CANCER_TYPE:Bone Cancer;ONCOTREE_CODE:CHS;TMB_NONSYNONYMOUS:4.64167742265;SEX:Male;FRACTION_GENOME_ALTERED:0.6024;PRIMARY_SITE:Bone;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Chondrosarcoma;HISTOLOGICAL_SUBTYPE:Dedifferentiated;HISTOLOGICAL_TYPE:Chondrosarcoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"DERMATOFIBROMA","CANCER_TYPE_DETAILED:Dermatofibroma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:DF;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0007;SAMPLE_TYPE:Primary;OS_MONTHS:23.5;OS_STATUS:0:LIVING;PRIMARY_SITE:Skin;SAMPLE_CLASS:Tumor;TUMOR_PURITY:30;SAMPLE_COVERAGE:697;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Unknown;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"DUCTAL/NST","CANCER_TYPE_DETAILED:Breast Invasive Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:0;SEX:Female;SAMPLE_TYPE:Primary;OS_MONTHS:140.5;OS_STATUS:0:LIVING;GRADE:3;VITAL_STATUS:Living;HISTOLOGICAL_SUBTYPE:Ductal/NST;AGE_AT_DIAGNOSIS:75.65;COHORT:1;TUMOR_STAGE:2;TUMOR_SIZE:22;LATERALITY:Right;ER_STATUS:Positive;CHEMOTHERAPY:NO;HER2_STATUS:Negative;PR_STATUS:Negative;RFS_STATUS:0:Not Recurred;LYMPH_NODES_EXAMINED_POSITIVE:10;RFS_MONTHS:138.65;BREAST_SURGERY:MASTECTOMY;CLAUDIN_SUBTYPE:claudin-low;ER_IHC:Positve;HER2_SNP6:NEUTRAL;HORMONE_THERAPY:YES;INFERRED_MENOPAUSAL_STATE:Post;INTCLUST:4ER+;NPI:6.044;RADIO_THERAPY:YES;THREEGENE:ER-/HER2-"
"EARLY T-CELL PRECURSOR LYMPHOBLASTIC LEUKEMIA","CANCER_TYPE_DETAILED:Early T-Cell Precursor Lymphoblastic Leukemia;CANCER_TYPE:T-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:ETPLL;TMB_NONSYNONYMOUS:4.53333333333;SEX:Male;AGE:16;FRACTION_GENOME_ALTERED:0.0691;NOTE:Lock;SAMPLE_SITE:Unknown;HISTOPATHOLOGY:Not noted;CANCER_SUBTYPE_CURATED:ETP-ALL;EXPRESSION:NO;INFERRED_ETHNICITY:European;PHASE:Diagnosis;REPORTED_ETHNICITY:Unknown;SITE_OF_SPECIMEN:Bone marrow"
"EMBRYONAL TUMOR WITH ABUNDANT NEUROPIL AND TRUE ROSETTES","CANCER_TYPE_DETAILED:Embryonal Tumor with Abundant Neuropil and True Rosettes;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:ETANTR;TMB_NONSYNONYMOUS:5.36666666667;SEX:Male;AGE:3;FRACTION_GENOME_ALTERED:0.1085;NOTE:Li, XN;SAMPLE_SITE:Brain stem;HISTOPATHOLOGY:sPNET, GFAP+, SYN+,P53+,Ki67+, Myc-, PTEN loss, C19MC amplification by genetics, ETMR by genetics;CANCER_SUBTYPE_CURATED:ETMR;EXPRESSION:NO;INFERRED_ETHNICITY:SouthAsianOrHispanic;PHASE:Diagnosis;REPORTED_ETHNICITY:Hispanic or Latino;SITE_OF_SPECIMEN:Brain stem"
"EMBT","CANCER_TYPE_DETAILED:Embryonal Tumor;CANCER_TYPE:Embryonal Tumor;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Female;AGE:2;SAMPLE_TYPE:Primary;SEQUENCING_TYPE:WGS;ONCOTREE_CODE_CANCER_TYPE:EMBT;TUMOR_DETAILS:Embryonal tumor with multilayered rosettes"
"ENDOCERVICAL ADENOCARCINOMA OF THE USUAL TYPE","CANCER_TYPE_DETAILED:Endocervical Adenocarcinoma;CANCER_TYPE:Cervical Cancer;ONCOTREE_CODE:ECAD;TMB_NONSYNONYMOUS:1.4;SOMATIC_STATUS:Matched;SEX:Female;AGE:37;FRACTION_GENOME_ALTERED:0.0954;SAMPLE_TYPE:Primary;OS_MONTHS:44.19;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:44.19;TISSUE_SOURCE_SITE:C5;ICD_O_3_SITE:C53.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C53.9;ICD_O_3_HISTOLOGY:8380/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:1/3/14;GRADE:G1;AJCC_STAGING_EDITION:1995;HISTOLOGICAL_DIAGNOSIS:Endocervical Adenocarcinoma of the Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2005;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:2199;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-C5-A2LS.0D3F75AE-DFF5-47DB-A875-78D35DE393E0.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:220;SMOKING_PACK_YEARS:11;WEIGHT:92;SITE_OF_TUMOR_TISSUE:Cervical;PHARMACEUTICAL_TX_ADJUVANT:NO;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T1b2;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:2;HEIGHT:173;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Biopsy (cervical / CT-guided / Other);SMOKING_YEAR_STARTED:17;TARGETED_MOLECULAR_THERAPY:NO;CLINICAL_STAGE:Stage IB2;HYSTERECTOMY_TYPE:Radical Hysterectomy;MARGINS_INVOLVED_HYSTERECTOMY:Other Location, specify;OTHER_INVOLVED_MARGINS:margins free of tumor;PREGNANT_AT_DIAGNOSIS:NO"
"EPENDYMOBLASTOMA","CANCER_TYPE_DETAILED:Embryonal Tumor;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:EMBT;TMB_NONSYNONYMOUS:4.26666666667;SEX:Female;AGE:2.17;FRACTION_GENOME_ALTERED:0.0001;NOTE:Li, XN;SAMPLE_SITE:Cerebrum;HISTOPATHOLOGY:Not noted;CANCER_SUBTYPE_CURATED:Ependymoblastoma;EXPRESSION:NO;INFERRED_ETHNICITY:SouthAsianOrHispanic;PHASE:Diagnosis;REPORTED_ETHNICITY:Hispanic or Latino;SITE_OF_SPECIMEN:Cerebrum"
"EPITHELIOID CELL TUMOR","CANCER_TYPE_DETAILED:Perivascular Epithelioid Cell Tumor;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:PECOMA;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Female;AGE:49;FRACTION_GENOME_ALTERED:0.0043;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Unknown;ANALYSIS_COHORT:MISC;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:4"
"ESCA","CANCER_TYPE_DETAILED:Esophageal Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:ESCA;TMB_NONSYNONYMOUS:4.53116129354;SEX:Female;FRACTION_GENOME_ALTERED:0.7452;PRIMARY_SITE:Oesophagus;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Esophagus;HISTOLOGICAL_SUBTYPE:Squamous_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"ESCA_GS","CANCER_TYPE_DETAILED:Esophageal Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:ESCA;TMB_NONSYNONYMOUS:2.4;SOMATIC_STATUS:Matched;SEX:Male;AGE:63;FRACTION_GENOME_ALTERED:0.2507;SAMPLE_TYPE:Primary;OS_MONTHS:26.33395798;OS_STATUS:1:DECEASED;RACE:White;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:26.33395798;TISSUE_SOURCE_SITE:University of Michigan;ICD_O_3_SITE:C15.5;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C15.5;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:2/12/13;GRADE:G3;PFS_MONTHS:26.33395798;AJCC_STAGING_EDITION:7TH;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Esophagus;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE IIB;SUBTYPE:ESCA_GS;TUMOR_TYPE:Esophagus Adenocarcinoma (NOS);PATH_T_STAGE:T1;RADIATION_THERAPY:No;DAYS_LAST_FOLLOWUP:112;DAYS_TO_BIRTH:-23194;MSI_SENSOR_SCORE:0.09;CANCER_TYPE_ACRONYM:ESCA;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3264;PATH_N_STAGE:N1;TISSUE_SOURCE_SITE_CODE:L5;DSS_MONTHS:26.33395798;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;WEIGHT:193;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"ESOPHAGUS/STOMACH","CANCER_TYPE_DETAILED:Esophagus/Stomach;CANCER_TYPE:Esophageal/Stomach Cancer, NOS;ONCOTREE_CODE:STOMACH;TMB_NONSYNONYMOUS:8.4;SUBTYPE:Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma;LINEAGE:lung;LINEAGE_SUB_SUBTYPE:NSCLC_squamous;LINEAGE_SUBTYPE:NSCLC;TYPE_REFINED:lung_NSC"
"ETMR","CANCER_TYPE_DETAILED:Embryonal Tumor with Abundant Neuropil and True Rosettes;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:ETANTR;TMB_NONSYNONYMOUS:5.36666666667;SEX:Male;AGE:3;FRACTION_GENOME_ALTERED:0.1085;NOTE:Li, XN;SAMPLE_SITE:Brain stem;HISTOPATHOLOGY:sPNET, GFAP+, SYN+,P53+,Ki67+, Myc-, PTEN loss, C19MC amplification by genetics, ETMR by genetics;CANCER_SUBTYPE_CURATED:ETMR;EXPRESSION:NO;INFERRED_ETHNICITY:SouthAsianOrHispanic;PHASE:Diagnosis;REPORTED_ETHNICITY:Hispanic or Latino;SITE_OF_SPECIMEN:Brain stem"
"ETP-ALL","CANCER_TYPE_DETAILED:Early T-Cell Precursor Lymphoblastic Leukemia;CANCER_TYPE:T-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:ETPLL;TMB_NONSYNONYMOUS:4.53333333333;SEX:Male;AGE:16;FRACTION_GENOME_ALTERED:0.0691;NOTE:Lock;SAMPLE_SITE:Unknown;HISTOPATHOLOGY:Not noted;CANCER_SUBTYPE_CURATED:ETP-ALL;EXPRESSION:NO;INFERRED_ETHNICITY:European;PHASE:Diagnosis;REPORTED_ETHNICITY:Unknown;SITE_OF_SPECIMEN:Bone marrow"
"EWING-LIKE SARCOMA","CANCER_TYPE_DETAILED:Ewing-like sarcoma;CANCER_TYPE:Sarcoma;SEX:Female;AGE:13.35523605;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Treated;ALKYLATING_TX:Yes;ALL_TX_AT_MSK:Yes;ANTHRACYCLINE_TX:Yes;ANTIMETABOLITE_TX:No;CARBOPLATIN_TX:No;CHEMO_TX:Yes;CISPLATIN_TX:No;CYTOTOXIC_TX:Yes;EQD_TERTILES:No radiation;IO_TX:No;MICROTUBULE_TX:Yes;OTHER_CYTOTOXIC_TX:No;OXALIPLATIN_TX:No;PLATINUM_TX:No;RADIOTHERAPY_TX:No;TARGETED_TX:No;TAXANE_TX:No;TERT_ALKYLATING_TX:3rd tertile;TERT_ANTHRACYCLINE_TX:2nd tertile;TERT_ANTIMETABOLITE_TX:No treatment;TERT_CARBOLATIN_TX:No treatment;TERT_CISPLATIN_TX:No treatment;TERT_CYTOTOXIC_TX:3rd tertile;TERT_IO_TX:No treatment;TERT_MICROTUBULE_TX:2nd tertile;TERT_OTHER_CYTOTOXIC_TX:No treatment;TERT_OXALIPLATIN_TX:No treatment;TERT_PLATINUM_TX:No treatment;TERT_TARGETED_TX:No treatment;TERT_TAXANE_TX:No treatment;TERT_TOPO_I_INH_TX:No treatment;TERT_TOPO_II_INH_TX:2nd tertile;TIME_FROM_DX_TO_SEQ:43;TIME_TO_BLOOD_DRAW_FROM_TX:20;TOPO_I_TX:No;TOPO_II_TX:Yes;XRT_TX:No"
"EXTRA-ADRENAL PHEOCHROMOCYTOMA","CANCER_TYPE_DETAILED:Paraganglioma;CANCER_TYPE:Miscellaneous Neuroepithelial Tumor;ONCOTREE_CODE:PGNG;TMB_NONSYNONYMOUS:0.4;SOMATIC_STATUS:Matched;SEX:Male;AGE:53;FRACTION_GENOME_ALTERED:0.0679;SAMPLE_TYPE:Primary;OS_MONTHS:9.205378571;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;TISSUE_SOURCE_SITE:QR;ICD_O_3_SITE:C49.3;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C49.3;ICD_O_3_HISTOLOGY:8680/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2/21/14;HISTOLOGICAL_DIAGNOSIS:Paraganglioma; Extra-adrenal Pheochromocytoma;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;DAYS_LAST_FOLLOWUP:280;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:155;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-QR-A6H0.25844561-A084-4F60-ACAF-69C5DD2A1525.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:30;TUMOR_SITE:Extra-adrenal Site;PHARMACEUTICAL_TX_ADJUVANT:NO;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;PRIMARY_SITE_OTHER:paraspinal;CT_SCAN_PREOP_RESULTS:YES;DISEASE_DETECTED_ON_SCREENING:YES;HISTORY_PHEO_OR_PARA_ANATOMIC_SITE:Mediastinal PGL;HISTORY_PHEO_OR_PARA_INCLUDE_BENIGN:YES"
"EXTRAHEPATIC CHOLANGIOCARCINOMA","CANCER_TYPE_DETAILED:Extrahepatic Cholangiocarcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:EHCH;TMB_NONSYNONYMOUS:3.2;SOMATIC_STATUS:Matched;SEX:Female;AGE:70;FRACTION_GENOME_ALTERED:0.2422;SAMPLE_TYPE:Primary;OS_MONTHS:12.09;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:12.09;TISSUE_SOURCE_SITE:3X;ICD_O_3_SITE:C24.0;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C24.0;ICD_O_3_HISTOLOGY:8160/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:7/9/14;GRADE:G1;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IVB;HISTOLOGICAL_DIAGNOSIS:Cholangiocarcinoma; distal;HISTORY_OTHER_MALIGNANCY:No;PROSPECTIVE_COLLECTION:NO;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:386;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3X-AAVB.BEA4C577-73ED-48F0-9417-AA8BD143B5C8.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:420;WEIGHT:76;TUMOR_SITE:Bile duct;AJCC_METASTASIS_PATHOLOGIC_PM:M1;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T3;ECOG_SCORE:0;HEIGHT:170;PERINEURAL_INVASION:YES;VASCULAR_INVASION:None;FAMILY_HISTORY_OF_CANCER:NO;CREATININE_LEVEL_PRERESECTION:0.9;CREATININE_NORM_RANGE_LOWER:0.4;CREATININE_NORM_RANGE_UPPER:1.1;YEAR_OF_INITIAL_PATHOLOGIC_DIAGNOSIS:2012;BILIRUBIN_TOTAL:1.7;BILIRUBIN_TOTAL_NORM_RANGE_LOWER:0;BILIRUBIN_TOTAL_NORM_RANGE_UPPER:1.2;CHILD_PUGH_CLASSIFICATION:A;DEFINITIVE_SURGICAL_PROCEDURE:Pancreaticoduodenectomy (Whipple Resection);HISTORY_HEPATO_CARCINOMA_RISK_FACTORS:No History of Primary Risk Factors;PLATELET_NORM_RANGE_LOWER:150;PLATELET_NORM_RANGE_UPPER:400;PROTHROM_TIME_INR_NORM_RANGE_LOWER:0.9;PROTHROMBIN_TIME_INR_AT_PROCUREMENT:1.1;PROTHROMBIN_TIME_NORM_RANGE_UPPER:1.1;SERUM_ALBUMIN_NORM_RANGE_LOWER:3.3;SERUM_ALBUMIN_NORM_RANGE_UPPER:4.8;SERUM_ALBUMIN_PRERESECTION:4.3"
"FOLLICULAR, PAPILLARY","CANCER_TYPE_DETAILED:Poorly Differentiated Thyroid Carcinoma;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPD;TMB_NONSYNONYMOUS:0.0666666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:64;FRACTION_GENOME_ALTERED:0.0025;SAMPLE_TYPE:Primary;OS_MONTHS:75.82;OS_STATUS:0:LIVING;SAMPLE_CLASS:Tumor;METASTATIC_SITE:No;TUMOR_PURITY:0.9;PATH_T_STAGE:T3/T4;PATH_N_STAGE:Nx/N0;SPECIMEN_PRESERVATION_TYPE:FFPE;M_STAGE:M0;CYTOLOGICAL_PHENOTYPE:follicular, papillary;GROWTH_PATTERN:solid;PDTC_DEFINITION:PDTC-Turin"
"GINET","CANCER_TYPE_DETAILED:Gastrointestinal Neuroendocrine Tumors;CANCER_TYPE:Gastrointestinal Neuroendocrine Tumor;ONCOTREE_CODE:GINET;TMB_NONSYNONYMOUS:2.796842924;SOMATIC_STATUS:Matched;SEX:Male;SAMPLE_TYPE:Metastasis;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Rectum;GENE_PANEL:ACCESS129;SAMPLE_CLASS:cfDNA;METASTATIC_SITE:Liver;MSI_SCORE:-1;SAMPLE_COVERAGE:1555;INSTITUTE:MSKCC;RELIGION:NONE;AGE_CURRENT:58;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:NO;PARTA_CONSENTED_12_245:NO"
"GLIOBLASTOMA, IDH-MUTANT","CANCER_TYPE_DETAILED:Glioblastoma;CANCER_TYPE:Glioma;ONCOTREE_CODE:GB;TMB_NONSYNONYMOUS:1.4;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.3091;SAMPLE_TYPE:Tumor Primary;OS_MONTHS:11;OS_STATUS:1:DECEASED;GENE_PANEL:WXS;SAMPLE_CLASS:Tumor;GRADE:IV;HISTOLOGY:Glioblastoma;TUMOR_LOCATION:Frontal lobe;TYPE_OF_SURGERY:Craniotomy;AGE_AT_DX:34;EXTENT_OF_RESECTION:Total;TUMOR_LATERALITY:Right;1P19Q_STATUS:noncodel;ALIQUOT_BARCODE:GLSS-19-0279-TP-01D-WXS-GQ9A87;ALKYLATING_AGENT:Yes;CASE_PROJECT:GLSS;CHEMO_OTHER:0;CONCURRENT_TMZ:Yes;HYPERMUTATION_STATUS:Yes;INITIAL_GRADE:IV;INITIAL_HISTOLOGY:Glioblastoma;POST_RECURRENCE_SURVIVAL_MONTHS:2;RADIATION_DOSE:60;RADIATION_OTHER:IMRT;RADIOTHERAPY:Yes;RADIOTHERAPY_FRACTIONS:30;SURGERY NUMBER:1;TIME_TO_FIRST_RECURRENCE:9;TISSUE_SOURCE:Case Western  Reserve University;TMZ_CYCLES:4;TMZ_TREATMENT:Yes;WHO_CLASSIFICATION:Glioblastoma, IDH-mutant;WHOLE_EXOME_SEQUENCED:Yes;WHOLE_GENOME_SEQUENCED:No"
"GLIONEURONAL TUMOR","CANCER_TYPE_DETAILED:Rosette-forming Glioneuronal Tumor of the Fourth Ventricle;CANCER_TYPE:CNS;SEX:Male;AGE:21.81519508;RACE:Black;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:37"
"GLOMANGIOSARCOMA","CANCER_TYPE_DETAILED:Glomangiosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;SEX:Male;FRACTION_GENOME_ALTERED:0.1513;SAMPLE_TYPE:Primary;OS_MONTHS:41.688;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Unknown;GENE_PANEL:IMPACT410;TUMOR_PURITY:90;MSI_SCORE:0.56;MSI_TYPE:Stable;SAMPLE_COVERAGE:639;PURITY:0.969139834;AGE_AT_SEQ_REPORT:48;DETAILED_PRIMARY_SITE:Femoral Tendon;FACETS:YES;FRACTION_CNA:0.210271238;FACETS_REVIEW:YES;FACETS_WGD:FALSE;FGA_REPORTED:0.1513"
"HEAD & NECK SQUAMOUS CELL CARCINOMA BASALOID TYPE","CANCER_TYPE_DETAILED:Head and Neck Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:HNSC;TMB_NONSYNONYMOUS:2.13333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.2801;SAMPLE_TYPE:Primary;OS_MONTHS:22.01;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:22.01;TISSUE_SOURCE_SITE:HD;ICD_O_3_SITE:C01.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C01;ICD_O_3_HISTOLOGY:8083/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:8/9/12;GRADE:G4;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;HISTOLOGICAL_DIAGNOSIS:Head & Neck Squamous Cell Carcinoma Basaloid Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2012;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;PATHOLOGY_REPORT_FILE_NAME:TCGA-HD-8314.b9c245ac-7857-4cae-9e8b-6a4f189f3604.pdf;VIAL_NUMBER:A;SITE_OF_TUMOR_TISSUE:Head and Neck;PHARMACEUTICAL_TX_ADJUVANT:NO;AJCC_NODES_PATHOLOGIC_PN:N1;AJCC_TUMOR_PATHOLOGIC_PT:T1;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:1;SPECIMEN_SECOND_LONGEST_DIMENSION:0.6;LATERALITY:Left;LONGEST_DIMENSION:1;SHORTEST_DIMENSION:0.5;PRIMARY_SITE_PATIENT:Base of tongue;CLINICAL_STAGE:Stage III;CLIN_M_STAGE:M0;CLIN_T_STAGE:T1;PERINEURAL_INVASION:NO;ANGIOLYMPHATIC_INVASION:YES;CLIN_N_STAGE:N1;PATH_MARGIN:Close;ALCOHOL_HISTORY_DOCUMENTED:NO;HPV_STATUS_P16:Positive;LYMPH_NODE_DISSECTION_METHOD:Modified Radical Neck Dissection;LYMPH_NODE_NECK_DISSECTION_INDICATOR:YES"
"HEAD AND NECK CARCINOMA OTHER","CANCER_TYPE_DETAILED:Head and Neck Carcinoma Other;CANCER_TYPE:Head and Neck Carcinoma;TMB_NONSYNONYMOUS:0.0333333333333;SEX:Male;SAMPLE_TYPE:Metastasis;AJCC_PATHOLOGIC_TUMOR_STAGE:IV;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Unknown;SPECIMEN_TYPE:Biopsy/Paracentesis;COVERAGE_MEAN:1043;DIAGNOSIS AGE:19;GDNA(NG):3594;SMOKE STATUS:Nonsmoker;TUMOR_PURTITY:30"
"HEAD AND NECK CARCINOMA, OTHER","CANCER_TYPE_DETAILED:Head and Neck Carcinoma, Other;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:OHNCA;TMB_NONSYNONYMOUS:12.8;SUBTYPE:Carcinoma, gingival;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:gingival;LINEAGE_SUBTYPE:upper_aerodigestive_carcinoma;TYPE_REFINED:upper_aerodigestive"
"HEAD AND NECK SQUAMOUS CELL CARCINOMA OF UNKNOWN PRIMARY","CANCER_TYPE_DETAILED:Head and Neck Squamous Cell Carcinoma of Unknown Primary;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:HNSCUP;TMB_NONSYNONYMOUS:11.7446363714;SOMATIC_STATUS:Matched;SEX:Female;AGE:48.0;FRACTION_GENOME_ALTERED:0.4034;SAMPLE_TYPE:Metastasis;OS_MONTHS:28.0;OS_STATUS:1:DECEASED;RACE:White;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:7.1;PRIMARY_SITE:Unknown;GENE_PANEL:IMPACT341;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Lymph Node;TUMOR_PURITY:30;SAMPLE_COVERAGE:890;VITAL_STATUS:DOD;SMOKING_HISTORY:Current;PARTC_CONSENTED_12_245:NO;HPV_STATUS:Positive;ALCOHOL_HISTORY_DOCUMENTED:Never;SITE_OF_RECURRENCE:Distant, Regional (lymph nodes and neck skin), Distant;AGENT:BKM120 + Carboplatin + Paclitaxel;DISEASE_EXTENT:Locoregional & Distant;DISTANT_METASTASIS_PATHOLOGIC_SPREAD:yes;DISTANT_METS:Yes;SMOKING:Smoking Pack:35;TNM:TxN2cMX;CLINICAL_TRIAL:10-192;DETAILED_METASTATIC_SITE:Lymph Node;DETAILED_PRIMARY_SITE:Unknown Primary;INITIAL_TREATMENT:Chemoradiation;SITE_SEQUENCED:Regional recurrence;PRIOR_TX_TO_IMPACT_SAMPLE:RT, Chemo, & Cetuximab;TOBACCO_TYPE:Cigarettes;VAR_12_245:Clinical"
"HEMANGIOPERICYTOMA OF THE CENTRAL NERVOUS SYSTEM","CANCER_TYPE_DETAILED:Hemangiopericytoma of the Central Nervous System;CANCER_TYPE:CNS Cancer;ONCOTREE_CODE:HPCCNS;TMB_NONSYNONYMOUS:1.109155301;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0012;SAMPLE_TYPE:Primary;OS_MONTHS:23.73;OS_STATUS:1:DECEASED;PRIMARY_SITE:Brain;SAMPLE_CLASS:Tumor;TUMOR_PURITY:60;SAMPLE_COVERAGE:756;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:165.6"
"HEPATOBILIARY CANCER","CANCER_TYPE_DETAILED:Intrahepatic Cholangiocarcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:IHCH;TMB_NONSYNONYMOUS:2.866666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:50;FRACTION_GENOME_ALTERED:0.2021;SAMPLE_TYPE:Primary;OS_MONTHS:14.62;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:8.71;TISSUE_SOURCE_SITE:3X;ICD_O_3_SITE:C22.1;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C22.1;ICD_O_3_HISTOLOGY:8160/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/2/14;GRADE:G2;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;HISTOLOGICAL_DIAGNOSIS:Cholangiocarcinoma; intrahepatic;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:510;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3X-AAVA.4C9A220D-03E9-41CF-8FA9-4B7FD05A625A.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:480;WEIGHT:92;TUMOR_SITE:Bile duct;PHARMACEUTICAL_TX_ADJUVANT:NO;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:NX;AJCC_TUMOR_PATHOLOGIC_PT:T2b;ECOG_SCORE:1;PERINEURAL_INVASION:YES;VASCULAR_INVASION:None;AFP_AT_PROCUREMENT:5.4;FAMILY_HISTORY_OF_CANCER:NO;ISHAK_FIBROSIS_SCORE:1,2 - Portal Fibrosis;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO;CREATININE_LEVEL_PRERESECTION:0.5;CREATININE_NORM_RANGE_LOWER:0.4;CREATININE_NORM_RANGE_UPPER:1.1;YEAR_OF_INITIAL_PATHOLOGIC_DIAGNOSIS:2012;AFP_NORM_RANGE_LOWER:0;AFP_NORM_RANGE_UPPER:10;DEFINITIVE_SURGICAL_PROCEDURE:Segmentectomy, Single;HISTORY_HEPATO_CARCINOMA_RISK_FACTORS:Diabetes mellitus|Smoking;PLATELET_NORM_RANGE_LOWER:150;PLATELET_NORM_RANGE_UPPER:400"
"HGGNOS","CANCER_TYPE_DETAILED:High-Grade Glioma, NOS;CANCER_TYPE:Glioma;ONCOTREE_CODE:HGGNOS;TMB_NONSYNONYMOUS:9.4;FRACTION_GENOME_ALTERED:0.7080;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Central_Nervous_System;SUBTYPE:Glioma;TUMOR_TYPE:glioma;HISTOLOGY:Glioma;MUTATION_RATE:157.8096027;DOUBLING_TIME:63;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:Garraway Lab;CHARACTERISTICS:Mix;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:RPMI-1640+ 5% FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:central_nervous_system;LINEAGE_SUBTYPE:glioma;NAME:SF268;PATHOLOGIST_ANNOTATION:CNS:Glioma_HighGrade;SITE_SUBTYPE1:brain;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:glioma"
"HNSC","CANCER_TYPE_DETAILED:Head and Neck Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:HNSC;TMB_NONSYNONYMOUS:338.633333333;SEX:Male;FRACTION_GENOME_ALTERED:0.7090;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Upper_Aerodigestive_Tract;SUBTYPE:Squamous Cell Carcinoma;TUMOR_TYPE:upper_aerodigestive;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:212.3890798;GENOME_DOUBLINGS:1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ECACC;HIST_SUBTYPE1:squamous_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:upper_aerodigestive;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:BICR 18;PATHOLOGIST_ANNOTATION:Upper_Aerodigestive_Tract:Carcinoma;SITE_SUBTYPE1:larynx;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:upper_aerodigestive"
"HURTHLE","CANCER_TYPE_DETAILED:Hurthle Cell Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THHC;TMB_NONSYNONYMOUS:2.218310601;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.9979;SAMPLE_TYPE:Primary;OS_MONTHS:26.1;OS_STATUS:0:LIVING;PRIMARY_SITE:Thyroid;SAMPLE_CLASS:Tumor;TUMOR_PURITY:80;SAMPLE_COVERAGE:1064;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Prev/Curr Smoker;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"HYPOPHARYNGEAL","CANCER_TYPE_DETAILED:Hypopharynx Squamous Cell Carcinoma;CANCER_TYPE:Head and Neck Cancer;ONCOTREE_CODE:HPHSC;TMB_NONSYNONYMOUS:7.73333333333;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Upper_Aerodigestive_Tract;SUBTYPE:Squamous Cell Carcinoma, hypopharyngeal;TUMOR_TYPE:upper_aerodigestive;HISTOLOGY:Carcinoma;MUTATION_RATE:148.1733319;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:epithelial; monolayer;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:upper_aerodigestive;LINEAGE_SUB_SUBTYPE:hypopharyngeal;LINEAGE_SUBTYPE:upper_aerodigestive_squamous;NAME:SNU-1041;PATHOLOGIST_ANNOTATION:Upper_Aerodigestive_Tract:Carcinoma;SITE_SUBTYPE1:pharynx;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:upper_aerodigestive"
"IDC","CANCER_TYPE_DETAILED:Infiltrating Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:2.53333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:46;GRADE:III;SUBTYPE:HER2;STAGE:III;PURITY:0.27;ER_STATUS:Negative;PR_STATUS:Negative;MENOPAUSE_STATUS:Premenopausal;HER2_AMPLIFICATION_STATUS:Yes;SILENT_RATE:0.72;NONSILENT_RATE:2.62"
"INFANTILE SARCOMA","CANCER_TYPE_DETAILED:Infantile Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;SEX:Female;FRACTION_GENOME_ALTERED:0.0790;SAMPLE_TYPE:Metastasis;OS_MONTHS:6.378;OS_STATUS:0:LIVING;RACE:NO VALUE ENTERED;ETHNICITY:Unknown whether Spanish or not;PRIMARY_SITE:Unknown;GENE_PANEL:IMPACT410;TUMOR_PURITY:40;MSI_SCORE:0.22;MSI_TYPE:Do not report;SAMPLE_COVERAGE:794;PURITY:0.436840784;CVR_TMB_SCORE:5.9;AGE_AT_SEQ_REPORT:2;DETAILED_PRIMARY_SITE:Soft Tissue;FACETS:YES;FRACTION_CNA:0.219465272;FACETS_REVIEW:YES;FACETS_WGD:FALSE;FGA_REPORTED:0.079"
"INFILTRATING DUCTAL & LOBULAR","CANCER_TYPE_DETAILED:Breast Mixed Ductal and Lobular Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:MDLC;TMB_NONSYNONYMOUS:1.533333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:51;FRACTION_GENOME_ALTERED:0.8633;SAMPLE_TYPE:Primary;OS_MONTHS:37.19;OS_STATUS:0:LIVING;RACE:WHITE;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:37.19;TISSUE_SOURCE_SITE:BH;ICD_O_3_SITE:C50.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C50.9;ICD_O_3_HISTOLOGY:8522/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:11/4/10;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IIIC;HISTOLOGICAL_DIAGNOSIS:Mixed Histology (please specify);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2006;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1266;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-BH-A0BA.142F03FE-5B60-416D-8DCD-EC34DB5495DB.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:360;SITE_OF_TUMOR_TISSUE:Breast;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N3a;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:Infiltrating ductal & lobular;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Core needle biopsy;PRIMARY_SITE_PATIENT:Left Upper Inner Quadrant|Left Upper Outer Quadrant|Left Lower Inner Quadrant|Left Lower Outer Quadrant|Left;IHC_HER2:Negative;MENOPAUSE_STATUS:Pre (<6 months since LMP AND no prior bilateral ovariectomy AND not on estrogen replacement);PATH_MARGIN:Negative;HER2_IHC_SCORE:1;ER_STATUS_BY_IHC:Positive;PR_STATUS_BY_IHC:Positive;STAGING_SYSTEM:Sentinel lymph node biopsy plus axillary dissection;ER_STATUS_IHC_PERCENT_POSITIVE:80-89%;IHC_SCORE:3;MICROMET_DETECTION_BY_IHC:NO;PR_POSITIVITY_IHC_INTENSITY_SCORE:1+;PR_STATUS_IHC_PERCENT_POSITIVE:40-49%;SURGICAL_PROCEDURE_FIRST:Modified Radical Mastectomy"
"INFILTRATING DUCTAL CARCINOMA","CANCER_TYPE_DETAILED:Infiltrating Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:2.53333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:46;GRADE:III;SUBTYPE:HER2;STAGE:III;PURITY:0.27;ER_STATUS:Negative;PR_STATUS:Negative;MENOPAUSE_STATUS:Premenopausal;HER2_AMPLIFICATION_STATUS:Yes;SILENT_RATE:0.72;NONSILENT_RATE:2.62"
"INITIAL CNS TUMOR","CANCER_TYPE_DETAILED:Atypical Teratoid/Rhabdoid Tumor;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:ATRT;SEX:Male;AGE:2;OS_MONTHS:14;OS_STATUS:1:DECEASED;RACE:Other/Unavailable/Not Reported;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:6;TUMOR_TISSUE_SITE:Frontal Lobe;TUMOR_TYPE:Primary;TREATMENT:New;CHEMOTHERAPY:Yes;SURGERY:Yes;SAMPLE_ORIGIN:Initial CNS Tumor Surgery;TREATMENT_STATUS:Treatment naive;AGE_AT_INITIAL_DIAGNOSIS:1038;AGE_CLASS:[0,5);AGE_AT_CHEMOTHERAPY_STOP:1163;AGE_AT_LAST_KNOWN_CLINICAL_STATUS:1471;AGE_AT_RADIATION_START:1183;AGE_AT_RADIATION_STOP:1225;AGE_AT_SPECIMEN_DIAGNOSIS:1038;CANCER_PREDISPOSITIONS:None documented;CHEMOTHERAPY_AGENTS:Not Reported;CHEMOTHERAPY_TYPE:Treatment follows a protocol and subject is enrolled on a protocol;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;COMPLETED_RADIATION_DOSE:Not Reported;COMPLETED_TOTAL_RADIATION_DOSE:5400 cGy;EXTENT_OF_TUMOR_RESECTION:Gross/Near total resection;FORMULATION:Not Reported;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Atypical Teratoid Rhabdoid Tumor (ATRT);INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Focal neurological deficit (cranial nerve palsies, motor deficits, sensory deficits),Other medical conditions NOS;MULTIPLE_CANCER_PREDISPOSITIONS:No;MULTIPLE_MEDICAL_CONDITIONS:Yes;MULTIPLE_TUMOR_LOCATIONS:No;PROTOCOL_AND_TREATMENT_ARM:SJYC07;RADIATION:Yes;RADIATION_SITE:Focal/Tumor bed;RADIATION_TYPE:Protons;SAMPLE_ANNOTATION:Treatment naive;TIMING_OTHER_NOTES:Protocol included Alisertib, occurred at an outside institution. In addition to protocol, subject received 4 cycles of high dose MTX, VCR, Cisplatin and Cyclophosphamide;TREATMENT_CHANGED:Diagnosis;TUMOR_LOCATION_CONDENSED:Supratentorial;UPDATED_GRADE:IV"
"INVASIVE_DUCTAL_CARCINOMA","CANCER_TYPE_DETAILED:Breast Invasive Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:11.9666666667;SEX:Female;AGE:56;FRACTION_GENOME_ALTERED:0.4968;SAMPLE_TYPE:Metastasis;RACE:African_American;ETHNICITY:African_american;PRIMARY_SITE:Breast;SUBTYPE:Breast Ductal Carcinoma;TUMOR_TYPE:breast;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:157.8873017;GENOME_DOUBLINGS:0;DOUBLING_TIME:133.7;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:Adherent;DISEASE_ONTOLOGY:invasive_ductal_carcinoma;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI+10%FBS;HIST_SUBTYPE1:ductal_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:breast;LINEAGE_MOLECULAR_SUBTYPE:HER2_amp;LINEAGE_SUB_SUBTYPE:ERpos_HER2neg;LINEAGE_SUBTYPE:breast_ductal_carcinoma;NAME:MDA-MB-175-VII;PATHOLOGIST_ANNOTATION:Breast:Carcinoma;SITE_OF_FINDING:pleura;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:breast"
"KICH","CANCER_TYPE_DETAILED:Chromophobe Renal Cell Carcinoma;CANCER_TYPE:Renal Non-Clear Cell Carcinoma;ONCOTREE_CODE:CHRCC;TMB_NONSYNONYMOUS:1;SOMATIC_STATUS:Matched;SEX:Female;AGE:57;FRACTION_GENOME_ALTERED:0.9477;SAMPLE_TYPE:Primary;OS_MONTHS:38.07081566;OS_STATUS:1:DECEASED;RACE:White;TISSUE_SOURCE_SITE:MSKCC;ICD_O_3_SITE:C64.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:Yes;ICD_10:C64.9;ICD_O_3_HISTOLOGY:8317/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:7/24/12;PFS_MONTHS:24.92027485;AJCC_STAGING_EDITION:5TH;PFS_STATUS:1:PROGRESSION;TUMOR_TISSUE_SITE:Kidney;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE III;SUBTYPE:KICH;TUMOR_TYPE:Kidney Chromophobe Renal Cell Carcinoma;PATH_T_STAGE:T3B;RADIATION_THERAPY:No;DSS_STATUS:1:DEAD WITH TUMOR;DAYS_TO_BIRTH:-20849;MSI_SENSOR_SCORE:0.52;CANCER_TYPE_ACRONYM:KICH;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3383;PATH_N_STAGE:NX;TISSUE_SOURCE_SITE_CODE:KL;DSS_MONTHS:38.07081566;PERSON_NEOPLASM_CANCER_STATUS:With Tumor;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;PATH_M_STAGE:M0;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:No"
"KIRC","CANCER_TYPE_DETAILED:Renal Clear Cell Carcinoma;CANCER_TYPE:Renal Clear Cell Carcinoma;ONCOTREE_CODE:CCRCC;TMB_NONSYNONYMOUS:2.666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:69;FRACTION_GENOME_ALTERED:0.2240;SAMPLE_TYPE:Primary;OS_MONTHS:12.65739554;OS_STATUS:0:LIVING;RACE:Black or African American;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:12.65739554;TISSUE_SOURCE_SITE:Mary Bird Perkins Cancer Center - Our Lady of the Lake;ICD_O_3_SITE:C64.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C64.9;ICD_O_3_HISTOLOGY:8310/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:11/11/14;GRADE:G2;PFS_MONTHS:12.65739554;AJCC_STAGING_EDITION:7TH;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Kidney;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE I;SUBTYPE:KIRC;TUMOR_TYPE:Kidney Clear Cell Renal Carcinoma;PATH_T_STAGE:T1A;RADIATION_THERAPY:No;DAYS_LAST_FOLLOWUP:385;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-25205;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:KIRC;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3119;PATH_N_STAGE:N0;TISSUE_SOURCE_SITE_CODE:3Z;DSS_MONTHS:12.65739554;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:Yes;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:No;PATH_M_STAGE:M0;BUFFA_HYPOXIA_SCORE:5;RAGNUM_HYPOXIA_SCORE:-8;WINTER_HYPOXIA_SCORE:-10;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:No"
"KIRP","CANCER_TYPE_DETAILED:Papillary Renal Cell Carcinoma;CANCER_TYPE:Renal Non-Clear Cell Carcinoma;ONCOTREE_CODE:PRCC;TMB_NONSYNONYMOUS:1.833333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:53;FRACTION_GENOME_ALTERED:0.0757;SAMPLE_TYPE:Primary;OS_MONTHS:7.035539337;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:7.035539337;TISSUE_SOURCE_SITE:Greenville Health System;ICD_O_3_SITE:C64.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C64.1;ICD_O_3_HISTOLOGY:8260/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:4/18/14;PFS_MONTHS:7.035539337;AJCC_STAGING_EDITION:7TH;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Kidney;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE II;SUBTYPE:KIRP;TUMOR_TYPE:Kidney Papillary Renal Cell Carcinoma;PATH_T_STAGE:T2B;RADIATION_THERAPY:No;DAYS_LAST_FOLLOWUP:214;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-19603;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:KIRP;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3053;PATH_N_STAGE:NX;TISSUE_SOURCE_SITE_CODE:2K;DSS_MONTHS:7.035539337;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;WEIGHT:97.73;PATH_M_STAGE:M0;BUFFA_HYPOXIA_SCORE:5;RAGNUM_HYPOXIA_SCORE:0;WINTER_HYPOXIA_SCORE:-6;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:No"
"LAML","CANCER_TYPE_DETAILED:Acute Myeloid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AML;TMB_NONSYNONYMOUS:0.366666667;SOMATIC_STATUS:Matched;FRACTION_GENOME_ALTERED:0.0002;SAMPLE_TYPE:Primary;OS_MONTHS:11.9998685;OS_STATUS:1:DECEASED;TISSUE_SOURCE_SITE:Washington University;TUMOR_TYPE:Acute Myeloid Leukemia;CANCER_TYPE_ACRONYM:LAML;IN_PANCANPATHWAYS_FREEZE:No;TISSUE_SOURCE_SITE_CODE:AB"
"LGSOC","CANCER_TYPE_DETAILED:Low-Grade Serous Ovarian Cancer;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:LGSOC;TMB_NONSYNONYMOUS:8.86666666667;SEX:Female;FRACTION_GENOME_ALTERED:0.4479;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Ovary;SUBTYPE:Adenocarcinoma, low grade serous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:111.0355795;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:Ovarian Cancer;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:low_grade_serous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:Hey-A8;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;PROTEOMICS_TMT_LABEL:127c;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"LIHB","CANCER_TYPE_DETAILED:Hepatoblastoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:LIHB;TMB_NONSYNONYMOUS:11.8666666667;SEX:Male;FRACTION_GENOME_ALTERED:0.5928;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Liver;SUBTYPE:Hepatoblastoma;TUMOR_TYPE:liver;HISTOLOGY:Other;PURITY:0.99;MUTATION_RATE:174.0189681;GENOME_DOUBLINGS:0;GEOGRAPHIC_DISTRIBUTION:japan;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:RIKEN;CHARACTERISTICS:epithelial-like;GROWTH_MEDIUM:DMEM + 10%FBS;HIST_SUBTYPE1:hepatoblastoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LIFE_STAGE:pediatric;LINEAGE:liver;LINEAGE_SUBTYPE:hepatoblastoma;NAME:HuH-6;PATHOLOGIST_ANNOTATION:Liver:Hepatoblastoma;PROTEOMICS_TMT_LABEL:128n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:liver"
"LIHC","CANCER_TYPE_DETAILED:Hepatocellular Carcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:HCC;TMB_NONSYNONYMOUS:2.866666667;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.2041;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;RACE:Asian;ETHNICITY:Not Hispanic Or Latino;DFS_STATUS:0:DiseaseFree;TISSUE_SOURCE_SITE:University of California San Diego;ICD_O_3_SITE:C22.0;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C22.0;ICD_O_3_HISTOLOGY:8170/3;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:6/15/15;GRADE:G3;AJCC_STAGING_EDITION:7TH;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Liver;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE II;SUBTYPE:LIHC;TUMOR_TYPE:Hepatocellular Carcinoma;PATH_T_STAGE:T2;RADIATION_THERAPY:No;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:LIHC;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3003;PATH_N_STAGE:NX;TISSUE_SOURCE_SITE_CODE:2V;PERSON_NEOPLASM_CANCER_STATUS:With Tumor;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;WEIGHT:78;PATH_M_STAGE:MX;BUFFA_HYPOXIA_SCORE:-13;RAGNUM_HYPOXIA_SCORE:-10;WINTER_HYPOXIA_SCORE:-16"
"LIPOFIBROMATOSIS-LIKE NEURAL TUMOR","CANCER_TYPE_DETAILED:Lipofibromatosis-like Neural tumor;CANCER_TYPE:Sarcoma;SEX:Female;AGE:0.881587982;RACE:Other;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;CHEMO_TX:Yes;TARGETED_TX:Yes;TERT_TARGETED_TX:2nd tertile;TIME_FROM_DX_TO_SEQ:321"
"LIVER CANCER, NOS","CANCER_TYPE_DETAILED:Liver Cancer, NOS;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:LIVER;SOMATIC_STATUS:Matched;SEX:Male;AGE:64;FRACTION_GENOME_ALTERED:0.4431;SAMPLE_TYPE:Recurrence;OS_MONTHS:79.24;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:20.89;TISSUE_SOURCE_SITE:ZS;ICD_O_3_SITE:C22.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C22.0;ICD_O_3_HISTOLOGY:8170/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:5/1/14;GRADE:G2;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;HISTOLOGICAL_DIAGNOSIS:Hepatocellular Carcinoma;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;RETROSPECTIVE_COLLECTION:YES;SITE_OF_TUMOR_TISSUE:Liver;PHARMACEUTICAL_TX_ADJUVANT:NO;AJCC_METASTASIS_PATHOLOGIC_PM:MX;AJCC_NODES_PATHOLOGIC_PN:NX;AJCC_TUMOR_PATHOLOGIC_PT:T2;ECOG_SCORE:0;VASCULAR_INVASION:Micro;ISHAK_FIBROSIS_SCORE:0 - No Fibrosis;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO;CREATININE_LEVEL_PRERESECTION:89;CREATININE_NORM_RANGE_LOWER:62;CREATININE_NORM_RANGE_UPPER:106;YEAR_OF_INITIAL_PATHOLOGIC_DIAGNOSIS:2008;BILIRUBIN_TOTAL:19;BILIRUBIN_TOTAL_NORM_RANGE_LOWER:0;BILIRUBIN_TOTAL_NORM_RANGE_UPPER:17;DEFINITIVE_SURGICAL_PROCEDURE:Lobectomy;HISTORY_HEPATO_CARCINOMA_RISK_FACTORS:Hemochromatosis;PLATELET_NORM_RANGE_LOWER:150;PLATELET_NORM_RANGE_UPPER:400;PROTHROM_TIME_INR_NORM_RANGE_LOWER:9;PROTHROMBIN_TIME_INR_AT_PROCUREMENT:10.2;PROTHROMBIN_TIME_NORM_RANGE_UPPER:12;SERUM_ALBUMIN_NORM_RANGE_LOWER:36;SERUM_ALBUMIN_NORM_RANGE_UPPER:50;SERUM_ALBUMIN_PRERESECTION:51;HEPATIC_INFLAMMATION_ADJ_TISSUE:None"
"LIVER TUMOR","CANCER_TYPE_DETAILED:Cholangiocarcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:CHOL;TMB_NONSYNONYMOUS:0.0;SEX:Female;AGE:40.28310152;FRACTION_GENOME_ALTERED:0.0003;OS_MONTHS:72.47837039;OS_STATUS:1:DECEASED;TUMOR_SIZE:5;SMOKING_STATUS:Never smoked;TUMOR_GRADE:Moderately differentiated;BMI:23.1;RFS_STATUS:1:RELAPSED;CIRRHOSIS:0;RFS_MONTHS:24.11564998;ADJUVANT_CHEMO:1;CHRONIC_HEPATITIS_ANY_TYPE:0;NEOADJ_CHEMO:0;PNI:1;TREATMENT_GROUP:Resected;CLIN_PSC:0;DIABETES_STATUS:0;DUCT_TYPE:Small bile duct type;DZ_EXTENT:Solitary liver tumor;ECOG_BIN:0;HAIC:1;HEP_B:0;HEP_C:0;LVI:No;OS_MONTHS_FROM_RX:71.32844157;PD_INF:0;POSITIVE_LYMPH_NODE:0;POSITIVE_MARGIN:0;STEATOSIS:0;SYSTEMIC_CHEMO:1"
"LIVER_CANCER","CANCER_TYPE_DETAILED:Hepatocellular Carcinoma;CANCER_TYPE:Hepatobiliary Cancer;ONCOTREE_CODE:HCC;TMB_NONSYNONYMOUS:9.03333333333;SEX:Male;AGE:15;FRACTION_GENOME_ALTERED:0.2212;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Liver;SUBTYPE:Hepatocellular Carcinoma;TUMOR_TYPE:liver;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:169.6811465;GENOME_DOUBLINGS:0;DOUBLING_TIME:40.7;GEOGRAPHIC_DISTRIBUTION:argentina;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI/ATCC;CHARACTERISTICS:Epithelial adherent;DISEASE_ONTOLOGY:liver_cancer;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:EMEM +10%FBS;HIST_SUBTYPE1:hepatocellular_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:liver;LINEAGE_SUBTYPE:hepatocellular_carcinoma;NAME:Hep G2;PATHOLOGIST_ANNOTATION:Liver:HCC;PROTEOMICS_TMT_LABEL:127n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:liver"
"LNET","CANCER_TYPE_DETAILED:Lung Neuroendocrine Tumor;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LNET;TMB_NONSYNONYMOUS:3.91487879046;SEX:Female;FRACTION_GENOME_ALTERED:0.4080;SAMPLE_TYPE:Metastasis;OS_MONTHS:5.87;OS_STATUS:1:DECEASED;RACE:Asian;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Lung;GENE_PANEL:IMPACT410;SAMPLE_CLASS:PDX;GRADE:High Grade;INSTITUTE:MSKCC;SMOKING_PACK_YEARS:0;SPECIMEN_PRESERVATION_TYPE:Frozen;AGE_AT_SEQ_REPORTED_YEARS:33;M_STAGE:M1;SMOKING_HISTORY:Never;TISSUE_SITE:Pleural Effusion, Right;T_STAGE:T2A;N_STAGE:N2;STAGE_AT_DIAGNOSIS:IV;OS_DAYS:176;YEAR_OF_DIAGNOSIS:2016;PROCEDURE_TYPE:Pleural Effusion;PRETREATED:No"
"LOW HYPODIPLOID","CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLL;TMB_NONSYNONYMOUS:0.2;SOMATIC_STATUS:Matched;SEX:Male;AGE:8;GENE_PANEL:WGS;PROTOCOL:99,009,907;CYTOGENETICS:36,X,+Y,+1,+5,+6,+8,+10,+11,+13,+15,+18,+19,+21,+22[cp17]/46,XY[3];BONE_MARROW_LEUKEMIC_BLAST_PERCENTAGE:95;SNAPSHOT_MUTATIONS:IKZF2,CDKN2A,TP53;DNA_INDEX:0.75;KNOWN_MOLECULAR_CLASSIFIER:Low hypodiploid"
"LOW-GRADE NEUROEPITHELIAL TUMOR","CANCER_TYPE_DETAILED:Low-Grade Neuroepithelial Tumor;CANCER_TYPE:Miscellaneous Brain Tumor;ONCOTREE_CODE:LGNET;TMB_NONSYNONYMOUS:0;SEX:Male;AGE:11;PFS_STATUS:Unknown/NA;RADIATION_THERAPY:Unknown/NA;STAGE:Stage IV;RFS_STATUS:Unknown/NA;SURGERY:Yes;DEATH:No;LOCALIZED_VS_METS_AT_DX:Unknown;ANY_LINE_CHEMO:Unknown/NA;ANY_LINE_HORMONE:Unknown/NA;ANY_LINE_IODINE:Unknown/NA;ANY_LINE_NTRK:Unknown/NA;ANY_LINE_TARGETED:Unknown/NA;ANY_SYSTX:No;CANCER_TYPE_HISTOLOGY:Neuroepithelial;DOB_LASTFU_TIME_YRS:12;DOB_REPORT_TIME_YRS:12;DOB_TISSUE_TIME_YRS:12;LINE_OBR_CHEMO_G:Unknown/NA;LINE_OBR_IMMUNO_G:Unknown/NA;LINE_OBR_NOTRK:Unknown;LINE_OBR_NOTRK_G:Unknown/NA;LINE_OBR_NTRK_G:Unknown/NA;LINE_OBR_TARGETED_G:Unknown/NA;LINE1_BR_NOTRK:Unknown;LINE1_BR_NOTRK_G:Unknown/NA;NUM_LINES:0;POS_ARCHER:Positive;POS_CYTOGENETICS:Negative;POS_IMPACT:Negative;POS_METHOD:Archer;PROG_DEATH:Unknown/NA;PROG_EVAL_C:No;RECUR_EVAL_C:No;TISSUE_REPORT_TIME_YRS:0"
"LUAD","CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:10.9333333333;SEX:Male;FRACTION_GENOME_ALTERED:0.6542;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Lung;SUBTYPE:Non-Small Cell Lung Cancer (NSCLC), Adenocarcinoma;TUMOR_TYPE:lung_NSC;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:215.9785902;GENOME_DOUBLINGS:1;DOUBLING_TIME:70.1;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:HSSRB;CHARACTERISTICS:adherent epithelial-like;FREEZING_MEDIUM:5% DMSO;GROWTH_MEDIUM:RPMI-1640+10% FBS;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUB_SUBTYPE:NSCLC_adenocarcinoma;LINEAGE_SUBTYPE:NSCLC;NAME:RERF-LC-Ad2;PATHOLOGIST_ANNOTATION:Lung:NSCLC_Adeno;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lung_NSC"
"LUNG BRONCHIOLOALVEOLAR CARCINOMA MUCINOUS","CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:0.666666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:60;FRACTION_GENOME_ALTERED:0.2923;SAMPLE_TYPE:Primary;OS_MONTHS:0.0657098;OS_STATUS:0:LIVING;ICD_O_3_SITE:C34.1;ICD_O_3_HISTOLOGY:8253/3;HISTOLOGICAL_SUBTYPE:Lung Bronchioloalveolar Carcinoma Mucinous;TOBACCO_SMOKING_HISTORY_INDICATOR:Current reformed smoker for < or = 15 years;PRETREATMENT_HISTORY:NO;PRIMARY_TUMOR_PATHOLOGIC_SPREAD:T1;PRIOR_DIAGNOSIS:NO"
"LUNG BRONCHIOLOALVEOLAR CARCINOMA NONMUCINOUS","CANCER_TYPE_DETAILED:Lung Adenocarcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUAD;TMB_NONSYNONYMOUS:4.83333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:51;FRACTION_GENOME_ALTERED:0.2515;SAMPLE_TYPE:Primary;OS_MONTHS:13.7333482;OS_STATUS:0:LIVING;ICD_O_3_SITE:C34.1;ICD_O_3_HISTOLOGY:8252/3;HISTOLOGICAL_SUBTYPE:Lung Bronchioloalveolar Carcinoma Nonmucinous;TOBACCO_SMOKING_HISTORY_INDICATOR:Current reformed smoker for < or = 15 years;TUMOR_STAGE_2009:Stage IIIB;DISTANT_METASTASIS_PATHOLOGIC_SPREAD:M0;PRETREATMENT_HISTORY:NO;PRIMARY_TUMOR_PATHOLOGIC_SPREAD:T4;PRIOR_DIAGNOSIS:NO"
"LUNG CARCINOID","CANCER_TYPE_DETAILED:Lung Carcinoid;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUCA;TMB_NONSYNONYMOUS:19.5666666667;SEX:Female;AGE:65;FRACTION_GENOME_ALTERED:0.7677;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Lung;SUBTYPE:Carcinoid;TUMOR_TYPE:other;HISTOLOGY:Carcinoid-Endocrine_Tumour;PURITY:0.99;MUTATION_RATE:165.1770758;GENOME_DOUBLINGS:1;DOUBLING_TIME:65.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:adherent;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI 1640 +10% FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUBTYPE:lung_carcinoid;NAME:NCI-H727;PATHOLOGIST_ANNOTATION:Endocrine;SITE_SUBTYPE1:bronchus;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:other"
"LUNG NEUROENDOCRINE","CANCER_TYPE_DETAILED:Lung Neuroendocrine Tumor;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LNET;TMB_NONSYNONYMOUS:3.91487879046;SEX:Female;FRACTION_GENOME_ALTERED:0.4080;SAMPLE_TYPE:Metastasis;OS_MONTHS:5.87;OS_STATUS:1:DECEASED;RACE:Asian;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Lung;GENE_PANEL:IMPACT410;SAMPLE_CLASS:PDX;GRADE:High Grade;INSTITUTE:MSKCC;SMOKING_PACK_YEARS:0;SPECIMEN_PRESERVATION_TYPE:Frozen;AGE_AT_SEQ_REPORTED_YEARS:33;M_STAGE:M1;SMOKING_HISTORY:Never;TISSUE_SITE:Pleural Effusion, Right;T_STAGE:T2A;N_STAGE:N2;STAGE_AT_DIAGNOSIS:IV;OS_DAYS:176;YEAR_OF_DIAGNOSIS:2016;PROCEDURE_TYPE:Pleural Effusion;PRETREATED:No"
"LUNG NEUROENDOCRINE TUMOR","CANCER_TYPE_DETAILED:Lung Neuroendocrine Tumor;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LNET;TMB_NONSYNONYMOUS:3.91487879046;SEX:Female;FRACTION_GENOME_ALTERED:0.4080;SAMPLE_TYPE:Metastasis;OS_MONTHS:5.87;OS_STATUS:1:DECEASED;RACE:Asian;ETHNICITY:Non-Spanish; Non-Hispanic;PRIMARY_SITE:Lung;GENE_PANEL:IMPACT410;SAMPLE_CLASS:PDX;GRADE:High Grade;INSTITUTE:MSKCC;SMOKING_PACK_YEARS:0;SPECIMEN_PRESERVATION_TYPE:Frozen;AGE_AT_SEQ_REPORTED_YEARS:33;M_STAGE:M1;SMOKING_HISTORY:Never;TISSUE_SITE:Pleural Effusion, Right;T_STAGE:T2A;N_STAGE:N2;STAGE_AT_DIAGNOSIS:IV;OS_DAYS:176;YEAR_OF_DIAGNOSIS:2016;PROCEDURE_TYPE:Pleural Effusion;PRETREATED:No"
"LUNG_CARCINOID","CANCER_TYPE_DETAILED:Lung Carcinoid;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUCA;TMB_NONSYNONYMOUS:19.5666666667;SEX:Female;AGE:65;FRACTION_GENOME_ALTERED:0.7677;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Lung;SUBTYPE:Carcinoid;TUMOR_TYPE:other;HISTOLOGY:Carcinoid-Endocrine_Tumour;PURITY:0.99;MUTATION_RATE:165.1770758;GENOME_DOUBLINGS:1;DOUBLING_TIME:65.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:adherent;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI 1640 +10% FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUBTYPE:lung_carcinoid;NAME:NCI-H727;PATHOLOGIST_ANNOTATION:Endocrine;SITE_SUBTYPE1:bronchus;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:other"
"LUSC","CANCER_TYPE_DETAILED:Lung Squamous Cell Carcinoma;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:LUSC;TMB_NONSYNONYMOUS:7.16666666667;SEX:Male;FRACTION_GENOME_ALTERED:0.1999;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Lung;SUBTYPE:Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma;TUMOR_TYPE:lung_NSC;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:93.36313254;GENOME_DOUBLINGS:0;DOUBLING_TIME:49.8;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;DISEASE_ONTOLOGY:lung_cancer;FREEZING_MEDIUM:5%DMSO;GROWTH_MEDIUM:RPMI-1640+10% FBS;HIST_SUBTYPE1:squamous_cell_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUB_SUBTYPE:NSCLC_squamous;LINEAGE_SUBTYPE:NSCLC;NAME:NCI-H226;PATHOLOGIST_ANNOTATION:Lung:NSCLC_Squamous;PROTEOMICS_TMT_LABEL:127c;SITE_OF_FINDING:pleura;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:lung_NSC"
"LYMPHATIC CANCER, NOS","CANCER_TYPE_DETAILED:Lymphoid Neoplasm;CANCER_TYPE:Lymphatic Cancer, NOS;ONCOTREE_CODE:LNM;TMB_NONSYNONYMOUS:1.7;FRACTION_GENOME_ALTERED:0.0251;SUBTYPE:Lymphoma;LINEAGE:fibroblast;LINEAGE_SUBTYPE:fibroblast_lymphocyte"
"M0","CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"M2","CANCER_TYPE_DETAILED:AML with Maturation;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AM;SOMATIC_STATUS:Matched;SEX:Male;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:61.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:16.5;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:61;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy;FAB:M2;HEMOGLOBIN_LEVEL:8.8;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:1.05;CURRENT_STAGE:Induction;FUSION:None;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,XY[20];PB_BLAST_PERCENTAGE:66;WHOLE_EXOME_SEQUENCING:No;BM_BLAST_PERCENTAGE:46;CUMULATIVE_TREATMENT_REGIMENS:3+7 (Cytarabine, Daunorubicin);CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:3+7 (Cytarabine, Daunorubicin);LDH_LEVEL:551;MOST_RECENT_TREATMENT_DURATION:7;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Normal;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:7;ELN_2008:Not Enough Information;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:26.4;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:89.1;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.2;PB_ALT_LEVEL:18;PB_AST_LEVEL:34;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:1;PB_LYMPHOCYTES_PERCENTAGE:24;PB_MONOCYTES_PERCENTAGE:5;PB_NEUTROPHILS_PERCENTAGE:4;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with maturation;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with maturation;SURFACE_ANTIGENS:CD13, CD33, CD34, CD117, dim CD123, HLA-DR,partial MPO (+);TOTAL_PROTEIN_LEVEL:7;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"M3","CANCER_TYPE_DETAILED:APL with PML-RARA;CANCER_TYPE:Leukemia;ONCOTREE_CODE:APLPMLRARA;TMB_NONSYNONYMOUS:0.9;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:0.23;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:65.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:9.8;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:65;CAUSE_OF_DEATH_SOURCE:Dead-Other;CENTER:1;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy;FAB:M3;HEMOGLOBIN_LEVEL:6.8;SAMPLE_SITE:Bone Marrow Aspirate;CREATININE_LEVEL_PRERESECTION:0.6;CURRENT_STAGE:Induction;FUSION:PML-RARA;GROUP:Initial Acute Leukemia Diagnosis;KARYOTYPE:46,X,der(X)add(X)(p22.1)add(X)(q22~24),add(7)(p15),der(15)t(15;17)(q22;q21),der(17)t(15;17)(q22;q21)inv(17)(q21q21)del(17)(q21)[17]/46,XX[3];PB_BLAST_PERCENTAGE:57;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:72;CEBPA_MUTATION:Negative;CUMULATIVE_TREATMENT_REGIMENS:ATRA (Tretinoin)|3+7 (Cytarabine, Daunorubicin);CUMULATIVE_TREATMENT_STAGES:Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:3+7 (Cytarabine, Daunorubicin);LDH_LEVEL:398;MOST_RECENT_TREATMENT_DURATION:3;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Unusual t(15;17), with the fusion signal on the derivative chromosome 15;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:5;ELN_2008:Adverse;ELN_2017:Favorable;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Positive;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:20.7;INDUCTION_RESPONSE:Unknown;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:90.2;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:2.9;PB_ALT_LEVEL:24;PB_AST_LEVEL:33;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:36;PB_MONOCYTES_PERCENTAGE:1;PB_NEUTROPHILS_PERCENTAGE:8;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA;SURFACE_ANTIGENS:partial CD2, CD13, CD33, partial CD34, CD117, CD123, MPO-positive;TOTAL_PROTEIN_LEVEL:5.6;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"M4","CANCER_TYPE_DETAILED:Adenoid Cystic Carcinoma;CANCER_TYPE:Salivary Gland Cancer;ONCOTREE_CODE:ACYC;TMB_NONSYNONYMOUS:1.366666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:50;SAMPLE_TYPE:Primary;PRIMARY_SITE:Head and Neck;TUMOR_TISSUE_SITE:Maxilla;PLATFORM:WGS;TUMOR_SIZE:2;STUDY:ACyC (MDA 2015);HISTOLOGICAL_TYPE:Cribriform/Solid/Tubular;PERINEURAL_INVASION:Yes;FUSION_STATUS:YES;GENOMIC_ALTERATIONS:55;MYB_MYBL1_FUSION:MYB-NFIB;MYB_NFIB_FISH:Positive;FUSION_OTHER:ATRNL1-ACVR1B, EGLN1-KCNH1, NEDD9-VPS54, RBM47-PDE8A, SLC8A1-ALK, ZFP37-UBR4;MYB_MYBL1_FUSION_METHOD:WGS;MYB_NFIB_TRANSLOCATION:t(6;9);NFIB_FUSION_OTHER:Negative"
"M5","CANCER_TYPE_DETAILED:B-Cell Acute Lymphoid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:BALL;TMB_NONSYNONYMOUS:3.35249282986;SOMATIC_STATUS:Matched;SEX:Female;AGE:0.06;GENE_PANEL:Targeted_Seq;COHORT:INF_MLLr_Validation;MLL_STATUS:INF_MLLr;LEUKEMIA_TYPE:MixedPreB-M5"
"M6","CANCER_TYPE_DETAILED:Acute Myeloid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AML;SOMATIC_STATUS:Matched;SEX:Male;AGE:4.0;OS_MONTHS:4.0;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic or Latino;ANALYSIS_COHORT:DISCOVERY;PROTOCOL:CCG-2961;WBC:13.9;OS_DAYS:112.0;AGE_IN_DAYS:1248.0;RISK_GROUP:Standard;DAYS_TO_EVENT:107.0;FAB:M6;FIRST_EVENT:Relapse;BONE_MARROW_LEUKEMIC_BLAST_PERCENTAGE:14.0;CNS_SITE_OF_RELAPSE:No;BONE_MARROW_SITE_OF_RELAPSE:Yes;CEBPA_MUTATION:No;OTHER_SITE_OF_RELAPSE:No;PERIPHERAL_BLASTS_PERCENTAGE:3.0;CBFT2A3_GLIS:Not Done;CHLOROMA:No;CHLOROMA_RELAPSE_SITE:No;CKIT_EXON_17_MUTATION:Not done;CKIT_EXON_8_MUTATION:Not done;CNS_DISEASE:No;CR_STATUS_AT_END_OF_COURSE_1:CR;CR_STATUS_AT_END_OF_COURSE_2:CR;CYTOGENETIC_COMPLEXITY:2;CYTOGENETIC_RELAPSE_SITE:No;DEL_5Q:No;DEL_7Q:No;DEL_9Q:Yes;FLT3_ITD_POSITIVE:No;FLT3_PM:No;INV_16:No;ISCN:46,XY,del(9)(q22q34)[13]/46,idem,add(18)(p13)[4]/46,XY[3];MINUS_X:No;MINUS_Y:No;MLL:No;MONOSOMY_5:No;MONOSOMY_7:No;MRD_AT_END_OF_COURSE_1:Unknown;MRD_AT_END_OF_COURSE_2:Unknown;NPM_MUTATION:Unknown;NUP98_NSD1:Not Done;OTHER_MLL:No;PRIMARY_CYTOGENETIC_CODE:Other;SCT_IN_FIRST_CR:No;T_10_11_P11_2_Q23:No;T_11_19_Q23_P13_1:No;T_3_5_Q25_Q34:No;T_6_11_Q27_Q23:No;T_6_9:No;T_8_21:No;T_9_11_P22_Q23:No;TRISOMY_21:No;TRISOMY_8:No;WT1_MUTATION:Unknown"
"M7","CANCER_TYPE_DETAILED:AML with Biallelic Mutations of CEBPA;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLCEBPA;TMB_NONSYNONYMOUS:0.666666667;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:8.98;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:42.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;KRAS_MUTATION:Negative;WBC:7.9;SAMPLE_TIMEPOINT:Denovo;AGE_AT_PROCUREMENT:42;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TP53_MUTATION:Negative;TREATMENT_TYPE:Standard Chemotherapy;FAB:M7;HEMOGLOBIN_LEVEL:12;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.81;CURRENT_STAGE:Re-induction;FUSION:Unknown;GROUP:Initial Acute Leukemia Diagnosis;PB_BLAST_PERCENTAGE:9;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:70;CEBPA_MUTATION:p.V119?M120insV; MAF 30%;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone);CUMULATIVE_TREATMENT_STAGES:Induction | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:MEC (Cytarabine, Etoposide, Mitoxantrone);LDH_LEVEL:762;MOST_RECENT_TREATMENT_DURATION:4;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Extra signals were observed for BCR (22q11.2), PML (15q22), MLL (11q23),     RUNX1T1 (8q21.3) and RUNX1 (21q22) in roughly 45-60% of interphase cells.     These results suggest the presence of a hyperdiploid clone.;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DNMT3A_MUTATION:Negative;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:6;ELN_2008:Not Enough Information;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;HEMATOCRIT_LEVEL:34.8;INDUCTION_RESPONSE:Refractory;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:85.2;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;NRAS_MUTATION:Negative;PB_ALBUMIN_LEVEL:3.5;PB_ALT_LEVEL:36;PB_AST_LEVEL:28;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:43;PB_MONOCYTES_PERCENTAGE:6;PB_NEUTROPHILS_PERCENTAGE:38;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with mutated CEBPA;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with mutated CEBPA;SURFACE_ANTIGENS:CD7, CD13, CD33, CD58, partial CD61, CD71, and Factor 8 positive;TOTAL_PROTEIN_LEVEL:6.8;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MALIGNANT FIBROUS HISTIOCYTOMA","CANCER_TYPE_DETAILED:Embryonal Rhabdomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:ERMS;TMB_NONSYNONYMOUS:9.39387097441;SEX:Male;FRACTION_GENOME_ALTERED:0.4426;PRIMARY_SITE:Soft Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Soft_Tissue;HISTOLOGICAL_TYPE:Malignant Fibrous Histiocytoma-Pleomorphic Sarcoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"MALIGNANT PT","CANCER_TYPE_DETAILED:Malignant Phyllodes Tumor of the Breast;CANCER_TYPE:Breast Sarcoma;ONCOTREE_CODE:MPT;TMB_NONSYNONYMOUS:0.833333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:53;ETHNICITY:Malay;HISTOLOGICAL_DIAGNOSIS:Malignant PT;TUMOR_SIZE:63;SURGERY:Wide Excision;MEAN_COVERAGE:71;NUM_SOMATIC_MUTATION:25"
"MALIGNANT_FIBROUS_HISTIOCYTOMA","CANCER_TYPE_DETAILED:Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma/High-Grade Spindle Cell Sarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:MFH;TMB_NONSYNONYMOUS:23.8666666667;SEX:Male;AGE:29;FRACTION_GENOME_ALTERED:0.4429;SAMPLE_TYPE:Metastasis;ETHNICITY:Caucasian;PRIMARY_SITE:Soft_Tissue;SUBTYPE:Pleomorphic Sarcoma;TUMOR_TYPE:soft_tissue;HISTOLOGY:Malignant_Fibrous_Histiocytoma-Pleomorphic_Sarcoma;PURITY:1;MUTATION_RATE:179.4906831;GENOME_DOUBLINGS:1;DOUBLING_TIME:64.6;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:soft_tissue;LINEAGE_SUBTYPE:pleomorphic_sarcoma;NAME:GCT;PATHOLOGIST_ANNOTATION:Soft_Tissue:Sarcoma_FibrousHistiocytoma;SITE_OF_FINDING:lung;SITE_SUBTYPE1:fibrous_tissue_and_uncertain_origin;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:soft_tissue"
"MASKED LOW HYPODIPLOID","CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLL;TMB_NONSYNONYMOUS:0.5;SOMATIC_STATUS:Matched;SEX:Male;AGE:16.1;GENE_PANEL:WGS;PROTOCOL:AALL03B1,ASCT0431;CYTOGENETICS:35,X,+1,+5,+6,+8,+10,der(10)t(7;10)(q11.2;q24),+11,+12,+14,+18,+19,+21,+mar[cp4]/61<2n>,X,+X,-Y,+1,+5,+6,+8,+8,+10,+10,der(10)t(7;10)x2,+11,+12,+12,i(13)(q10), +14,+18,+19,+21,+21[cp7]/61<2n>,X,+X,-Y,+1,+5,+6,+8,+8,+10,+10,der(10)t(7;10)x2,+11,+12,+12,i(1;BONE_MARROW_LEUKEMIC_BLAST_PERCENTAGE:90;SNAPSHOT_MUTATIONS:TP53,RB1;DNA_INDEX:0.791 in 58%; 37% hyperdiploid peak;KNOWN_MOLECULAR_CLASSIFIER:Masked low hypodiploid"
"MBL","CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;SOMATIC_STATUS:Matched;SEX:Male;AGE:66;FRACTION_GENOME_ALTERED:0.2678;SAMPLE_TYPE:Primary;OS_MONTHS:59.33;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:59.33;TISSUE_SOURCE_SITE:ZF;ICD_O_3_SITE:C67.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C67.9;ICD_O_3_HISTOLOGY:8120/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:11/15/14;GRADE:High Grade;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;HISTOLOGICAL_DIAGNOSIS:Muscle invasive urothelial carcinoma (pT2 or above);HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2008;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:1850;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-ZF-AA4V.52B54951-E580-49D6-BBB5-4F2329A271B0.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:290;SMOKING_PACK_YEARS:28;WEIGHT:85;SITE_OF_TUMOR_TISSUE:Bladder;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T3b;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;HISTOLOGICAL_SUBTYPE:Non-Papillary;LYMPH_NODES_EXAMINED:YES;ECOG_SCORE:0;TOBACCO_SMOKING_HISTORY_INDICATOR:2;HEIGHT:177;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Transurethral resection (TURBT);PRIMARY_SITE_PATIENT:Bladder - NOS;SMOKING_YEAR_STARTED:15;CLIN_T_STAGE:T2;ANGIOLYMPHATIC_INVASION:[Not Reported];FAMILY_HISTORY_CANCER_RELATIONSHIP:Father|Child;FAMILY_HISTORY_CANCER_TYPE:Lung/Bronchus|Breast-Fem;OCCUPATION_PRIMARY:radio and tv engineer;OCCUPATION_PRIMARY_YEARS_WORKED:34;EXTRACAPSULAR_EXTENSION:NO;NONINVASIVE_BLADDER_HISTORY:NO;OCCUPATION_CURRENT:retired;OCCUPATION_PRIMARY_CHEMICAL_EXPOSURE:soldering, assembling and repairng electrical goods;OCCUPATION_PRIMARY_INDUSTRY:telecommunications"
"MDS WITH EXCESS BLASTS-2","CANCER_TYPE_DETAILED:MDS with excess blasts-2;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSEB2;TMB_NONSYNONYMOUS:4.6626176495;SOMATIC_STATUS:Matched;STUDY:MSKCC;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:MDS with excess blasts-2"
"MDS WITH MULTILINEAGE DYSPLASIA","CANCER_TYPE_DETAILED:MDS with Multilineage Dysplasia;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSMD;SOMATIC_STATUS:Unmatched;SEX:Female;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:59.0;CHEMOTHERAPY:No;DIAGNOSIS:Myelodysplastic Syndromes;WBC:2.8;AGE_AT_PROCUREMENT:59;CENTER:5;TREATMENT_TYPE:Unknown;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Unknown;FUSION:None;GROUP:Post-Chemotherapy;KARYOTYPE:46,XX,del(9)(q21q31-33)[10]/46,XX[10];WHOLE_EXOME_SEQUENCING:No;BM_BLAST_PERCENTAGE:2;CEBPA_MUTATION:p.E10K; MAF 26.7%;CUMULATIVE_TREATMENT_REGIMENS:R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone);CUMULATIVE_TREATMENT_STAGES:Unknown;CUMULATIVE_TREATMENT_TYPES:Unknown;CURRENT_REGIMEN:R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone);MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Unknown;PRIOR_MDS:Yes;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:positive for a low level of findings consistent with trisomy 8, seen in 1.7% of cells.;DIAGNOSIS_AT_INCLUSION:Myelodysplastic Syndromes;DRUG_TESTING_IN_ANALYSIS:No;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Refractory cytopenia with multilineage dysplasia;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Refractory cytopenia with multilineage dysplasia"
"MDS WITH SINGLE LINEAGE DYSPLASIA","CANCER_TYPE_DETAILED:MDS with Single Lineage Dysplasia;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSSLD;TMB_NONSYNONYMOUS:6.5276647093;SOMATIC_STATUS:Matched;STUDY:MSKCC;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:MDS with Single Lineage Dysplasia"
"MDS/MPN WITH RING SIDEROBLASTS AND THROMBOCYTOSIS","CANCER_TYPE_DETAILED:MDS/MPN with Ring Sideroblasts and Thrombocytosis;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:MDSMPNRST;TMB_NONSYNONYMOUS:0.033333333;SEX:Male;AGE:77;SAMPLE_TYPE:Primary;OS_STATUS:1:DECEASED;SAMPLE_CLASS:Tumor;ICD_10:D75.81;HISTOLOGY:Refractory anemia with sideroblasts;PURITY:0.745;PROJECT_CODE:CMDI-UK;WGD:no_wgd;FIRST_THERAPY:Other Therapy;FIRST THERAPY_RESPONSE:Stable Disease;PURITY_CONFUGURATION:0.121"
"MDS/MPN, UNCLASSIFIABLE","CANCER_TYPE_DETAILED:MDS/MPN, Unclassifiable;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:MDSMPNU;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;ETHNICITY:White;PLATFORM:WES;CHEMOTHERAPY:No;DIAGNOSIS:Myelodysplastic/Myeloproliferative Neoplasms;AGE_AT_PROCUREMENT:74;CENTER:7;SAMPLE_SITE:Bone Marrow Aspirate;CURRENT_STAGE:NONE;FUSION:None;GROUP:Unknown;KARYOTYPE:46,XX[20], normal female chromosome complement.;WHOLE_EXOME_SEQUENCING:Yes;CURRENT_REGIMEN:NONE;MOST_RECENT_TREATMENT_TYPE:NONE;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Myelodysplastic/Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-2;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:u;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Myelodysplastic/myeloproliferative neoplasm, unclassifiable;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Myelodysplastic/myeloproliferative neoplasm, unclassifiable"
"MEDULLARY","CANCER_TYPE_DETAILED:Ampullary Carcinoma;CANCER_TYPE:Ampullary Cancer;ONCOTREE_CODE:AMPCA;TMB_NONSYNONYMOUS:40;SOMATIC_STATUS:Matched;OS_MONTHS:67.93;OS_STATUS:0:LIVING;PRIMARY_SITE:DUODENUM;GRADE:Undifferentiated;VITAL_STATUS:NED;TNMSTAGE:III;DAYS_TO_LAST_FOLLOWUP:2065;NOTE:MSI tumor;DATA_SOURCE:Technical University of Dresden;PB_BLAST_PERCENTAGE:0.0;ALLELE_FREQUENCY_CELLULARITY:43;IHC_SUBTYPE:Pancreatobiliary;MORPHOLOGY_SUBTYPE:Intestinal;ASSOCIATED_ADENOMA:Absent;INTESTINAL_PERCENTAGE:100;MORPHOLOGY_OTHER_FEATURES:Medullary"
"MED_GROUP_3","CANCER_TYPE_DETAILED:Medulloblastoma;CANCER_TYPE:Embryonal Tumor;ONCOTREE_CODE:MBL;TMB_NONSYNONYMOUS:7.1;SEX:Male;AGE:6;FRACTION_GENOME_ALTERED:0.1837;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Central_Nervous_System;SUBTYPE:Medulloblastoma;TUMOR_TYPE:medulloblastoma;HISTOLOGY:Primitive_Neuroectodermal_Tumour-Medulloblastoma;PURITY:1;MUTATION_RATE:85.48175072;GENOME_DOUBLINGS:0;DOUBLING_TIME:243.4;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:central_nervous_system;LINEAGE_MOLECULAR_SUBTYPE:MYC_exp;LINEAGE_SUB_SUBTYPE:med_group_3;LINEAGE_SUBTYPE:medulloblastoma;NAME:D283 Med;PATHOLOGIST_ANNOTATION:CNS:Medulloblastoma;SITE_OF_FINDING:peritoneum;SITE_SUBTYPE1:cerebellum;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:medulloblastoma"
"MENINGOTHELIAL TUMOR","CANCER_TYPE_DETAILED:Meningothelial Tumor;CANCER_TYPE:CNS Cancer;ONCOTREE_CODE:MNGT;SEX:Female;AGE:47.39219666;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALKYLATING_TX:Yes;ALL_TX_AT_MSK:No;CHEMO_TX:Yes;CYTOTOXIC_TX:Yes;EQD_TERTILES:3rd tertile;TERT_ALKYLATING_TX:3rd tertile;TERT_CYTOTOXIC_TX:1st tertile;TIME_FROM_DX_TO_SEQ:5113;TIME_TO_BLOOD_DRAW_FROM_TX:2587;XRT_TX:Yes"
"METASTATIC CARCINOMA","CANCER_TYPE_DETAILED:Prostate;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PROSTATE;TMB_NONSYNONYMOUS:45.83333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:69;FRACTION_GENOME_ALTERED:0.2989;SAMPLE_TYPE:Metastasis;HISTOLOGICAL_SUBTYPE:prostate; metastatic site: brain; carcinoma (patient with metastatic carcinoma of the prostate and a 3 year history of lymphocytic leukemia.);PRIOR_TREATMENT:Androgen independent and unresposive to hormone therapy;DOUBLING_TIME:32.3;P53:?;CATEGORY_SAMPLE:Metastasis;EPITHELIAL:Yes;MDR:4"
"METASTATIC HORMONE-SENSITIVE","CANCER_TYPE_DETAILED:Prostate Adenocarcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRAD;TMB_NONSYNONYMOUS:1.109155301;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0023;RACE:White;GENE_PANEL:IMPACT341;SAMPLE_CLASS:Tumor;TUMOR_PURITY:60;MSI_SCORE:0.09;MSI_TYPE:Stable;SAMPLE_COVERAGE:708;INSTITUTE:MSKCC;MSI_COMMENT:MICROSATELLITE STABLE (MSS). See MSI note below.;ARCHER:NO;TISSUE_SITE:Lymph Node;PED_IND:No;PARTC_CONSENTED_12_245:YES;PARTA_CONSENTED_12_245:YES;PSA:6;DISEASE_EXTENT:Metastatic hormone-sensitive;SURVIVAL_STATUS:Dead;ANDROGEN_DEPRIVATION_THERAPY:No;BIOPSY_GLEASON_SCORE:9-10;AGE_AT_SAMPLE_COLLECTION:55;DENOVO_METASTATSIS:De-novo metastatic;DZ_VOLUME:Low-volume disease;IS_CRPC:Yes;OS_SMP_MONTHS:38.75;SMP_CRPC_MONTHS:20.03"
"METASTATIC, VARIANT HISTOLOGY","CANCER_TYPE_DETAILED:Prostate Adenocarcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRAD;TMB_NONSYNONYMOUS:3.45879238;SOMATIC_STATUS:Matched;FRACTION_GENOME_ALTERED:0.3258;SAMPLE_TYPE:Metastatic;RACE:White;GENE_PANEL:IMPACT468;SAMPLE_CLASS:Tumor;VITAL_STATUS:Dead;AGE_AT_DIAGNOSIS:81.2;M_STAGE:M1;PSA:6.2;TUMOR_SAMPLE_HISTOLOGY:Adenocarcinoma / poorly differentiated carcinoma;AGE_AT_PROCUREMENT:81.2;DISEASE_EXTENT:Metastatic, variant histology;SMOKING:Former;TISSUE_TYPE:Prostate;8Q_ARM:Gain"
"METATYPICAL","CANCER_TYPE_DETAILED:Skin Cancer, Non-Melanoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:BCC;TMB_NONSYNONYMOUS:25.5042984552;SOMATIC_STATUS:No;GENE_PANEL:CancerPanel;HISTOLOGICAL_SUBTYPE:Metatypical;MULTIPLE_TUMORS:No;AGE_RESECTED:78;GORLIN_SPORADIC:sporadic;POPULATION:non-reduntant sample;SCNA_ANALYSIS:No;TUMOR_NUMBER:T1;VISMO_STATUS:naive"
"MIT FAMILY TRANSLOCATION RENAL CELL CARCINOMA","CANCER_TYPE_DETAILED:MiT family translocation renal cell carcinoma;CANCER_TYPE:Kidney Renal Cell Carcinoma;TMB_NONSYNONYMOUS:0.0666666666667;SEX:Male;SAMPLE_TYPE:Primary;AJCC_PATHOLOGIC_TUMOR_STAGE:III;SPECIMEN_PRESERVATION_TYPE:FFPE;TREATMENT:Treatment-naive;SPECIMEN_TYPE:Surgery;COVERAGE_MEAN:1264;DIAGNOSIS AGE:18;GDNA(NG):5184;SMOKE STATUS:Unknown;TUMOR_PURTITY:90"
"MIXED 80% ALVEOLAR","CANCER_TYPE_DETAILED:Rhabdomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:RMS;TMB_NONSYNONYMOUS:0.2;SOMATIC_STATUS:Matched;SEX:Male;AGE:3;HISTOLOGICAL_SUBTYPE:Mixed 80% Alveolar;TUMOR_SAMPLE_HISTOLOGY:Mixed Alveolar/Embryonal;RISK_GROUP:Intermediate;PRIMARY_TUMOR_LOCATION:Extremity;PAX_FUSION:Fusion Negative (RT-PCR)"
"MIXED ACINAR-NEUROENDOCRINE CARCINOMA","CANCER_TYPE_DETAILED:Acinar Cell Carcinoma of the Pancreas;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAC;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Female;AGE:19;ETHNICITY:White;STAGE:1B;DIAGNOSIS:Mixed Acinar-Neuroendocrine Carcinoma;IMMUNOHISTOCHEMISTRY:Alpha-1-Antitrypsin +, Lipase +"
"MIXED PHENOTYPE ACUTE LEUKAEMIA, T/MYELOID, NOS","CANCER_TYPE_DETAILED:Mixed Phenotype Acute Leukemia, T/Myeloid, NOS;CANCER_TYPE:Leukemia;ONCOTREE_CODE:MPALTNOS;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:13.29;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:52.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Leukaemias of Ambiguous Lineage;WBC:14;AGE_AT_PROCUREMENT:53;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s);HEMOGLOBIN_LEVEL:11.1;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.68;CURRENT_STAGE:Salvage;FUSION:None;GROUP:Post-Transplant|Post-Chemotherapy|Residual Disease;KARYOTYPE:45~48,XY,+5,add(5)(q11.2)x2,t(7;7)(q22;q36),+11,add(13)(q13),-22[cp9]/45~47,sl,-add(5)(q11.2),der(11)t(11;12)(p11.2;q13),-12[cp6]/46,sl,t(Y;18)(p11.2;q21),der(9)t(9;17)(p13;q11.2),-17[2]/46,XY[3];PB_BLAST_PERCENTAGE:59;WHOLE_EXOME_SEQUENCING:No;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|Sunitinib|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide;CUMULATIVE_TREATMENT_STAGES:Salvage | Induction | Re-induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Decitabine;LDH_LEVEL:167;MOST_RECENT_TREATMENT_DURATION:80;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Deleted 5q;DIAGNOSIS_AT_INCLUSION:Acute Leukaemias of Ambiguous Lineage;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:6;ELN_2008:Adverse;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:34;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-2;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:102.8;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.7;PB_ALT_LEVEL:32;PB_AST_LEVEL:34;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:9;PB_MONOCYTES_PERCENTAGE:2;PB_NEUTROPHILS_PERCENTAGE:29;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Mixed phenotype acute leukaemia, T/myeloid, NOS;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Mixed phenotype acute leukaemia, T/myeloid, NOS;TOTAL_PROTEIN_LEVEL:6.7;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MIXED PHENOTYPE ACUTE LEUKEMIA, B/MYELOID, NOS","CANCER_TYPE_DETAILED:Mixed Phenotype Acute Leukemia, B/Myeloid, NOS;CANCER_TYPE:Leukemia;ONCOTREE_CODE:MPALBNOS;TMB_NONSYNONYMOUS:0.9325235299;SOMATIC_STATUS:Matched;STUDY:MSKCC;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:Mixed Phenotype Acute Leukemia, B/Myeloid, NOS"
"MIXED PHENOTYPE ACUTE LEUKEMIA, T/MYELOID, NOS","CANCER_TYPE_DETAILED:Mixed Phenotype Acute Leukemia, T/Myeloid, NOS;CANCER_TYPE:Leukemia;ONCOTREE_CODE:MPALTNOS;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:13.29;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:52.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Leukaemias of Ambiguous Lineage;WBC:14;AGE_AT_PROCUREMENT:53;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s);HEMOGLOBIN_LEVEL:11.1;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.68;CURRENT_STAGE:Salvage;FUSION:None;GROUP:Post-Transplant|Post-Chemotherapy|Residual Disease;KARYOTYPE:45~48,XY,+5,add(5)(q11.2)x2,t(7;7)(q22;q36),+11,add(13)(q13),-22[cp9]/45~47,sl,-add(5)(q11.2),der(11)t(11;12)(p11.2;q13),-12[cp6]/46,sl,t(Y;18)(p11.2;q21),der(9)t(9;17)(p13;q11.2),-17[2]/46,XY[3];PB_BLAST_PERCENTAGE:59;WHOLE_EXOME_SEQUENCING:No;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|Sunitinib|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide;CUMULATIVE_TREATMENT_STAGES:Salvage | Induction | Re-induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Decitabine;LDH_LEVEL:167;MOST_RECENT_TREATMENT_DURATION:80;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Deleted 5q;DIAGNOSIS_AT_INCLUSION:Acute Leukaemias of Ambiguous Lineage;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:6;ELN_2008:Adverse;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:34;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-2;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:102.8;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.7;PB_ALT_LEVEL:32;PB_AST_LEVEL:34;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:9;PB_MONOCYTES_PERCENTAGE:2;PB_NEUTROPHILS_PERCENTAGE:29;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Mixed phenotype acute leukaemia, T/myeloid, NOS;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Mixed phenotype acute leukaemia, T/myeloid, NOS;TOTAL_PROTEIN_LEVEL:6.7;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"MIXED SEROUS AND ENDOMETRIOID","CANCER_TYPE_DETAILED:Endometrial Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UCEC;SOMATIC_STATUS:Matched;SEX:Female;AGE:70;FRACTION_GENOME_ALTERED:0.3765;SAMPLE_TYPE:Primary;OS_MONTHS:23.03;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:23.03;TISSUE_SOURCE_SITE:AX;ICD_O_3_SITE:C54.1;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C54.1;ICD_O_3_HISTOLOGY:8441/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:5/12/11;GRADE:G3;AJCC_STAGING_EDITION:1988;HISTOLOGICAL_DIAGNOSIS:Mixed serous and endometrioid;HISTORY_OTHER_MALIGNANCY:Yes;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:274;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-AX-A1CR.7623CA86-87C5-43E8-A0A7-25BD9526D1AA.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:110;WEIGHT:97;SITE_OF_TUMOR_TISSUE:Endometrial;HEIGHT:165;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Dilation and curettage procedure;CLINICAL_STAGE:Stage IIB;MENOPAUSE_STATUS:Post (prior bilateral ovariectomy OR >12 mo since LMP with no prior hysterectomy);LYMPH_NODES_AORTIC_POS_TOTAL:0;LYMPH_NODES_PELVIC_POS_TOTAL:0;PERITONEAL_WASHING:negative;SURGICAL_APPROACH_AT_DIAGNOSIS:open;TUMOR_INVASION_PERCENT:50"
"MLL-ALL","CANCER_TYPE_DETAILED:Acute Leukemias of Ambiguous Lineage;CANCER_TYPE:Leukemia;ONCOTREE_CODE:ALAL;TMB_NONSYNONYMOUS:4.4;SEX:Female;AGE:12.92;FRACTION_GENOME_ALTERED:0.0004;NOTE:Lock;SAMPLE_SITE:Unknown;HISTOPATHOLOGY:t(11;19), MLL-MLLT1;CANCER_SUBTYPE_CURATED:MLL-ALL;EXPRESSION:NO;INFERRED_ETHNICITY:European;PHASE:Diagnosis;REPORTED_ETHNICITY:Unknown;SITE_OF_SPECIMEN:Bone marrow;TX_17-DMAG:2;TX_19D12:1;TX_ABRAXANE:0;TX_ABT-199:0;TX_ABT-263:5;TX_ACTINOMYCIN D:0;TX_AZD-2171:1;TX_AZD-6244:2;TX_AZD1480:0;TX_AZD8055:0;TX_BAL101553:0;TX_BI6727 (VOLASERTIB):0;TX_BMN-673:0;TX_BMS-354825:3;TX_BMS-754807:1;TX_BORTEZOMIB:2;TX_CABOZANTINIB (XL-148):0;TX_CBL0137:0;TX_CDX-011 (GLEMBATUMUMAB):0;TX_CGC(PG)-11047:2;TX_CISPLATIN:2;TX_CLORETAZINE:0;TX_CPX351:0;TX_CX-5461 (POL1):0;TX_CYTARABINE:0;TX_E7438/EPZ6438:0;TX_EC1456:0;TX_ERIBULIN:0;TX_GENZ-644282:0;TX_GS-9820:0;TX_GSK690693:1;TX_GSK923295A:0;TX_HGS-ETR1:1;TX_IMC-A12:0;TX_INK128-1110-028:0;TX_JNJ26481585:3;TX_JNJ26854165:4;TX_KPT-330:0;TX_LAPATINIB:1;TX_LY 2606368:0;TX_MK-2206:0;TX_MK-8242:0;TX_MLN4924:3;TX_MLN8237:5;TX_MM-141:0;TX_NSC060043:0;TX_NSC750854:0;TX_PCI-32765:1;TX_PF-03084014:0;TX_PIXANTRONE:0;TX_PR-104:6;TX_RAPAMYCIN:2;TX_RG7112:0;TX_RO4929097:1;TX_RUXOLITINIB:0;TX_SAHA:1;TX_SAR3419:2;TX_SB-715992:4;TX_SCH 727965:0;TX_SGI-1776:1;TX_SGN-CD19A:0;TX_SORAFENIB:1;TX_STA9090 (GANETESPIB):0;TX_STF-118804:0;TX_SU11248:2;TX_SVV-001:0;TX_TAK-701:0;TX_TB-403:0;TX_TL32711:0;TX_TOPOTECAN:5;TX_TRISENOX(ATO):0;TX_VINCRISTINE:6;TX_VS-4718:0;TX_XL147:0;TX_XL765:0"
"MMMT","CANCER_TYPE_DETAILED:Uterine Carcinosarcoma/Uterine Malignant Mixed Mullerian Tumor;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UCS;TMB_NONSYNONYMOUS:7.3;SEX:Female;AGE:70;FRACTION_GENOME_ALTERED:0.7482;SAMPLE_TYPE:Primary;RACE:Asian;ETHNICITY:Asian;PRIMARY_SITE:Endometrium;SUBTYPE:Malignant Mixed Mullerian Tumor (MMMT);TUMOR_TYPE:endometrium;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:133.0971004;GENOME_DOUBLINGS:2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:KCLB;CHARACTERISTICS:polypoid; monolayer;DOUBLING_TIME_FROM_VENDOR:20 hrs;GROWTH_MEDIUM:RPMI 1640  with L-glutamine (300mg/L), 90%; heat inactivated fetal bovine serum (FBS),10%;HIST_SUBTYPE1:carcinosarcoma-malignant_mesodermal_mixed_tumour;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:uterus;LINEAGE_SUBTYPE:MMMT;NAME:SNU-685;PATHOLOGIST_ANNOTATION:Endometrium:Others;PROTEOMICS_TMT_LABEL:129n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;SUPPLEMENTS:25mM Hepes and 25mM NaHCo3;TYPE_REFINED:endometrium"
"MULTIPLE MYELOMA","CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:6.13333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:74;FRACTION_GENOME_ALTERED:0.2382;SAMPLE_TYPE:Primary;OS_MONTHS:17.71;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:8.21;TISSUE_SOURCE_SITE:DK;ICD_O_3_SITE:C67.4;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C67.4;ICD_O_3_HISTOLOGY:8120/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:3/12/12;GRADE:High Grade;AJCC_STAGING_EDITION:6th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage III;HISTOLOGICAL_DIAGNOSIS:Muscle invasive urothelial carcinoma (pT2 or above);HISTORY_OTHER_MALIGNANCY:Yes;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2011;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:230;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-DK-A3IQ.11C9802C-072A-4B09-96FB-0CAC21BF43D8.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:280;SMOKING_PACK_YEARS:40;WEIGHT:75.4;SITE_OF_TUMOR_TISSUE:Bladder;AJCC_METASTASIS_PATHOLOGIC_PM:M0;AJCC_NODES_PATHOLOGIC_PN:N0;AJCC_TUMOR_PATHOLOGIC_PT:T3;HISTOLOGICAL_SUBTYPE:Papillary;LYMPH_NODES_EXAMINED:YES;TOBACCO_SMOKING_HISTORY_INDICATOR:3;HEIGHT:173;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Transurethral resection (TURBT);PRIMARY_SITE_PATIENT:Wall Posterior;METASTATIC_SITE_PATIENT:None;FAMILY_HISTORY_CANCER_RELATIONSHIP:Mother|Father|Brother;FAMILY_HISTORY_CANCER_TYPE:Breast-Fem|Lung/Bronchus|Colon|Kidney-except Pelvis|Multiple Myeloma;OCCUPATION_PRIMARY:Real Estate Developer;OCCUPATION_CURRENT:Retired;OCCUPATION_PRIMARY_INDUSTRY:Real Estate"
"MULTIPLE_MYELOMA","CANCER_TYPE_DETAILED:Plasma Cell Myeloma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:PCM;TMB_NONSYNONYMOUS:6.1889032302;SEX:Female;FRACTION_GENOME_ALTERED:0.5516;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Multiple_Myeloma;HISTOLOGICAL_SUBTYPE:Plasma_Cell_Myeloma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE","CANCER_TYPE_DETAILED:MDS/MPN, Unclassifiable;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:MDSMPNU;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;ETHNICITY:White;PLATFORM:WES;CHEMOTHERAPY:No;DIAGNOSIS:Myelodysplastic/Myeloproliferative Neoplasms;AGE_AT_PROCUREMENT:74;CENTER:7;SAMPLE_SITE:Bone Marrow Aspirate;CURRENT_STAGE:NONE;FUSION:None;GROUP:Unknown;KARYOTYPE:46,XX[20], normal female chromosome complement.;WHOLE_EXOME_SEQUENCING:Yes;CURRENT_REGIMEN:NONE;MOST_RECENT_TREATMENT_TYPE:NONE;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:No;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Myelodysplastic/Myeloproliferative Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-2;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:u;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Myelodysplastic/myeloproliferative neoplasm, unclassifiable;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Myelodysplastic/myeloproliferative neoplasm, unclassifiable"
"MYELOMA","CANCER_TYPE_DETAILED:Plasma Cell Myeloma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:PCM;SOMATIC_STATUS:Matched;SEX:Female;OS_STATUS:0:LIVING;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:63.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Mature B-Cell Neoplasms;WBC:7.14;AGE_AT_PROCUREMENT:63;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy;HEMOGLOBIN_LEVEL:7;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.99;CURRENT_STAGE:Re-induction;FUSION:None;GROUP:Unknown;KARYOTYPE:44,XX,+5,add(5)(q11.1),der(8)t(8;13)(p12;q12),-13,-14,t(15;21)(q10;q10),add(20)(p13)[13]/46,XX[7];WHOLE_EXOME_SEQUENCING:Yes;CUMULATIVE_TREATMENT_REGIMENS:CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone)|RVD (Bortezomib, Dexamethasone, Lenalidomide);CUMULATIVE_TREATMENT_STAGES:Induction | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:RVD (Bortezomib, Dexamethasone, Lenalidomide);LDH_LEVEL:249;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Abnormal;DIAGNOSIS_AT_INCLUSION:Mature B-Cell Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:16;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:22;INDUCTION_RESPONSE:Unknown;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:102.8;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:2.6;PB_ALT_LEVEL:22;PB_AST_LEVEL:24;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_IMMATURE_GRANULOCYTES_PERCENTAGE:0.9;PB_LYMPHOCYTES_PERCENTAGE:28.7;PB_MONOCYTES_PERCENTAGE:8.3;PB_NEUTROPHILS_PERCENTAGE:60.2;PB_NUCLEATED_RBC_PERCENTAGE:0.6;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Plasma cell myeloma;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Plasma cell myeloma;TOTAL_PROTEIN_LEVEL:4.9;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"NESTED STROMAL EPITHELIAL TUMOR OF THE LIVER","CANCER_TYPE_DETAILED:Nested stromal epithelial tumor of the liver;CANCER_TYPE:Nested stromal epithelial tumor of the liver;ONCOTREE_CODE:LIVER;TMB_NONSYNONYMOUS:2.3;SEX:Male;OS_MONTHS:97;OS_STATUS:1:DECEASED;PRIMARY_SITE:Liver;SAMPLE_CLASS:Tumor;SPECIMEN_PRESERVATION_TYPE:FFPE;AGE_AT_DIAGNOSIS:9;SAMPLE_TIMEPOINT:Relapse;TISSUE_SEQUENCED:Diaphragmatic mass;NGS_TEST:Tumor-normal  WES;AGE_TESTING_YEARS:18.0;DIAGNOSTIC_CATEGORY:Other- Solid Tumor;GMED_OS_MONTHS:97;SAMPLE_TESTED_CATEGORY:Relapse/refractory"
"NEUROTROPIC","CANCER_TYPE_DETAILED:Desmoplastic Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:DESM;TMB_NONSYNONYMOUS:16.9666666667;SOMATIC_STATUS:Matched;AGE:71;GENE_PANEL:Exome, Whole Genome;HISTOLOGICAL_SUBTYPE:Neurotropic;PLATFORM:Agilent 1Mil;COHORT:Discovery;SOURCE:Fresh Frozen;TOTAL_MUTATIONS:797;ANATOMIC_REGION:Shoulder;DETAILED_SAMPLE_HISTOLOGY_CATEGORY:Pure;SECONDARY_PLATFORM:Exome CN Inference"
"NKC","CANCER_TYPE_DETAILED:Natural Killer (NK) Cell Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:T-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:NKCLL;TMB_NONSYNONYMOUS:18.2;SUBTYPE:Natural Killer Cell Lymphoblastic Leukemia/Lymphoma;LINEAGE:blood;LINEAGE_SUBTYPE:NKC"
"NON-SEMINOMA","CANCER_TYPE_DETAILED:Non-Seminomatous Germ Cell Tumor;CANCER_TYPE:Germ Cell Tumor;TMB_NONSYNONYMOUS:0.433333333333;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.1543;SPECIMEN_PRESERVATION_TYPE:Fresh;PLATFORM:WES;PATIENT_DISPLAY_NAME:P-0003533;SAMPLE_DISPLAY_NAME:s_AML_GCT_2T1"
"NORMAL-LIKE","CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;TMB_NONSYNONYMOUS:3.5;SEX:Female;AGE:51;ETHNICITY:Hispanic or Latino;ESTIMATE_IMMUNE_SCORE:1442.230636;ESTIMATE_STROMAL_SCORE:1521.072943;ESTIMATE_TUMORPURITY:0.50625;STEMNESS_SCORE:0.45327286;TMT_CHANNEL:126;CANCER TYPE:Breast Cancer;CD3_TILS_STATUS:not performed;CHROMOSOME_INSTABILITY_INDEX_CIN_:0.158407665;CIBERSORT_ABSOLUTE_SCORE:0.882338;ER_UPDATED_CLINICAL_STATUS:Negative;ERBB2_GENE_AMPLIFIED:1;ERBB2_PROTEOGENOMIC_STATUS:Positive;ERBB2_UPDATED_CLINICAL_STATUS:equivocal;ISCHEMIA_TIME_IN_MINUTES:14;NMF_CLUSTER:LumA-I;NMF_CLUSTER_MEMBERSHIP_SCORE:0.824;NUMBER_OF_NON_SYNONYMOUS_MUTATIONS:109;ONCOTREE CODE:BRCA;PAM50:Normal-like;PR_CLINICAL_STATUS:negative;TMT_PLEX:2;TNBC_UPDATED_CLINICAL_STATUS:Negative;TOP2A_GENE_AMPLIFIED:0;TOP2A_PROTEOGENOMIC_STATUS:Negative;XCELL_IMMUNE_SCORE:0.0071;XCELL_STROMAL_SCORE:0.3597"
"NO_FUSION","CANCER_TYPE_DETAILED:Ewing's sarcoma;CANCER_TYPE:Bone Cancer;TMB_NONSYNONYMOUS:0.033333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:13;SAMPLE_TYPE:Primary;SEQUENCING_TYPE:WES;ONCOTREE_CODE_CANCER_TYPE:ES;SUBTYPE_DETAILS:No_Fusion;TUMOR_DETAILS:Ewing's sarcoma"
"NSCLC","CANCER_TYPE_DETAILED:Non-Small Cell Lung Cancer;CANCER_TYPE:Non-Small Cell Lung Cancer;ONCOTREE_CODE:NSCLC;TMB_NONSYNONYMOUS:3.75754838976;SEX:Male;FRACTION_GENOME_ALTERED:0.4936;PRIMARY_SITE:Lung;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Lung_Nsc;HISTOLOGICAL_SUBTYPE:Non_Small_Cell_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"OV","CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"PAAD","CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;TMB_NONSYNONYMOUS:3.42600000243;SEX:Female;FRACTION_GENOME_ALTERED:0.9761;PRIMARY_SITE:Pancreas;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Pancreas;HISTOLOGICAL_SUBTYPE:Ductal_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"PAPILLARY INFILTRATING DUCTAL CARCINOMA-MAMMARY GLAND","CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:5.833333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:72;FRACTION_GENOME_ALTERED:0.3550;SAMPLE_TYPE:Metastasis;HISTOLOGICAL_SUBTYPE:Papillary infiltrating ductal carcinoma-mammary gland; breast;DOUBLING_TIME:53.9;P53:?;CATEGORY_SAMPLE:Metastasis;EPITHELIAL:Yes;MDR:-45"
"PAPILLARY INFILTRATING DUCTAL CARCINOMA-MAMMARY GLAND; BREAST","CANCER_TYPE_DETAILED:Invasive Breast Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:BRCA;TMB_NONSYNONYMOUS:5.833333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:72;FRACTION_GENOME_ALTERED:0.3550;SAMPLE_TYPE:Metastasis;HISTOLOGICAL_SUBTYPE:Papillary infiltrating ductal carcinoma-mammary gland; breast;DOUBLING_TIME:53.9;P53:?;CATEGORY_SAMPLE:Metastasis;EPITHELIAL:Yes;MDR:-45"
"PAPILLARY, FOLLICULAR","CANCER_TYPE_DETAILED:Poorly Differentiated Thyroid Carcinoma;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPD;TMB_NONSYNONYMOUS:0.533333333333;SOMATIC_STATUS:Unmatched;SEX:Male;AGE:71;FRACTION_GENOME_ALTERED:0.0571;SAMPLE_TYPE:Primary;OS_MONTHS:56.88;OS_STATUS:1:DECEASED;SAMPLE_CLASS:Tumor;METASTATIC_SITE:lungs,bone;TUMOR_PURITY:0.64;PATH_T_STAGE:T3/T4;PATH_N_STAGE:Nx/N0;SPECIMEN_PRESERVATION_TYPE:FFPE;M_STAGE:M1;CYTOLOGICAL_PHENOTYPE:papillary, follicular;GROWTH_PATTERN:solid;PDTC_DEFINITION:PDTC-Turin"
"PAST","CANCER_TYPE_DETAILED:Ependymomal Tumor;CANCER_TYPE:CNS Cancer;ONCOTREE_CODE:EPMT;SEX:Male;AGE:1;OS_MONTHS:16;OS_STATUS:0:LIVING;RACE:Other/Unavailable/Not Reported;ETHNICITY:Not Hispanic or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:5;TUMOR_TISSUE_SITE:Cerebellum/Posterior Fossa;TUMOR_TYPE:Progression;TREATMENT:Modified Treatment;CHEMOTHERAPY:Yes;SURGERY:No;TREATMENT_STATUS:Post-treatment;BRAF_STATUS:RELA Wild Type;AGE_AT_INITIAL_DIAGNOSIS:616;AGE_CLASS:[0,5);AGE_AT_CHEMOTHERAPY_START:1076;AGE_AT_LAST_KNOWN_CLINICAL_STATUS:1104;AGE_AT_SPECIMEN_DIAGNOSIS:797;BRAF_RELA_STATUS:RELA Wild Type;CANCER_PREDISPOSITIONS:Not Reported;CHEMOTHERAPY_AGENTS:Temozolomide;CHEMOTHERAPY_TYPE:Treatment follows other standard of care not associated with a current or past protocol;CLINICAL_STATUS_AT_COLLECTION_EVENT:Alive;CTNNB1_STATUS:CTNNB1 WT;EPENDYMOMA_RELA_STATUS:RELA Wild Type;FORMULATION:Not Reported;H3F3A_CTNNB1_STATUS:CTNNB1 WT;INITIAL_CNS_TUMOR_DIAGNOSIS_RELATED_TO_OS:Ependymoma;INITIAL_DIAGNOSIS_TYPE:Initial CNS Tumor;MEDICAL_CONDITIONS:Focal neurological deficit (cranial nerve palsies, motor deficits, sensory deficits),Other medical conditions NOS,Seizure disorder;MULTIPLE_MEDICAL_CONDITIONS:Yes;MULTIPLE_TUMOR_LOCATIONS:No;PROTOCOL_AND_TREATMENT_ARM:Not Reported;RADIATION:No;SAMPLE_ANNOTATION:Post-treatment;TIMING_OTHER_NOTES:Not Reported;TREATMENT_CHANGED:12 Month Update;TUMOR_LOCATION_CONDENSED:Posterior Fossa;UPDATED_GRADE:III"
"PDA - MIXED DUCTAL ENDOCRINE CARCINOMA","CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;TMB_NONSYNONYMOUS:0.666666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:87;SAMPLE_TYPE:Primary;ETHNICITY:White/Caucasian;SAMPLE_CLASS:Tumour;AJCC_PATHOLOGIC_TUMOR_STAGE:IIA;HISTOLOGICAL_SUBTYPE:PDA - Mixed ductal endocrine carcinoma;TUMOR_GRADE:3 - Poorly differentiated;STATUS:NED;LOCATION:Head"
"PDA - MUCINOUS NON-CYSTIC CARCINOMA","CANCER_TYPE_DETAILED:Pancreatic Adenocarcinoma;CANCER_TYPE:Pancreatic Cancer;ONCOTREE_CODE:PAAD;TMB_NONSYNONYMOUS:0.0333333333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:72;SAMPLE_TYPE:Primary;ETHNICITY:Black/African;SAMPLE_CLASS:Tumour;AJCC_PATHOLOGIC_TUMOR_STAGE:IIB;HISTOLOGICAL_SUBTYPE:PDA - Mucinous Non-cystic carcinoma;SMOKER:Never Smoked;TUMOR_GRADE:3 - Poorly differentiated;STATUS:DOD;LOCATION:Head"
"PENILE SQUAMOUS CELL CARCINOMA","CANCER_TYPE_DETAILED:Penile Squamous Cell Carcinoma;CANCER_TYPE:Penile Cancer;ONCOTREE_CODE:PSCC;TMB_NONSYNONYMOUS:8.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:54;FRACTION_GENOME_ALTERED:0.2564;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Penis;ANALYSIS_COHORT:HNSC;BIOPSY_SITE:Bone;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:6"
"PERITONEAL MESOTHELIOMA","CANCER_TYPE_DETAILED:Peritoneal Mesothelioma;CANCER_TYPE:Mesothelioma;ONCOTREE_CODE:PEMESO;SEX:Male;AGE:61.31964493;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALKYLATING_TX:Yes;ALL_TX_AT_MSK:No;ANTIMETABOLITE_TX:Yes;CHEMO_TX:Yes;CISPLATIN_TX:Yes;CYTOTOXIC_TX:Yes;PLATINUM_TX:Yes;TERT_ALKYLATING_TX:1st tertile;TERT_ANTIMETABOLITE_TX:2nd tertile;TERT_CISPLATIN_TX:3rd tertile;TERT_CYTOTOXIC_TX:2nd tertile;TERT_PLATINUM_TX:3rd tertile;TIME_FROM_DX_TO_SEQ:245;TIME_TO_BLOOD_DRAW_FROM_TX:166"
"PERIVASCULAR EPITHELIOID CELL TUMOR","CANCER_TYPE_DETAILED:Perivascular Epithelioid Cell Tumor;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:PECOMA;TMB_NONSYNONYMOUS:0.3;SOMATIC_STATUS:Matched;SEX:Female;AGE:49;FRACTION_GENOME_ALTERED:0.0043;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Unknown;ANALYSIS_COHORT:MISC;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:4"
"PFA","CANCER_TYPE_DETAILED:Ependymoma;CANCER_TYPE:Glioma;TMB_NONSYNONYMOUS:0.033333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:4.8;SAMPLE_TYPE:Primary;SEQUENCING_TYPE:WES;ONCOTREE_CODE_CANCER_TYPE:EPM;SUBTYPE_DETAILS:PFA;TUMOR_DETAILS:Ependymoma infratentorial"
"PH-LIKEALL","CANCER_TYPE_DETAILED:B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1 Like;CANCER_TYPE:B-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:BLLBCRABL1L;TMB_NONSYNONYMOUS:3.43333333333;SEX:Male;AGE:4;FRACTION_GENOME_ALTERED:0.0017;NOTE:Lock;SAMPLE_SITE:Unknown;HISTOPATHOLOGY:Not noted;CANCER_SUBTYPE_CURATED:Ph-likeALL;EXPRESSION:NO;INFERRED_ETHNICITY:European;PHASE:Diagnosis;REPORTED_ETHNICITY:Unknown;SITE_OF_SPECIMEN:Bone marrow"
"PITUITARY ADENOMA","CANCER_TYPE_DETAILED:Pituitary Adenoma;CANCER_TYPE:Sellar Tumor;ONCOTREE_CODE:PTAD;TMB_NONSYNONYMOUS:1.957439395;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.6172;SAMPLE_TYPE:Primary;OS_MONTHS:2.83;OS_STATUS:0:LIVING;PRIMARY_SITE:Pituitary Gland;SAMPLE_CLASS:Tumor;TUMOR_PURITY:80;SAMPLE_COVERAGE:735;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Biopsy;SAMPLE_COLLECTION_SOURCE:In-House;MATCHED_STATUS:Matched;DNA_INPUT:250"
"PLASMA CELL MYELOMA","CANCER_TYPE_DETAILED:Plasma Cell Myeloma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:PCM;SOMATIC_STATUS:Matched;SEX:Female;OS_STATUS:0:LIVING;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:63.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Mature B-Cell Neoplasms;WBC:7.14;AGE_AT_PROCUREMENT:63;CAUSE_OF_DEATH_SOURCE:Alive;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy;HEMOGLOBIN_LEVEL:7;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.99;CURRENT_STAGE:Re-induction;FUSION:None;GROUP:Unknown;KARYOTYPE:44,XX,+5,add(5)(q11.1),der(8)t(8;13)(p12;q12),-13,-14,t(15;21)(q10;q10),add(20)(p13)[13]/46,XX[7];WHOLE_EXOME_SEQUENCING:Yes;CUMULATIVE_TREATMENT_REGIMENS:CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone)|RVD (Bortezomib, Dexamethasone, Lenalidomide);CUMULATIVE_TREATMENT_STAGES:Induction | Re-induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:RVD (Bortezomib, Dexamethasone, Lenalidomide);LDH_LEVEL:249;MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Abnormal;DIAGNOSIS_AT_INCLUSION:Mature B-Cell Neoplasms;DRUG_TESTING_IN_ANALYSIS:No;DURATION_OF_INDUCTION_TREATMENT:16;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:22;INDUCTION_RESPONSE:Unknown;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:102.8;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:2.6;PB_ALT_LEVEL:22;PB_AST_LEVEL:24;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_IMMATURE_GRANULOCYTES_PERCENTAGE:0.9;PB_LYMPHOCYTES_PERCENTAGE:28.7;PB_MONOCYTES_PERCENTAGE:8.3;PB_NEUTROPHILS_PERCENTAGE:60.2;PB_NUCLEATED_RBC_PERCENTAGE:0.6;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Plasma cell myeloma;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Plasma cell myeloma;TOTAL_PROTEIN_LEVEL:4.9;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"PLASMA_CELL_MYELOMA","CANCER_TYPE_DETAILED:Plasma Cell Myeloma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:PCM;TMB_NONSYNONYMOUS:6.1889032302;SEX:Female;FRACTION_GENOME_ALTERED:0.5516;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Multiple_Myeloma;HISTOLOGICAL_SUBTYPE:Plasma_Cell_Myeloma;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"PLEURAL MESOTHELIOMA","CANCER_TYPE_DETAILED:Pleural Mesothelioma, Epithelioid Type;CANCER_TYPE:Mesothelioma;ONCOTREE_CODE:PLEMESO;TMB_NONSYNONYMOUS:2.87341935688;FRACTION_GENOME_ALTERED:0.3969;PRIMARY_SITE:Pleura;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Mesothelioma;HISTOLOGICAL_TYPE:Mesothelioma;DATA_SOURCE:RIKEN;SAMPLE_ORIGIN:Solid"
"PLMESO","CANCER_TYPE_DETAILED:Pleural Mesothelioma;CANCER_TYPE:Mesothelioma;ONCOTREE_CODE:PLMESO;TMB_NONSYNONYMOUS:9.93333333333;SEX:Male;AGE:48;FRACTION_GENOME_ALTERED:0.5526;SAMPLE_TYPE:Metastasis;RACE:Caucasian;ETHNICITY:African_american;PRIMARY_SITE:Pleura;SUBTYPE:Mesothelioma;TUMOR_TYPE:mesothelioma;HISTOLOGY:Mesothelioma;PURITY:1;MUTATION_RATE:144.0712209;GENOME_DOUBLINGS:1;DOUBLING_TIME:81.2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:ATCC;CHARACTERISTICS:adherent;FREEZING_MEDIUM:10% DMSO;GROWTH_MEDIUM:RPMI+10%FBS;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lung;LINEAGE_SUBTYPE:mesothelioma;NAME:NCI-H28;PATHOLOGIST_ANNOTATION:Lung:Mesothelioma;SITE_OF_FINDING:pleura;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:mesothelioma"
"PNET","CANCER_TYPE_DETAILED:Neuroblastoma;CANCER_TYPE:Peripheral Nervous System;ONCOTREE_CODE:NBL;TMB_NONSYNONYMOUS:7.43333333333;SEX:Female;AGE:0.75;FRACTION_GENOME_ALTERED:0.0846;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Autonomic_Ganglia;TUMOR_TYPE:neuroblastoma;HISTOLOGY:Neuroblastoma;PURITY:1;MUTATION_RATE:115.6076715;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:HSSRB;CHARACTERISTICS:fibroblast-like;DISEASE_ONTOLOGY:neuroblastoma;GROWTH_MEDIUM:alpha-MEM with 10% fetal calf serum;HIST_SUBTYPE1:NS;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:peripheral_nervous_system;LINEAGE_MOLECULAR_SUBTYPE:MYCN_amp;LINEAGE_SUBTYPE:neuroblastoma;NAME:NH-6;PATHOLOGIST_ANNOTATION:PNET:Neuroblastoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:neuroblastoma"
"POORLY DIFFERENTIATED OR PLEOMORPHIC OR EPITHELIOID LEIOMYOSARCOMA","CANCER_TYPE_DETAILED:Leiomyosarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:LMS;TMB_NONSYNONYMOUS:0.966666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:46;FRACTION_GENOME_ALTERED:0.7129;SAMPLE_TYPE:Primary;OS_MONTHS:34.86;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:22.44;TISSUE_SOURCE_SITE:HB;ICD_O_3_SITE:C55.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C55;ICD_O_3_HISTOLOGY:8890/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:4/23/12;HISTOLOGICAL_DIAGNOSIS:Leiomyosarcoma (LMS);HISTORY_OTHER_MALIGNANCY:No;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2009;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:735;OCT_EMBEDDED:FALSE;PATHOLOGY_REPORT_FILE_NAME:TCGA-HB-A3L4.5394ACFD-3583-4E61-9BEC-DB0BB1C1B656.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:190;SITE_OF_TUMOR_TISSUE:Gynecological - Uterus|Gynecological - Cervix;HISTOLOGICAL_SUBTYPE:Poorly differentiated or pleomorphic or epithelioid leiomyosarcoma;METASTATIC_SITE_PATIENT:Lung;PATH_MARGIN:Negative;DISEASE_MULTIFOCAL_INDICATOR:NO;LEIOMYO_MAJOR_VESSEL_INVOLVEMENT:No Major Vessel Involvement;TUMOR_TOTAL_DEPTH:Deep;LEIOMYOSARCOMA_UTERINE_INVOLVEMENT:YES;METASTATIC_DISEASE_CONFIRMED:YES;NTE_LESION_PATHOLOGIC_DEPTH:8;NTE_LESION_PATHOLOGIC_LENGTH:18;NTE_LESION_RADIOLOGIC_DEPTH:9.6;NTE_LESION_RADIOLOGIC_LENGTH:14;TUMOR_BURDEN_PATHOLOGIC:18;TUMOR_BURDEN_RADIOLOGIC:14"
"PRAD","CANCER_TYPE_DETAILED:Prostate Adenocarcinoma;CANCER_TYPE:Prostate Cancer;ONCOTREE_CODE:PRAD;TMB_NONSYNONYMOUS:28.5131613106;SEX:Male;FRACTION_GENOME_ALTERED:0.1976;PRIMARY_SITE:Prostate;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Prostate;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"PRE-T","CANCER_TYPE_DETAILED:Breast Invasive Ductal Carcinoma;CANCER_TYPE:Breast Cancer;ONCOTREE_CODE:IDC;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Unmatched;SEX:Female;SAMPLE_CLASS:Tumor;TREATMENT_BEST_RESPONSE:Stable Disease;OFF_STUDY_REASON:Toxicity;SAMPLE_COLLECTION_TIMEPOINT:pre-treatment;ALPELISIB_DOSE:300;ALPELISIB_SCHEDULING:Continious;BREAST_CANCER_SUBTYPE:HR+/HER2-;CLINICAL_BENEFIT:No;ENDOCRINE_THERAPY:Exemestane;MEASURABLE_DISEASE:No;PIK3CA_MUT_PRE_TREATMENT_TUMOR:WT;PIK3CA_PRE_TREATMENT_TUMOR:WT;SEQUENCING_PLATFORM:Sequenom;TREATMENT_ARM:B;WEEKS_ON_STUDY:4"
"PRIMARY CNS MELANOMA","CANCER_TYPE_DETAILED:Primary CNS Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:PCNSM;TMB_NONSYNONYMOUS:4.43662120239;SOMATIC_STATUS:Matched;SEX:Male;SAMPLE_TYPE:Primary;OS_MONTHS:7;OS_STATUS:1:DECEASED;PRIMARY_SITE:Skin;GENE_PANEL:IMPACT341;SAMPLE_CLASS:Tumor;TUMOR_PURITY:60;SAMPLE_COVERAGE:617;INSTITUTE:MSKCC;AGE_AT_SEQ_REPORT:65;AGE_GROUP:61-70;DRUG_TYPE:CTLA4"
"PRO MYELOCYTIC LEUKEMIA","CANCER_TYPE_DETAILED:Myeloid Neoplasm;CANCER_TYPE:Blood Cancer;ONCOTREE_CODE:MNM;TMB_NONSYNONYMOUS:4.733333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:36;FRACTION_GENOME_ALTERED:0.2614;HISTOLOGICAL_SUBTYPE:Pro myelocytic leukemia;PRIOR_TREATMENT:None;DOUBLING_TIME:28.6;P53:MT;CATEGORY_SAMPLE:PBL;EPITHELIAL:No;MDR:-11"
"RAEB","CANCER_TYPE_DETAILED:MDS with Excess Blasts;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSEB;TMB_NONSYNONYMOUS:0.533333333333;SOMATIC_STATUS:Matched;STUDY:BeatAML;SEQUENCING_TYPE:Whole-exome;DETAILED_CANCER_TYPE:RAEB"
"RARS","CANCER_TYPE_DETAILED:MDS/MPN with Ring Sideroblasts and Thrombocytosis;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:MDSMPNRST;TMB_NONSYNONYMOUS:5.95514584152;SOMATIC_STATUS:Unmatched;STUDY:Papaemmanuil_MDS_2013;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:RARS"
"RARS-T","CANCER_TYPE_DETAILED:MDS/MPN with Ring Sideroblasts and Thrombocytosis;CANCER_TYPE:Myelodysplastic/Myeloproliferative Neoplasms;ONCOTREE_CODE:MDSMPNRST;TMB_NONSYNONYMOUS:5.95514584152;SOMATIC_STATUS:Unmatched;STUDY:Papaemmanuil_MDS_2013;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:RARS-T"
"RCMD","CANCER_TYPE_DETAILED:MDS with Multilineage Dysplasia;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSMD;TMB_NONSYNONYMOUS:5.95514584152;SOMATIC_STATUS:Unmatched;STUDY:Papaemmanuil_MDS_2013;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:RCMD"
"READ","CANCER_TYPE_DETAILED:AML with Recurrent Genetic Abnormalities;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AMLRGA;TMB_NONSYNONYMOUS:0.166666667;SOMATIC_STATUS:Unmatched;SEX:Female;ETHNICITY:Black;PLATFORM:WES;AGE_AT_DIAGNOSIS:30.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:5.3;AGE_AT_PROCUREMENT:31;CENTER:6;TREATMENT_TYPE:Standard Chemotherapy;HEMOGLOBIN_LEVEL:8.5;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:1.01;CURRENT_STAGE:Consolidation;FUSION:MLLT3-KMT2A;GROUP:Post-Chemotherapy|Residual Disease;KARYOTYPE:46,XX,t(4;15)(q31;q22),t(9;11)(p22;q23)[19]/46,XX[1];PB_BLAST_PERCENTAGE:43;WHOLE_EXOME_SEQUENCING:Yes;BM_BLAST_PERCENTAGE:27;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|HiDAC;CUMULATIVE_TREATMENT_STAGES:Consolidation | Induction;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy;CURRENT_REGIMEN:HiDAC;MOST_RECENT_TREATMENT_DURATION:93;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:This test has detected t(4;15) and t(9;11) in 19 of 20 cells analyzed. Translocation t(9;11) was reported previously in this case as the primary abnormality. Translocation t(4;15) represents a secondary chromosome change, that was already reported on prev;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:27;ELN_2008:Intermediate-II;ELN_2017:Intermediate;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:Yes;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:26.1;INDUCTION_RESPONSE:Complete Response i;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:90.6;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:4.6;PB_ALT_LEVEL:35;PB_AST_LEVEL:62;PB_LYMPHOCYTES_PERCENTAGE:12;PB_MONOCYTES_PERCENTAGE:40;PB_NEUTROPHILS_PERCENTAGE:5;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:AML with t(9;11)(p22;q23); MLLT3-MLL;SPECIFIC_DIAGNOSIS_AT_INCLUSION:AML with t(9;11)(p22;q23); MLLT3-MLL;SURFACE_ANTIGENS:There are increased abnormal cells in the monocyte gate that stain positive for CD38, CD11b, CD14, CD64, CD33, with partial MPO, HLADR, CD13 expression.;TOTAL_PROTEIN_LEVEL:7.3;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"READ_GS","CANCER_TYPE_DETAILED:Rectal Adenocarcinoma;CANCER_TYPE:Colorectal Cancer;ONCOTREE_CODE:READ;TMB_NONSYNONYMOUS:3.233333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:64;FRACTION_GENOME_ALTERED:0.0000;SAMPLE_TYPE:Primary;OS_MONTHS:0.986290561;OS_STATUS:0:LIVING;TISSUE_SOURCE_SITE:Christiana Healthcare;ICD_O_3_SITE:C20.9;HISTORY_NEOADJUVANT_TRTYN:No;ICD_10:C20;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:5/18/10;PFS_MONTHS:0.986290561;AJCC_STAGING_EDITION:6TH;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Rectum;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE I;SUBTYPE:READ_GS;TUMOR_TYPE:Rectal Adenocarcinoma;PATH_T_STAGE:T2;DAYS_LAST_FOLLOWUP:30;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-23527;MSI_SENSOR_SCORE:0.06;CANCER_TYPE_ACRONYM:READ;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.2791;PATH_N_STAGE:N0;TISSUE_SOURCE_SITE_CODE:AG;DSS_MONTHS:0.986290561;PERSON_NEOPLASM_CANCER_STATUS:With Tumor;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;PATH_M_STAGE:M0;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"REFRACTORY ANEMIA WITH EXCESS BLASTS-2","CANCER_TYPE_DETAILED:Myelodysplastic Syndromes;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDS;TMB_NONSYNONYMOUS:0.366666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:75;TUMOR_TISSUE_SITE:Bone marrow;WHO_CLASS:Refractory Anemia With Excess Blasts-2;CYTOGENETICS:46,XX;GERMLINE_CONTROL:CD3+ T cell;IPSS_SCORE:2"
"REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA","CANCER_TYPE_DETAILED:MDS with Multilineage Dysplasia;CANCER_TYPE:Myelodysplastic Syndromes;ONCOTREE_CODE:MDSMD;SOMATIC_STATUS:Unmatched;SEX:Female;ETHNICITY:White;PLATFORM:WES + RNA-seq;AGE_AT_DIAGNOSIS:59.0;CHEMOTHERAPY:No;DIAGNOSIS:Myelodysplastic Syndromes;WBC:2.8;AGE_AT_PROCUREMENT:59;CENTER:5;TREATMENT_TYPE:Unknown;SAMPLE_SITE:Peripheral Blood;CURRENT_STAGE:Unknown;FUSION:None;GROUP:Post-Chemotherapy;KARYOTYPE:46,XX,del(9)(q21q31-33)[10]/46,XX[10];WHOLE_EXOME_SEQUENCING:No;BM_BLAST_PERCENTAGE:2;CEBPA_MUTATION:p.E10K; MAF 26.7%;CUMULATIVE_TREATMENT_REGIMENS:R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone);CUMULATIVE_TREATMENT_STAGES:Unknown;CUMULATIVE_TREATMENT_TYPES:Unknown;CURRENT_REGIMEN:R-CVP (Rituximab, Cyclophosphamide, Vincristine, Prednisolone);MOST_RECENT_TREATMENT_DURATION:-1;MOST_RECENT_TREATMENT_TYPE:Unknown;PRIOR_MDS:Yes;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:No;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:positive for a low level of findings consistent with trisomy 8, seen in 1.7% of cells.;DIAGNOSIS_AT_INCLUSION:Myelodysplastic Syndromes;DRUG_TESTING_IN_ANALYSIS:No;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:No;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;FLT3_NEGATIVE:Negative;JAK2_NEGATIVE:Negative;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:0;KIT_NEGATIVE:Negative;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:True;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Refractory cytopenia with multilineage dysplasia;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Refractory cytopenia with multilineage dysplasia"
"RENAL SPINDLE CELL CARCINOMA","CANCER_TYPE_DETAILED:Renal Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:RCC;TMB_NONSYNONYMOUS:8.8;SOMATIC_STATUS:Matched;SEX:Male;AGE:43;FRACTION_GENOME_ALTERED:0.3015;HISTOLOGICAL_SUBTYPE:Renal Spindle cell carcinoma;PRIOR_TREATMENT:None;DOUBLING_TIME:51.3;P53:MT;EPITHELIAL:Yes;MDR:-4"
"ROSAI-DORFMAN DISEASE","CANCER_TYPE_DETAILED:Rosai-Dorfman Disease;CANCER_TYPE:Histiocytosis;ONCOTREE_CODE:RDD;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Male;SAMPLE_TYPE:Unknown;OS_MONTHS:69.699;OS_STATUS:0:LIVING;RACE:WHITE;PRIMARY_SITE:Brain;GENE_PANEL:ACCESS129;SAMPLE_CLASS:cfDNA;MSI_SCORE:-1;SAMPLE_COVERAGE:1242;INSTITUTE:MSKCC;RELIGION:CATHOLIC/ROMAN;AGE_CURRENT:36;ARCHER:NO;PED_IND:No;PARTC_CONSENTED_12_245:NO;PARTA_CONSENTED_12_245:YES;CRDB_CONSENT_DATE_DAYS:11029;CRDB_SURVIVAL_STATUS:Alive"
"ROUND CELL SARCOMA, OTHER","CANCER_TYPE_DETAILED:Round Cell Sarcoma, Other;CANCER_TYPE:Soft Tissue Sarcoma;SEX:Female;FRACTION_GENOME_ALTERED:0.3691;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;RACE:NO VALUE ENTERED;ETHNICITY:Unknown whether Spanish or not;PRIMARY_SITE:Unknown;GENE_PANEL:IMPACT341;TUMOR_PURITY:30;MSI_SCORE:2.04;MSI_TYPE:Stable;SAMPLE_COVERAGE:159;PURITY:0.629866189;CVR_TMB_SCORE:1.1;AGE_AT_SEQ_REPORT:8;DETAILED_PRIMARY_SITE:Bone;FACETS:YES;FRACTION_CNA:0.859147128;FACETS_REVIEW:YES;FACETS_WGD:TRUE;FGA_REPORTED:0.3691"
"RT","CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"SARC LMS","CANCER_TYPE_DETAILED:Uterine Leiomyosarcoma;CANCER_TYPE:Uterine Sarcoma;ONCOTREE_CODE:ULMS;TMB_NONSYNONYMOUS:5.54577650299;SEX:Female;FRACTION_GENOME_ALTERED:0.3446;SAMPLE_TYPE:Primary;OS_MONTHS:3.35;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Uterus;GENE_PANEL:IMPACT341;TUMOR_PURITY:90;SUBTYPE:Sarcoma Leiomyo;MSI_SCORE:0.55;MSI_TYPE:Stable;SAMPLE_COVERAGE:1065;AGE_AT_SURGERY:60.08;FGA:0.345;AGE_AT_SEQUENCING:60.49;ORGAN_SYSTEM:Soft Tissue;AGE_AT_DEATH:60.77;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:No;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:SARC LMS"
"SARC LS","CANCER_TYPE_DETAILED:Dedifferentiated Liposarcoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:DDLS;TMB_NONSYNONYMOUS:0.0;SEX:Male;FRACTION_GENOME_ALTERED:0.0316;SAMPLE_TYPE:Metastasis;OS_MONTHS:18.14;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Retroperitoneum;GENE_PANEL:IMPACT341;METASTATIC_SITE:Bowel;TUMOR_PURITY:90;SUBTYPE:Sarcoma Lipo;MSI_SCORE:0;MSI_TYPE:Stable;SAMPLE_COVERAGE:557;AGE_AT_SURGERY:56.43;FGA:0.032;AGE_AT_SEQUENCING:57.44;ORGAN_SYSTEM:Soft Tissue;AGE_AT_DEATH:58.95;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:Yes;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:Yes;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:No;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:No;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:No;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:SARC LS"
"SARCOMA LEIOMYO","CANCER_TYPE_DETAILED:Uterine Leiomyosarcoma;CANCER_TYPE:Uterine Sarcoma;ONCOTREE_CODE:ULMS;TMB_NONSYNONYMOUS:5.54577650299;SEX:Female;FRACTION_GENOME_ALTERED:0.3446;SAMPLE_TYPE:Primary;OS_MONTHS:3.35;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Uterus;GENE_PANEL:IMPACT341;TUMOR_PURITY:90;SUBTYPE:Sarcoma Leiomyo;MSI_SCORE:0.55;MSI_TYPE:Stable;SAMPLE_COVERAGE:1065;AGE_AT_SURGERY:60.08;FGA:0.345;AGE_AT_SEQUENCING:60.49;ORGAN_SYSTEM:Soft Tissue;AGE_AT_DEATH:60.77;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:No;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:SARC LMS"
"SARC_DDLPS","CANCER_TYPE_DETAILED:Dedifferentiated Liposarcoma;CANCER_TYPE:Sarcoma;ONCOTREE_CODE:DDLS;TMB_NONSYNONYMOUS:0.6;SOMATIC_STATUS:Matched;SEX:Male;AGE:68;FRACTION_GENOME_ALTERED:0.0042;SAMPLE_TYPE:Primary;OS_MONTHS:36.29549265;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Not Hispanic Or Latino;TISSUE_SOURCE_SITE:Moffitt Cancer Center;ICD_O_3_SITE:C49.5;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C49.5;ICD_O_3_HISTOLOGY:8858/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:12/5/14;PFS_MONTHS:36.29549265;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Groin;SUBTYPE:SARC_DDLPS;TUMOR_TYPE:Dedifferentiated Liposarcoma;RADIATION_THERAPY:Yes;DAYS_LAST_FOLLOWUP:1104;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-24962;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:SARC;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.321;TISSUE_SOURCE_SITE_CODE:3B;DSS_MONTHS:36.29549265;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:Yes;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes"
"SARC_LMS","CANCER_TYPE_DETAILED:Leiomyosarcoma;CANCER_TYPE:Sarcoma;ONCOTREE_CODE:LMS;TMB_NONSYNONYMOUS:1.8;SOMATIC_STATUS:Matched;SEX:Female;AGE:57;FRACTION_GENOME_ALTERED:0.1762;SAMPLE_TYPE:Primary;OS_MONTHS:53.48982477;OS_STATUS:1:DECEASED;RACE:White;ETHNICITY:Not Hispanic Or Latino;TISSUE_SOURCE_SITE:Moffitt Cancer Center;ICD_O_3_SITE:C48.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:Yes;ICD_10:C48.0;ICD_O_3_HISTOLOGY:8890/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:12/5/14;PFS_MONTHS:16.99707401;PFS_STATUS:1:PROGRESSION;TUMOR_TISSUE_SITE:Retroperitoneum;SUBTYPE:SARC_LMS;TUMOR_TYPE:Leiomyosarcoma (LMS);RADIATION_THERAPY:Yes;DSS_STATUS:1:DEAD WITH TUMOR;DAYS_TO_BIRTH:-21094;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:SARC;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.36;TISSUE_SOURCE_SITE_CODE:3B;DSS_MONTHS:53.48982477;PERSON_NEOPLASM_CANCER_STATUS:With Tumor;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes"
"SARC_OTHER","CANCER_TYPE_DETAILED:Synovial Sarcoma;CANCER_TYPE:Sarcoma;ONCOTREE_CODE:SYNS;TMB_NONSYNONYMOUS:0.533333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:20;FRACTION_GENOME_ALTERED:0.0899;SAMPLE_TYPE:Primary;OS_MONTHS:152.1188809;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Hispanic Or Latino;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:152.1188809;TISSUE_SOURCE_SITE:Memorial Sloan Kettering;ICD_O_3_SITE:C49.6;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:No;ICD_10:C49.6;ICD_O_3_HISTOLOGY:9043/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:1/10/14;PFS_MONTHS:152.1188809;PFS_STATUS:0:CENSORED;TUMOR_TISSUE_SITE:Flank;SUBTYPE:SARC_Other;TUMOR_TYPE:Synovial Sarcoma, Biphasic Type;RADIATION_THERAPY:Yes;DAYS_LAST_FOLLOWUP:4121;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-7604;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:SARC;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.33;TISSUE_SOURCE_SITE_CODE:DX;DSS_MONTHS:152.1188809;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes"
"SBS","CANCER_TYPE_DETAILED:Small Bowel Cancer;CANCER_TYPE:Small Bowel Cancer;ONCOTREE_CODE:SBC;TMB_NONSYNONYMOUS:13.3098636072;SEX:Male;FRACTION_GENOME_ALTERED:0.5859;SAMPLE_TYPE:Primary;OS_MONTHS:12.45;OS_STATUS:1:DECEASED;RACE:Other;PRIMARY_SITE:Duodenum-Jejunum;GENE_PANEL:IMPACT341;TUMOR_PURITY:20;SUBTYPE:Small Bowel cancer;MSI_SCORE:3.44;MSI_TYPE:Indeterminate;SAMPLE_COVERAGE:569;AGE_AT_SURGERY:56.7;FGA:0.586;AGE_AT_SEQUENCING:57.6;ORGAN_SYSTEM:Core GI;AGE_AT_DEATH:58.63;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:Yes;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:No;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:SBS"
"SCCOHT","CANCER_TYPE_DETAILED:Small Cell Carcinoma of the Ovary;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:SCCO;TMB_NONSYNONYMOUS:4.9;SUBTYPE:Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT);LINEAGE:ovary;LINEAGE_SUBTYPE:SCCOHT"
"SCHMINKE TUMOR/LYMPHOEPITHELIAL CARCINOMA","CANCER_TYPE_DETAILED:SCHMINKE TUMOR/LYMPHOEPITHELIAL CARCINOMA;CANCER_TYPE:Carcinoma;SEX:Male;AGE:15.86036968;RACE:Asian;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;TIME_FROM_DX_TO_SEQ:78"
"SEROUS BORDERLINE OVARIAN TUMOR, MICROPAPILLARY","CANCER_TYPE_DETAILED:Serous Borderline Ovarian Tumor, Micropapillary;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:SBMOV;TMB_NONSYNONYMOUS:1.109155301;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.4721;SAMPLE_TYPE:Primary;OS_MONTHS:24.16;OS_STATUS:0:LIVING;PRIMARY_SITE:Ovary;SAMPLE_CLASS:Tumor;TUMOR_PURITY:40;SAMPLE_COVERAGE:209;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Prev/Curr Smoker;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"SEROUS_CARCINOMA","CANCER_TYPE_DETAILED:Ovarian Carcinosarcoma/Malignant Mixed Mesodermal Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OCS;TMB_NONSYNONYMOUS:3.20496774421;SEX:Female;FRACTION_GENOME_ALTERED:0.6815;PRIMARY_SITE:Ovary;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Ovary;HISTOLOGICAL_SUBTYPE:Serous_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"SKCM","CANCER_TYPE_DETAILED:Cutaneous Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:SKCM;TMB_NONSYNONYMOUS:2.43135484044;SEX:Male;FRACTION_GENOME_ALTERED:0.7563;PRIMARY_SITE:Skin;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Melanoma;HISTOLOGICAL_TYPE:Malignant Melanoma;DATA_SOURCE:ATCC;SAMPLE_ORIGIN:Solid"
"SMALL CELL CARCINOMA OF UNKNOWN PRIMARY","CANCER_TYPE_DETAILED:Small Cell Carcinoma of Unknown Primary;CANCER_TYPE:Cancer of Unknown Primary;ONCOTREE_CODE:SCUP;TMB_NONSYNONYMOUS:2.16666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:50;FRACTION_GENOME_ALTERED:0.6758;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Unknown;ANALYSIS_COHORT:MISC;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:10"
"SMOLDERING MYELOMA","CANCER_TYPE_DETAILED:Plasma Cell Myeloma;CANCER_TYPE:Mature B-Cell Neoplasms;ONCOTREE_CODE:PCM;TMB_NONSYNONYMOUS:0.333333333333;SOMATIC_STATUS:Matched;SEX:Male;AGE:50;RACE:Caucasian;ETHNICITY:Not Hispanic or Latino;DIAGNOSIS:Smoldering Myeloma;PREVIOUS_TREATMENT:No;PRIOR_MGUS:No"
"SOFT TISSUE MYOEPITHELIAL CARCINOMA","CANCER_TYPE_DETAILED:Soft Tissue Myoepithelial Carcinoma;CANCER_TYPE:Soft Tissue Sarcoma;ONCOTREE_CODE:STMYEC;TMB_NONSYNONYMOUS:1.56666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:65;FRACTION_GENOME_ALTERED:0.7221;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Foot;ANALYSIS_COHORT:SECR;BIOPSY_SITE:Liver;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:46"
"SPECIFIC_DX_AT_ACQUISITION_MDSMPN","CANCER_TYPE_DETAILED:Acute Myeloid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:AML;SEX:Female;OS_MONTHS:48.0986301369863;OS_STATUS:1:DECEASED;RACE:White;ETHNICITY:NON-HISPANIC;AGE_AT_DIAGNOSIS:27;COHORT:Waves1+2;SPECIMEN_TYPE:Bone Marrow Aspirate;CAUSE_OF_DEATH:Dead-Disease;CURRENT_STAGE:Experimental;KARYOTYPE:46,XX[20];CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine;CUMULATIVE_TREATMENT_STAGES:Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Sorafenib;FLT3_ITD:Positive;MOST_RECENT_TREATMENT_DURATION:99;MOST_RECENT_TREATMENT_TYPE:Targeted Therapy - Kinase Inhibitor(s);PRIOR_MDS:No;PRIOR_MPN:No;AGE_AT_SPECIMEN_ACQUISITION:27;ALLELIC_RATIO:0.96078431372549;CUMULATIVE_CHEMO:Yes;DISEASE_STAGE_AT_SPECIMEN_COLLECTION:Initial Diagnosis;DX_AT_INCLUSION:Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms;ELN2017:Intermediate;FAB_BLAST_MORPHOLOGY:M1;IS_DENOVO:False;IS_RELAPSE:False;IS_TRANSFORMED:False;NON_AML_MDSMPN_SPECIFIC_DX_AT_ACQUISITION:False;NPM1:Positive;OTHER_CYTOGENETICS:Normal;PRIOR_MALIGNANCY_RADIATION_TX:No;PRIOR_MALIGNANCY_TYPE:Juvenile pilocytic astrocytoma;PRIOR_MDS_MORE_THAN_TWO_MTHS:No;PRIOR_MDS_MPN:No;PRIOR_MDS_MPN_MORE_THAN_TWO_MTHS:No;PRIOR_MPN_MORE_THAN_TWO_MONTHS:No;RESPONSE_DURATION_TO_INDUCTION_TX:2;RESPONSE_TO_INDUCTION_TX:Complete Response;SPECIFIC_DX_AT_ACQUISITION_MDSMPN:False;SPECIFIC_DX_AT_INCLUSION:AML with mutated NPM1;SPECIMEN_GROUPS:Initial Acute Leukemia Diagnosis;SURFACE_ANTIGENS_IMMUNOHISTOCHEMICAL_STAINS:CD7, CD13, CD33, partial CD34, dim CD45, CD117, CD123, HLA-DR and MPO positive;TIME_OF_SAMPLE_COLLECTION_RELATIVE_TO_INCLUSION:0;TYPE_INDUCTION_TX:Standard Chemotherapy;USED_IN_MANUSCRIPT:Yes;VARIANT_SUMMARY:CEBPA|FLT3-ITD|NPM1"
"ST-RELPOS","CANCER_TYPE_DETAILED:Ependymoma;CANCER_TYPE:Glioma;TMB_NONSYNONYMOUS:0.666666667;SOMATIC_STATUS:Matched;SEX:Female;AGE:8;SAMPLE_TYPE:Primary;SEQUENCING_TYPE:WES;ONCOTREE_CODE_CANCER_TYPE:EPM;SUBTYPE_DETAILS:St-Relpos;TUMOR_DETAILS:Ependymoma supratentorial"
"ST-YAP","CANCER_TYPE_DETAILED:Ependymoma;CANCER_TYPE:Glioma;TMB_NONSYNONYMOUS:0.033333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:0.5;SAMPLE_TYPE:Primary;SEQUENCING_TYPE:WES;ONCOTREE_CODE_CANCER_TYPE:EPM;SUBTYPE_DETAILS:St-Yap;TUMOR_DETAILS:Ependymoma supratentorial"
"STAD","CANCER_TYPE_DETAILED:Ovarian Epithelial Tumor;CANCER_TYPE:Ovarian Cancer;ONCOTREE_CODE:OVT;TMB_NONSYNONYMOUS:8.03333333333;SEX:Female;AGE:62;FRACTION_GENOME_ALTERED:0.9354;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Ovary;SUBTYPE:Cystadenocarcinoma, mucinous;TUMOR_TYPE:ovary;HISTOLOGY:Carcinoma;PURITY:1;MUTATION_RATE:178.9165928;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;HIST_SUBTYPE1:adenocarcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:ovary;LINEAGE_SUB_SUBTYPE:mucinous;LINEAGE_SUBTYPE:ovary_adenocarcinoma;NAME:RMUG-S;PATHOLOGIST_ANNOTATION:Ovary:Carcinoma;PROTEOMICS_TMT_LABEL:129n;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:ovary"
"STAD_GS","CANCER_TYPE_DETAILED:Stomach Adenocarcinoma;CANCER_TYPE:Esophagogastric Cancer;ONCOTREE_CODE:STAD;TMB_NONSYNONYMOUS:3.566666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:51;FRACTION_GENOME_ALTERED:0.1752;SAMPLE_TYPE:Primary;OS_STATUS:1:DECEASED;RACE:White;ETHNICITY:Not Hispanic Or Latino;TISSUE_SOURCE_SITE:University of Kansas Medical Center;ICD_O_3_SITE:C16.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:Yes;ICD_10:C16.9;ICD_O_3_HISTOLOGY:8140/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:7/16/14;GRADE:G3;PFS_MONTHS:12.98615906;AJCC_STAGING_EDITION:6TH;PFS_STATUS:1:PROGRESSION;TUMOR_TISSUE_SITE:Stomach;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE IIIB;SUBTYPE:STAD_GS;TUMOR_TYPE:Stomach Adenocarcinoma (NOS);PATH_T_STAGE:T3;RADIATION_THERAPY:Yes;DSS_STATUS:1:DEAD WITH TUMOR;MSI_SENSOR_SCORE:0;CANCER_TYPE_ACRONYM:STAD;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3131;PATH_N_STAGE:N2;TISSUE_SOURCE_SITE_CODE:3M;PERSON_NEOPLASM_CANCER_STATUS:With Tumor;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:No;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:Yes;PATH_M_STAGE:MX;PRIMARY_LYMPH_NODE_PRESENTATION_ASSESSMENT:Yes"
"SUPERFICIAL SPREADING","CANCER_TYPE_DETAILED:Melanoma;CANCER_TYPE:Melanoma;ONCOTREE_CODE:MEL;TMB_NONSYNONYMOUS:7.36666666667;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:43.86666667;OS_STATUS:0:LIVING;PFS_MONTHS:43.86666667;PFS_STATUS:0:CENSORED;HISTOLOGY:Superficial spreading;M_STAGE:M1c;PURITY:0.6;TOTAL_MUTATIONS:315;BIOPSY_SITE:soft tissue;LDH_ELEVATED:No;MUTS_CLONAL:180;MUTS_SUBCLONAL:25;ALKYLATING_CHEMOTHERAPY:11.0774311;BIOPSY_CONTEXT:Pre-PD1;BIOPSY_SITE_CATEG:soft tissue;BR:Partial Response;CNA_PROP:0.072497872;COSMIC_AGING:52.3271629;CUT_SUBQ_MET:Yes;CYCLES_ON_THERAPY:33;HETEROGENEITY:0.12195122;IO_THERAPY:MK3475;LIVER_VISC_MET:Yes;LN_MET:Yes;LUNG_MET:Yes;MET_BONE:No;MET_BRAIN:No;NUM_PRIOR_THERAPIES:2;POAR_COMBINED_CTLA_PD1:No;POST_CTLA4:No;POST_MAPK_TX:No;PRIMARY_TYPE:skin;PRIOR_CTLA4:Yes;PRIOR_MAPK_TX:No;TIME_TO_BR:83;TOTAL_NEOANTIGEN:729;TX_START_ECOG:1;TX_START_LDH:161;UV_INDUCED_MUTATIONS:231.593849"
"SUPERFICIAL SPREADING MELANOMA","CANCER_TYPE_DETAILED:SUPERFICIAL SPREADING MELANOMA;CANCER_TYPE:Other;SEX:Female;AGE:22.57631683;RACE:White;SMOKING_STATUS:Never smoker;TREATMENT_STATUS:Unknown;ALL_TX_AT_MSK:No;EQD_TERTILES:No radiation;TIME_FROM_DX_TO_SEQ:2076;XRT_TX:No"
"SWEAT GLAND ADENOCARCINOMA","CANCER_TYPE_DETAILED:Sweat Gland Adenocarcinoma;CANCER_TYPE:Skin Cancer, Non-Melanoma;ONCOTREE_CODE:SGAD;TMB_NONSYNONYMOUS:3.327465902;SOMATIC_STATUS:Matched;SEX:Male;FRACTION_GENOME_ALTERED:0.0990;SAMPLE_TYPE:Metastasis;OS_MONTHS:12.46;OS_STATUS:0:LIVING;PRIMARY_SITE:Sweat Gland;SAMPLE_CLASS:Tumor;METASTATIC_SITE:Kidney;SAMPLE_COVERAGE:946;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Unknown;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"S_T_MDS","TMB_NONSYNONYMOUS:21.74626888391624;SEX:Male;AGE:64;OS_MONTHS:13.38082192;OS_STATUS:1:DECEASED;WBC:2.8;CYTOGENETICS:46,xy,del(20)(q12)[2]/46,xy[18];FLT3_ITD:FALSE;ANC:0.2;BM_BLAST:14;CHR_TP53_LOCUS:normal;COMPLEX_KARYOTYPE:non-complex;CYTO_IPSSR:Good;HB:7.6;IPSSM:Very-High;IPSSM_SCORE:3.48;IPSSR:High;IPSSR_SCORE:6;LFS_MONTHS:1.117808219;LFS_STATUS:1:Transformed/Deceased;MDS_TYPE:s_t_MDS;MLL_PTD:FALSE;MONOCYTES:0.7;PB_BLAST:0;PLT:119;WHO_2016:MDS-EB2"
"T-CELL, NON-HODGKINS, CUTANEOUS","CANCER_TYPE_DETAILED:Mycosis Fungoides;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:MYCF;TMB_NONSYNONYMOUS:5.33333333333;SEX:Male;AGE:53;FRACTION_GENOME_ALTERED:0.4604;SAMPLE_TYPE:Primary;RACE:Caucasian;ETHNICITY:Caucasian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:T-cell, Non-Hodgkins, Cutaneous;TUMOR_TYPE:lymphoma_other;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:118.2175686;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:NIBRI;DISEASE_ONTOLOGY:sezary_syndrome;HIST_SUBTYPE1:mycosis_fungoides-Sezary_syndrome;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:t_cell_cutaneous;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:HuT 78;PATHOLOGIST_ANNOTATION:Lymphoma:NH_T_cell;SITE_SUBTYPE1:skin;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:T-cell_lymphoma_other"
"T-CELL, NON-HODGKINS, CUTANEOUS, SEZARY SYNDROME","CANCER_TYPE_DETAILED:Non-Hodgkin Lymphoma;CANCER_TYPE:Non-Hodgkin Lymphoma;ONCOTREE_CODE:NHL;TMB_NONSYNONYMOUS:10.9333333333;SUBTYPE:T-cell, Non-Hodgkins, Cutaneous, Sezary Syndrome;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:t_cell_cutaneous;LINEAGE_SUBTYPE:non_hodgkin_lymphoma"
"T-CELL_ALL","CANCER_TYPE_DETAILED:T-Lymphoblastic Leukemia/Lymphoma;CANCER_TYPE:T-Lymphoblastic Leukemia/Lymphoma;ONCOTREE_CODE:TLL;TMB_NONSYNONYMOUS:24.8661290499;SEX:Male;FRACTION_GENOME_ALTERED:0.1179;PRIMARY_SITE:Haematopoietic And Lymphoid Tissue;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:T-Cell_All;HISTOLOGICAL_SUBTYPE:Acute_Lymphoblastic_T_Cell_Leukaemia;HISTOLOGICAL_TYPE:Lymphoid Neoplasm;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Haematopoietic"
"TALL","CANCER_TYPE_DETAILED:T-Cell Acute Lymphoid Leukemia;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TALL;TMB_NONSYNONYMOUS:1.67624641493;SOMATIC_STATUS:Matched;SEX:Male;AGE:0.925;GENE_PANEL:Targeted_Seq;COHORT:INF_NON_MLLr_Validation;MLL_STATUS:INF_NON_MLLr;LEUKEMIA_TYPE:T-ALL"
"TC:SCC","CANCER_TYPE_DETAILED:Thymic Epithelial Tumor;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:TET;TMB_NONSYNONYMOUS:1.133333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:76;TISSUE_SOURCE_SITE:Frozen;GENE_PANEL:WXS, RNASeq;TUMOR_STAGE:III;DIAGNOSIS:Thymic Carcinoma;WHO_CLASS:TC:SCC;ACGH_DATA:CGH;GTF2I_MUTATION_STATUS:WT"
"TGCT SEM","CANCER_TYPE_DETAILED:Seminoma;CANCER_TYPE:Germ Cell Tumor;ONCOTREE_CODE:SEM;TMB_NONSYNONYMOUS:3.32746590179;SEX:Male;FRACTION_GENOME_ALTERED:0.4731;SAMPLE_TYPE:Primary;OS_MONTHS:76.09;OS_STATUS:0:LIVING;RACE:White;PRIMARY_SITE:Testis;GENE_PANEL:IMPACT341;TUMOR_PURITY:90;SUBTYPE:Testicular Seminoma;MSI_SCORE:0.09;MSI_TYPE:Stable;SAMPLE_COVERAGE:772;AGE_AT_SURGERY:28.83;FGA:0.473;AGE_AT_SEQUENCING:28.97;ORGAN_SYSTEM:Genitourinary;AGE_AT_LAST_CONTACT:35.31;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:No;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:Yes;DMETS_DX_DIST_LN:Yes;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:Yes;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:TGCT SEM"
"THCA","CANCER_TYPE_DETAILED:Bladder Urothelial Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:BLCA;TMB_NONSYNONYMOUS:9.86666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:76;FRACTION_GENOME_ALTERED:0.3163;SAMPLE_TYPE:Primary;OS_MONTHS:31.04;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:NOT HISPANIC OR LATINO;DFS_STATUS:0:DiseaseFree;DFS_MONTHS:31.04;TISSUE_SOURCE_SITE:FJ;ICD_O_3_SITE:C67.9;HISTORY_NEOADJUVANT_TRTYN:Yes;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:NO;ICD_10:C67.9;ICD_O_3_HISTOLOGY:8120/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:9/27/12;GRADE:High Grade;AJCC_STAGING_EDITION:7th;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage IV;HISTOLOGICAL_DIAGNOSIS:Muscle invasive urothelial carcinoma (pT2 or above);HISTORY_OTHER_MALIGNANCY:Yes;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2010;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:539;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-FJ-A3Z7.67B47EFA-A6C9-40B6-AF17-8A4E1FF6656B.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:120;WEIGHT:84;SITE_OF_TUMOR_TISSUE:Bladder;PHARMACEUTICAL_TX_ADJUVANT:YES;AJCC_METASTASIS_PATHOLOGIC_PM:MX;AJCC_NODES_PATHOLOGIC_PN:N2;AJCC_TUMOR_PATHOLOGIC_PT:T4a;TREATMENT_OUTCOME_FIRST_COURSE:Complete Remission/Response;HISTOLOGICAL_SUBTYPE:Non-Papillary;LYMPH_NODES_EXAMINED:YES;ECOG_SCORE:0;TOBACCO_SMOKING_HISTORY_INDICATOR:1;HEIGHT:175;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Other method, specify:;PRIMARY_SITE_PATIENT:Dome|Wall Anterior|Wall Lateral|Wall Posterior;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT_OTHER:Radical Cystectomy w/Nodal Dissection;METASTATIC_SITE_PATIENT:Lymph node only;ANGIOLYMPHATIC_INVASION:YES;OCCUPATION_PRIMARY:Carpenter;EXTRACAPSULAR_EXTENSION:NO;NONINVASIVE_BLADDER_CA_TX_TYPE:Bacillus Calmette-Guerin (BCG);NONINVASIVE_BLADDER_HISTORY:YES;OCCUPATION_CURRENT:Retired;OCCUPATION_PRIMARY_INDUSTRY:Healthcare;TIME_TO_COMPLETE_RESPONSE:26;TX_90DAYS_POST_RESECTION:NO;TX_COMPLETE_RESPONSE:YES;TX_INDUCTION_COURSES_INDICATOR:YES;TX_MAINTENANCE_COURSES_INDICATOR:YES"
"THERAPY-RELATED MYELODYSPLASTIC SYNDROME","CANCER_TYPE_DETAILED:Therapy-Related Myelodysplastic Syndrome;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMDS;TMB_NONSYNONYMOUS:2.7975705897;SOMATIC_STATUS:Matched;STUDY:MSKCC;SEQUENCING_TYPE:Targeted;DETAILED_CANCER_TYPE:Therapy-Related Myelodysplastic Syndrome"
"THERAPY-RELATED MYELOID NEOPLASMS","CANCER_TYPE_DETAILED:Therapy-Related Myeloid Neoplasms;CANCER_TYPE:Leukemia;ONCOTREE_CODE:TMN;SOMATIC_STATUS:Matched;SEX:Female;OS_MONTHS:4.84;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:81.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;WBC:37.1;SAMPLE_TIMEPOINT:After or at the time transformation from another heme malignancy;AGE_AT_PROCUREMENT:81;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Supportive/Palliative Care;FAB:M5;HEMOGLOBIN_LEVEL:8.8;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:1.08;CURRENT_STAGE:Supportive/Palliative Care;FUSION:None;GROUP:Post-Chemotherapy|Residual Disease;KARYOTYPE:46,XX,t(8;16)(p11.2;p13.3)[8]/46,XX,del(7)(q11.2q22),del(20)(q13.1q13.3)[cp3]/46,XX[12];WHOLE_EXOME_SEQUENCING:No;CUMULATIVE_TREATMENT_REGIMENS:Azacitidine;CUMULATIVE_TREATMENT_STAGES:Supportive/Palliative Care;CUMULATIVE_TREATMENT_TYPES:Supportive/Palliative Care;CURRENT_REGIMEN:Azacitidine;LDH_LEVEL:2700;MOST_RECENT_TREATMENT_DURATION:42;MOST_RECENT_TREATMENT_TYPE:Supportive/Palliative Care;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;DIAGNOSIS_AT_INCLUSION:Acute Myeloid Leukaemia (AML) and Related Precursor Neoplasms;DRUG_TESTING_IN_ANALYSIS:Yes;ELN_2008:Adverse;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:26.6;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-112;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:92.4;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.2;PB_ALT_LEVEL:60;PB_AST_LEVEL:64;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:12;PB_MONOCYTES_PERCENTAGE:33;PB_NEUTROPHILS_PERCENTAGE:7;PRIOR_CANCER:Anal carcinoma|Breast Cancer;PRIOR_MDSMPN:Yes;PRIORRADIATIONFOROTHERCANCER:Yes;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Therapy-related myeloid neoplasms;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Therapy-related myeloid neoplasms;TOTAL_PROTEIN_LEVEL:6.3"
"THPA","CANCER_TYPE_DETAILED:Papillary Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPA;TMB_NONSYNONYMOUS:8.46666666667;SEX:Female;AGE:76;FRACTION_GENOME_ALTERED:0.3951;SAMPLE_TYPE:Primary;ETHNICITY:Caucasian;PRIMARY_SITE:Thyroid;SUBTYPE:Carcinoma, papillary;TUMOR_TYPE:thyroid;HISTOLOGY:Carcinoma;PURITY:0.98;MUTATION_RATE:112.5260944;GENOME_DOUBLINGS:1;DOUBLING_TIME:36.2;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:DSMZ;CHARACTERISTICS:Spindle- or round-shaped cells growing adherently as monolayer;DOUBLING_TIME_FROM_VENDOR:~  30 hrs;FREEZING_MEDIUM:10%DMSO;GROWTH_MEDIUM:90% RPMI 1640 + 10% h.i.FBS;HIST_SUBTYPE1:papillary_carcinoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:thyroid;LINEAGE_SUB_SUBTYPE:papillary;LINEAGE_SUBTYPE:thyroid_carcinoma;NAME:B-CPAP;PATHOLOGIST_ANNOTATION:Thyroid:Carcinoma;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:thyroid"
"THPD","CANCER_TYPE_DETAILED:Poorly Differentiated Thyroid Cancer;CANCER_TYPE:Thyroid Cancer;ONCOTREE_CODE:THPD;TMB_NONSYNONYMOUS:4.42064516443;SEX:Female;FRACTION_GENOME_ALTERED:0.5518;PRIMARY_SITE:Thyroid;GENE_PANEL:NOVARTIS_BROAD_1651;TUMOR_TYPE:Thyroid;HISTOLOGICAL_SUBTYPE:Anaplastic_Carcinoma;HISTOLOGICAL_TYPE:Carcinoma;DATA_SOURCE:DSMZ;SAMPLE_ORIGIN:Solid"
"THYMOMA; TYPE C","CANCER_TYPE_DETAILED:Thymoma;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:THYM;TMB_NONSYNONYMOUS:1.06666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:63;FRACTION_GENOME_ALTERED:0.5624;SAMPLE_TYPE:Primary;OS_MONTHS:21.12;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:7.36;TISSUE_SOURCE_SITE:3S;ICD_O_3_SITE:C37.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C37;ICD_O_3_HISTOLOGY:8586/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;HISTOLOGICAL_DIAGNOSIS:Thymoma; Type C;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2013;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:112;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3S-A8YW.F59BF4F4-ED39-45DD-AD20-FC3BDD08F73A.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:220;WEIGHT:91;TUMOR_SITE:Thymus;PHARMACEUTICAL_TX_ADJUVANT:NO;HEIGHT:172;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Surgical Resection;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO"
"TRANSLOCATION-ASSOCIATED RENAL CELL CARCINOMA","CANCER_TYPE_DETAILED:Translocation-Associated Renal Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:TRCC;TMB_NONSYNONYMOUS:0;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.0015;SAMPLE_TYPE:Primary;OS_STATUS:1:DECEASED;PRIMARY_SITE:Kidney;SAMPLE_CLASS:Tumor;TUMOR_PURITY:70;SAMPLE_COVERAGE:424;VITAL_STATUS:DECEASED;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"TYPE A","CANCER_TYPE_DETAILED:Mixed Phenotype Acute Leukemia, T/Myeloid, NOS;CANCER_TYPE:Leukemia;ONCOTREE_CODE:MPALTNOS;SOMATIC_STATUS:Matched;SEX:Male;OS_MONTHS:13.29;OS_STATUS:1:DECEASED;ETHNICITY:White;PLATFORM:RNA-seq;AGE_AT_DIAGNOSIS:52.0;CHEMOTHERAPY:Yes;DIAGNOSIS:Acute Leukaemias of Ambiguous Lineage;WBC:14;AGE_AT_PROCUREMENT:53;CAUSE_OF_DEATH_SOURCE:Dead-Disease;CENTER:1;TREATMENT_TYPE:Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s);HEMOGLOBIN_LEVEL:11.1;SAMPLE_SITE:Peripheral Blood;CREATININE_LEVEL_PRERESECTION:0.68;CURRENT_STAGE:Salvage;FUSION:None;GROUP:Post-Transplant|Post-Chemotherapy|Residual Disease;KARYOTYPE:45~48,XY,+5,add(5)(q11.2)x2,t(7;7)(q22;q36),+11,add(13)(q13),-22[cp9]/45~47,sl,-add(5)(q11.2),der(11)t(11;12)(p11.2;q13),-12[cp6]/46,sl,t(Y;18)(p11.2;q21),der(9)t(9;17)(p13;q11.2),-17[2]/46,XY[3];PB_BLAST_PERCENTAGE:59;WHOLE_EXOME_SEQUENCING:No;CUMULATIVE_TREATMENT_REGIMENS:7+3 (Cytarabine, Idarubicin)|Sunitinib|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide;CUMULATIVE_TREATMENT_STAGES:Salvage | Induction | Re-induction | Supportive/Palliative Care | Allogeneic - Matched Unrelated Donor;CUMULATIVE_TREATMENT_TYPES:Standard Chemotherapy | Bone Marrow Transplant | Targeted Therapy - Kinase Inhibitor(s);CURRENT_REGIMEN:Decitabine;LDH_LEVEL:167;MOST_RECENT_TREATMENT_DURATION:80;MOST_RECENT_TREATMENT_TYPE:Standard Chemotherapy;PRIOR_MDS:No;PRIOR_MPN:No;RNA_SEQ_ANALYSIS:Yes;RNA_SEQUENCED:Yes;CEBPA_BIALLELIC_MUTATION:No;CYTOGENETICS_OTHER:Deleted 5q;DIAGNOSIS_AT_INCLUSION:Acute Leukaemias of Ambiguous Lineage;DRUG_TESTING_IN_ANALYSIS:Yes;DURATION_OF_INDUCTION_TREATMENT:6;ELN_2008:Adverse;ELN_2017:Adverse;EX_VIVO_DRUG_TESTING:Yes;EXOME_SEQ_ANALYSIS:No;FLT3_ITD_CONSENSUS_CALL:Negative;HEMATOCRIT_LEVEL:34;INDUCTION_RESPONSE:Refractory;KARYOTYPE_SAMPLE_ACQUISITION_INTERVAL_DIFFERENCE:-2;MDS_TWO_MONTHS_PRIOR_AML:No;MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;MDSMPN_TWO_MONTHS_PRIOR_AML:No;MEAN_CORPUSCULAR_VOLUME:102.8;MPN_TWO_MONTHS_PRIOR_AML:No;NON_AML_MDSMPN_DIAGNOSIS_AT_ACQUISITION:False;NPM1_CONSENSUS_CALL:Negative;PB_ALBUMIN_LEVEL:3.7;PB_ALT_LEVEL:32;PB_AST_LEVEL:34;PB_BASOPHILS_PERCENTAGE:0;PB_EOSINOPHILS_PERCENTAGE:0;PB_LYMPHOCYTES_PERCENTAGE:9;PB_MONOCYTES_PERCENTAGE:2;PB_NEUTROPHILS_PERCENTAGE:29;PRIOR_MDSMPN:No;PRIORRADIATIONFOROTHERCANCER:No;SPECIFIC_DIAGNOSIS_AT_ACQUISITION:Mixed phenotype acute leukaemia, T/myeloid, NOS;SPECIFIC_DIAGNOSIS_AT_INCLUSION:Mixed phenotype acute leukaemia, T/myeloid, NOS;TOTAL_PROTEIN_LEVEL:6.7;TYPE_INDUCTION_TREATMENT:Standard Chemotherapy"
"TYPE C","CANCER_TYPE_DETAILED:Thymoma;CANCER_TYPE:Thymic Tumor;ONCOTREE_CODE:THYM;TMB_NONSYNONYMOUS:1.06666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:63;FRACTION_GENOME_ALTERED:0.5624;SAMPLE_TYPE:Primary;OS_MONTHS:21.12;OS_STATUS:0:LIVING;RACE:WHITE;ETHNICITY:HISPANIC OR LATINO;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:7.36;TISSUE_SOURCE_SITE:3S;ICD_O_3_SITE:C37.9;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C37;ICD_O_3_HISTOLOGY:8586/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;HISTOLOGICAL_DIAGNOSIS:Thymoma; Type C;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:YES;TUMOR_STATUS:TUMOR FREE;PROSPECTIVE_COLLECTION:YES;INITIAL_PATHOLOGIC_DX_YEAR:2013;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:NO;DAYS_TO_COLLECTION:112;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-3S-A8YW.F59BF4F4-ED39-45DD-AD20-FC3BDD08F73A.pdf;VIAL_NUMBER:A;SAMPLE_INITIAL_WEIGHT:220;WEIGHT:91;TUMOR_SITE:Thymus;PHARMACEUTICAL_TX_ADJUVANT:NO;HEIGHT:172;METHOD_OF_INITIAL_SAMPLE_PROCUREMENT:Surgical Resection;ABLATION_EMBOLIZATION_TX_ADJUVANT:NO"
"T_CELL_ALCL","CANCER_TYPE_DETAILED:Anaplastic Large Cell Lymphoma;CANCER_TYPE:Mature T and NK Neoplasms;ONCOTREE_CODE:ALCL;TMB_NONSYNONYMOUS:20.3;SEX:Male;AGE:15;FRACTION_GENOME_ALTERED:0.4817;SAMPLE_TYPE:Primary;ETHNICITY:Asian;PRIMARY_SITE:Haematopoietic_And_Lymphoid_Tissue;SUBTYPE:T-cell, Non-Hodgkins, Anaplastic Large Cell (ALCL);TUMOR_TYPE:lymphoma_other;HISTOLOGY:Lymphoid_Neoplasm;PURITY:1;MUTATION_RATE:208.2736925;GENOME_DOUBLINGS:0;ANNOTATION_SOURCE:CCLE;CELL_LINE_SOURCE:HSSRB;CHARACTERISTICS:lymphoblast-like;GROWTH_MEDIUM:RPMI 1640 medium with 10% fetal calf serum.;HIST_SUBTYPE1:anaplastic_large_cell_lymphoma;HIST_SUBTYPE2:NS;HIST_SUBTYPE3:NS;LINEAGE:lymphocyte;LINEAGE_SUB_SUBTYPE:t_cell_ALCL;LINEAGE_SUBTYPE:non_hodgkin_lymphoma;NAME:Ki-JK;PATHOLOGIST_ANNOTATION:Lymphoma:NH_T_cell;SITE_SUBTYPE1:NS;SITE_SUBTYPE2:NS;SITE_SUBTYPE3:NS;TYPE_REFINED:T-cell_lymphoma_other"
"UCEC ENDO","CANCER_TYPE_DETAILED:Uterine Endometrioid Carcinoma;CANCER_TYPE:Endometrial Cancer;ONCOTREE_CODE:UEC;TMB_NONSYNONYMOUS:6.65493180359;SEX:Female;FRACTION_GENOME_ALTERED:0.3878;SAMPLE_TYPE:Metastasis;OS_MONTHS:35.06;OS_STATUS:1:DECEASED;RACE:White;PRIMARY_SITE:Uterus;GENE_PANEL:IMPACT341;METASTATIC_SITE:Lung;TUMOR_PURITY:40;SUBTYPE:Uterine Endometrioid;MSI_SCORE:0.72;MSI_TYPE:Stable;SAMPLE_COVERAGE:1016;AGE_AT_SURGERY:61;FGA:0.388;AGE_AT_SEQUENCING:61.33;ORGAN_SYSTEM:Gynecologic;AGE_AT_DEATH:64.25;DMETS_DX_ADRENAL_GLAND:No;DMETS_DX_BILIARY_TRACT:No;DMETS_DX_BLADDER_UT:No;DMETS_DX_BONE:Yes;DMETS_DX_BOWEL:No;DMETS_DX_BREAST:No;DMETS_DX_CNS_BRAIN:No;DMETS_DX_DIST_LN:No;DMETS_DX_FEMALE_GENITAL:No;DMETS_DX_HEAD_NECK:No;DMETS_DX_INTRA_ABDOMINAL:Yes;DMETS_DX_LIVER:Yes;DMETS_DX_LUNG:Yes;DMETS_DX_MALE_GENITAL:No;DMETS_DX_MEDIASTINUM:No;DMETS_DX_OVARY:No;DMETS_DX_PLEURA:No;DMETS_DX_PNS:No;DMETS_DX_SKIN:No;DMETS_DX_UNSPECIFIED:Yes;IS_DIST_MET_MAPPED:TRUE;SUBTYPE_ABBREVIATION:UCEC ENDO"
"UCS","CANCER_TYPE_DETAILED:Intrahepatic Cholangiocarcinoma;CANCER_TYPE:Cholangiocarcinoma;ONCOTREE_CODE:IHCH;TMB_NONSYNONYMOUS:1.233333333;SOMATIC_STATUS:Matched;SEX:Female;AGE:46;FRACTION_GENOME_ALTERED:0.2993;SAMPLE_TYPE:Primary;OS_MONTHS:26.56409245;OS_STATUS:0:LIVING;RACE:White;ETHNICITY:Hispanic Or Latino;DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:18.04911727;TISSUE_SOURCE_SITE:UCSF;ICD_O_3_SITE:C22.1;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:Yes;ICD_10:C22.1;ICD_O_3_HISTOLOGY:8160/3;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:Yes;FORM_COMPLETION_DATE:8/16/14;GRADE:G2;PFS_MONTHS:18.04911727;AJCC_STAGING_EDITION:7TH;PFS_STATUS:1:PROGRESSION;TUMOR_TISSUE_SITE:Bile Duct;AJCC_PATHOLOGIC_TUMOR_STAGE:STAGE I;SUBTYPE:CHOL;TUMOR_TYPE:Cholangiocarcinoma, Intrahepatic;PATH_T_STAGE:T1;RADIATION_THERAPY:No;DAYS_LAST_FOLLOWUP:549;DSS_STATUS:0:ALIVE OR DEAD TUMOR FREE;DAYS_TO_BIRTH:-16951;MSI_SENSOR_SCORE:0.24;CANCER_TYPE_ACRONYM:CHOL;IN_PANCANPATHWAYS_FREEZE:Yes;MSI_SCORE_MANTIS:0.3208;PATH_N_STAGE:N0;TISSUE_SOURCE_SITE_CODE:W6;DSS_MONTHS:26.56409245;PERSON_NEOPLASM_CANCER_STATUS:Tumor Free;PRIOR_DX:No;TISSUE_PROSPECTIVE_COLLECTION_INDICATOR:Yes;TISSUE_RETROSPECTIVE_COLLECTION_INDICATOR:No;WEIGHT:61;PATH_M_STAGE:MX"
"UM","CANCER_TYPE_DETAILED:Adrenocortical Carcinoma;CANCER_TYPE:Adrenocortical Carcinoma;ONCOTREE_CODE:ACC;TMB_NONSYNONYMOUS:1.26666666667;SOMATIC_STATUS:Matched;SEX:Male;AGE:58;FRACTION_GENOME_ALTERED:0.0585;SAMPLE_TYPE:Primary;OS_MONTHS:44.51;OS_STATUS:1:DECEASED;RACE:WHITE;ETHNICITY:[Not Evaluated];DFS_STATUS:1:Recurred/Progressed;DFS_MONTHS:24.77;TISSUE_SOURCE_SITE:OR;ICD_O_3_SITE:C74.0;HISTORY_NEOADJUVANT_TRTYN:No;NEW_TUMOR_EVENT_AFTER_INITIAL_TREATMENT:YES;ICD_10:C74.0;ICD_O_3_HISTOLOGY:8370/1;DAYS_TO_INITIAL_PATHOLOGIC_DIAGNOSIS:0;INFORMED_CONSENT_VERIFIED:YES;FORM_COMPLETION_DATE:2014-4-2;AJCC_PATHOLOGIC_TUMOR_STAGE:Stage II;PATH_T_STAGE:T2;HISTOLOGICAL_DIAGNOSIS:Adrenocortical carcinoma- Usual Type;HISTORY_OTHER_MALIGNANCY:No;RADIATION_TREATMENT_ADJUVANT:NO;TUMOR_STATUS:WITH TUMOR;PROSPECTIVE_COLLECTION:NO;INITIAL_PATHOLOGIC_DX_YEAR:2000;IS_FFPE:NO;RETROSPECTIVE_COLLECTION:YES;DAYS_TO_COLLECTION:4691;OCT_EMBEDDED:TRUE;PATHOLOGY_REPORT_FILE_NAME:TCGA-OR-A5J1.8866FD87-4F6F-4D7E-B99A-7DD427ED3BB3.pdf;VIAL_NUMBER:A;PATH_N_STAGE:N0;SAMPLE_INITIAL_WEIGHT:40;SITE_OF_TUMOR_TISSUE:Adrenal;PHARMACEUTICAL_TX_ADJUVANT:NO;LYMPH_NODES_EXAMINED:[Unknown];LATERALITY:Left;CLIN_M_STAGE:M0;CT_SCAN_PREOP_RESULTS:[Unknown];MITOTIC_RATE:Mitotic Rate > 5/50 HPF Absent;MOLECULAR_STUDIES_OTHERS_PERFORMED:NO;ATYPICAL_MITOTIC_FIGURES:Atypical Mitotic Figures Absent;CAPSULAR_INVASION:Invasion of Tumor Capsule Absent;CYTOPLASM_PRESENCE_LESS_THAN_EQUAL_25_PERCENT:Cytoplasm presence <= 25% Present;DIFFUSE_ARCHITECTURE:Diffuse Architecture Present;HISTORY_ADRENAL_HORMONE_EXCESS:Mineralocorticoids;HISTORY_BASIS_ADRENAL_HORMONE_DX:[Unknown];MITOSES_PER_50_HPF:5;NECROSIS:Necrosis Present;NUCLEAR_GRADE_III_IV:Nuclear Grade III or IV Absent;PHARM_TX_MITOTANE_INDICATOR:NO;WEISS_SCORE_OVERALL:3;WEISS_VENOUS_INVASION:Venous Invasion Absent"
"UNCLASSIFIED RENAL CELL CARCINOMA","CANCER_TYPE_DETAILED:Unclassified Renal Cell Carcinoma;CANCER_TYPE:Renal Cell Carcinoma;ONCOTREE_CODE:URCC;TMB_NONSYNONYMOUS:0.266666666667;FRACTION_GENOME_ALTERED:0.2557"
"UNKNOWN TUMOR","CANCER_TYPE_DETAILED:Biliary Tract;CANCER_TYPE:Biliary Tract Cancer;ONCOTREE_CODE:BILIARY_TRACT;TMB_NONSYNONYMOUS:0.2;SOMATIC_STATUS:Matched;SEX:Female;SAMPLE_TYPE:Unknown Tumor;OS_MONTHS:1.64;OS_STATUS:Uknown;RACE:Uknown;ETHNICITY:Uknown;PRIMARY_SITE:Biliary Tract;GENE_PANEL:MSK-ACCESS_v1;SAMPLE_CLASS:cfDNA;INSTITUTE:MSKCC;RELIGION:Uknown;AGE_CURRENT:Uknown;PED_IND:No;BEST_OVERALL_RESPONSE_BOR:NE"
"URACHAL ADENOCARCINOMA","CANCER_TYPE_DETAILED:Urachal Adenocarcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:UA;TMB_NONSYNONYMOUS:6.5;SOMATIC_STATUS:Matched;SEX:Female;AGE:46;FRACTION_GENOME_ALTERED:0.4041;SAMPLE_TYPE:Metastasis;RACE:Caucasian;PRIMARY_SITE:Urachus;ANALYSIS_COHORT:BLCA;BIOPSY_SITE:Subcut. Periumbilical;PRIOR_THERAPY:Yes;INTERVAL_MONTHS:64"
"URACHAL CARCINOMA","CANCER_TYPE_DETAILED:Urachal Carcinoma;CANCER_TYPE:Bladder Cancer;ONCOTREE_CODE:URCA;PFS_MONTHS:0.2;COHORT:Other;AMPLIFICATION_STATUS:no;BUBBLE_GROUP:S310 Hotspot;CENTRAL:NONE;CRITERIA:NE;DATA:NONE;DOMAIN:Furin-like _ECD;DURATION_OF_THERAPY_DAYS:2;GENE:ERBB2;LOCAL_TEST:NGS-GUARDANT HEALTH;ONCOPRINT:NO;ONGOING_TREATMENT:NO;QUALIFYING_MUT:S310F;WATERFALL_GROUP:S310 Hotspot"
"UTERINE PERIVASCULAR EPITHELIOID CELL TUMOR","CANCER_TYPE_DETAILED:Uterine Perivascular Epithelioid Cell Tumor;CANCER_TYPE:Uterine Sarcoma;ONCOTREE_CODE:UPECOMA;TMB_NONSYNONYMOUS:2.218310601;SOMATIC_STATUS:Matched;SEX:Female;FRACTION_GENOME_ALTERED:0.2905;SAMPLE_TYPE:Primary;OS_STATUS:0:LIVING;PRIMARY_SITE:Uterus;SAMPLE_CLASS:Tumor;TUMOR_PURITY:90;SAMPLE_COVERAGE:841;VITAL_STATUS:ALIVE;SPECIMEN_PRESERVATION_TYPE:FFPE;SMOKING_HISTORY:Never;SPECIMEN_TYPE:Resection;SAMPLE_COLLECTION_SOURCE:Outside;MATCHED_STATUS:Matched;DNA_INPUT:250"
"UVM","TMB_NONSYNONYMOUS:8.80847727853;SEX:Male;FRACTION_GENOME_ALTERED:0.0035;SMOKING_PACK_YEARS:30;CLINICAL_STAGE:Stage I;SMOKING_STATUS:Ever Smoker;WGD:FALSE;FGA_FACETS:0.008106495;LN_STATUS:pN-Negative;AGE_AT_RESECTION:70;BIOPSY_CONTAINS_MIP:FALSE;CLIN_N_STAGE_CODE:cN0;TUMOR_MORPHOLOGIC_APPEARANCE_ON_CT:Nonsolid;TUMOR_SIZE_ON_CT:1.5;TUMOR_SUVMAX:0"
